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ABSTRACT 
 
Background 
 
Type 1 diabetes is an immune-mediated endocrine disorder that affects approximately 0.8% of 
children and adolescents in Finland, which has the highest incidence of type 1 diabetes in the world. 
The burden of type 1 diabetes on affected individuals, their families, and the healthcare system is 
notable, and the increasing incidence of type 1 diabetes worldwide calls for preventive measures. The 
disease process is driven by progressive destruction of pancreatic insulin-producing beta cells, 
eventually leading to total insulin deficiency and causing symptoms of severe hyperglycemia. The 
etiology of type 1 diabetes is considered to be highly multifactorial, and both genetic and 
environmental factors are likely to contribute to the disease pathogenesis. A presymptomatic period 
of highly variable duration precedes the onset of clinical type 1 diabetes, during which autoantibodies 
to multiple beta-cell antigens are detected in the circulation of prediabetic individuals. Together with 
human leukocyte antigen (HLA) genotypes, the autoantibodies may be used for disease prediction. 
However, the factors decisive for individual disease risk and the progression rate to clinical type 1 
diabetes have thus far remained incompletely understood. The highly variable duration of the 
preclinical period suggests that the genetic, immunological, epigenetic, and/or environmental factors 
substantially affect the pace of progression to clinical disease. 
 
Aims 
 
This thesis aims at improving the early prediction of clinical type 1 diabetes and the timing of disease 
onset by characterizing the genetic, immunological, and demographic factors associated with the 
progression rate to type 1 diabetes and by describing the predictive islet autoantibody dynamics 
during the first 15 years in HLA-predisposed children. 
 
Subjects and methods 
 
The study subjects in this thesis are participants in the Finnish Type 1 Diabetes Prediction and 
Prevention (DIPP) study. The prospective DIPP study aims at monitoring the development of islet 
autoimmunity and type 1 diabetes in HLA-predisposed children and at identifying means for delaying 
or preventing the onset of clinical diabetes. Newborn infants born in the Turku, Oulu, and Tampere 
University Hospitals, Finland, are screened for HLA genotypes predisposing to type 1 diabetes from 
cord blood. Eligible infants are invited to clinical follow-up, including islet autoantibody assessment 
starting from the age of 3 months. Islet cell antibodies (ICA) and autoantibodies to insulin (IAA), 
glutamic acid decarboxylase (GADA), islet antigen-2 (IA-2A), and zinc transporter 8 (ZnT8A) are 
analyzed as markers of islet autoimmunity from venous blood samples obtained at clinical visits every 
3–12 months. 
 
To assess the dynamics of islet autoantibodies in childhood, the first 1006 DIPP children (53.0% 
boys) born in 1994–1997 were followed from birth up to 15 years of age (Study I). In this study, 
ZnT8A had been analyzed from all samples available. In Studies II and III, a population of 7410 DIPP 
children (52.6% boys) was followed from birth for a median time of 16.2 years in order to identify 
genetic, immunological, and demographic characteristics of rapid and slow progression to type 1 
diabetes. Multiple non-HLA single-nucleotide polymorphisms (SNPs) predisposing to type 1 diabetes 
were analyzed for potential associations with the progression rate. No data on ZnT8A were available 
for the study population in Studies II and III. 
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Results 
 
Among the 1006 DIPP children, the ICA seroconversion rate increased during the first 15 years, but 
the biochemical autoantibodies showed age-dependent decreasing seroconversion rates. In young 
children, IAA and ZnT8A appeared commonly as the primary autoantibodies, but in preschool years, 
IA-2A and especially GADA-initiated autoimmunity became common. One frequent phenomenon, 
loss of IAA positivity, indicated delayed progression from seroconversion to diagnosis compared 
with steady IAA positivity (median delay 8.2 vs. 3.4 years; P=0.01). 
 
Among the 7410 DIPP children, 42 (16.9% of progressors) progressed to type 1 diabetes rapidly, 
within 1.5 years from seroconversion. Relative to slower progressors, the rapid progressors had a 
higher frequency of positivity for multiple (≥2) autoantibodies, higher titers of ICA, IAA, and IA-2A 
at seroconversion, and a higher prevalence of the homozygous FUT2 secretor genotype and the high-
risk HLA-DQB1*02/*03:02 genotype. Rapid progression occurred in both young (age <5 years) and 
early pubertal children (age >7 years), resulting in a double-peak profile in seroconversion age. The 
young rapid progressors were characterized by IAA positivity and high IAA titers at seroconversion, 
while in the older subgroup GADA positivity and high GADA titers were frequent. Slow progressors 
were distinguished from other progressors by lower titers of ICA and IAA, and lower rate of positivity 
for IA-2A and multiple autoantibodies at seroconversion. Appearance of multiple autoantibodies was 
delayed among slow progressors. Season of birth differed between slow and other progressors. Slow 
progressors (n=62, 25.1%) were born more often in the fall than other progressors (31% vs. 22%), 
while the other progressors tended to be born more often in the spring (31% vs. 15%). No significant 
differences emerged in the non-HLA SNP distributions between slow and other progressors after 
correction for multiple testing. 
 
Conclusions 
 
This thesis presents a detailed prospective description of the dynamics of islet autoantibodies during 
the first 15 years in HLA-susceptible children from the Finnish pediatric population. It also provides 
the first combined characterization of genetic, immunological, and demographic factors associated 
with both rapid and slow progression from seroconversion to type 1 diabetes. This was the first study 
to systematically assess the role of ZnT8A in the context of preclinical autoantibody testing used for 
prediction of type 1 diabetes. 
 
Novel findings in this thesis were the double-peak profile of seroconversion age among rapid 
progressors to type 1 diabetes, the variation in the seasonality of birth among progressors to type 1 
diabetes, the association of the FUT2 SNP with rapid progression, and the early appearance of ZnT8A 
in young children. This study demonstrated that rapid progressors differ from slower progressors by 
genetic, immunological, and demographic factors present at seroconversion. Depending on age, the 
immunological characteristics of rapid progressors are diverse, suggesting that triggers of aggressive 
islet autoimmunity may be heterogeneous. 
 
As expected, the primary islet autoantibody turned out to be highly characteristic of age. This 
highlights the existence of more than one endotype of islet autoimmunity and suggests that age and 
the stage of immunological maturation contribute substantially to the characteristics of beta-cell 
autoimmunity. The stability of islet autoantibodies might affect the risk for type 1 diabetes. The 
findings in this thesis improve the estimation of preclinical diabetes risk and the timing of disease 
onset, providing a clinically valuable framework for individualizing the efforts to delay or prevent 
type 1 diabetes. As soon as a safe and reliable preventive measure is available, the discoveries now 
made can be utilized to apply these methods to suitable populations at risk.  
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ABBREVIATIONS 
 
ABCD Autoimmune Beta Cell Disorder 
AIDA Anti-Interleukin-1 in Diabetes Action 
AIRE Autoimmune regulator 
APC Antigen-presenting cell 
BCR B-cell receptor 
BMI Body mass index 
CD Cluster of Differentiation; attached number indicates the cluster, e.g. CD4 
CI Confidence interval 
COVID-19 Coronavirus disease 2019 
CXCR5 C-X-C chemokine receptor type 5 
DAISY Diabetes Autoimmunity Study in the Young 
DASP Diabetes Autoantibody Standardization Program 
DEFEND-1 Durable Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes 
DENIS Deutsche Nicotinamide Intervention Study 
DIAPREV-IT Diabetes Prevention – Immune Tolerance 
DIPP Type 1 Diabetes Prediction and Prevention 
DPT-1 Diabetes Prevention Trial—Type 1 
EBI2 Ebstein-Barr virus-induced G protein coupled receptor 
ENDIT European Nicotinamide Diabetes Intervention Trial 
ER Endoplasmic reticulum 
FDR First-degree relative 
FOXP3 Forkhead box P3 
FPIR First-phase insulin response 
FUT2 1,2-α-Fucosyltransferase 
GABA γ-aminobutyric acid 
GAD Glutamic acid decarboxylase 
GADA Autoantibodies to glutamic acid decarboxylase 
GPR183 G-protein coupled receptor 183 
GWAS Genome-wide association study 
HbA1c Glycated hemoglobin 
HLA Human leukocyte antigen 
HR Hazard ratio 
IAA Autoantibodies to insulin 
IASP Islet Autoantibody Standardization Program 
IA-2 Islet antigen-2 
IA-2A Autoantibodies to islet antigen-2 
IA-2β Islet antigen-2 beta 
ICA Islet cell antibodies 
IDDM Insulin-dependent diabetes mellitus 
IFN-γ Interferon-γ 
Ig Immunoglobulin; attached letter indicates the subtype, e.g. IgA 
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IGF Insulin-like growth factor; attached number indicates the subtype, e.g. IGF1 
IGT Impaired glucose tolerance 
IKZF4 IKAROS family zinc finger 4 
IL-2 Interleukin-2 
IL-6 Interleukin-6 
INIT-II Intranasal Insulin Trial II 
INS Insulin gene 
JDFU Juvenile Diabetes Foundation Unit 
JDRF Juvenile Diabetes Research Foundation 
LD Linkage disequilibrium 
LYP Lymphoid tyrosine phosphatase 
NA Not available 
NOD Non-obese diabetic 
NS Non-significant  
OGTT Oral glucose tolerance test 
OR Odds ratio 
Pc Corrected P-value 
PCR Polymerase chain reaction 
PD-1 Programmed cell death protein 1 
PHTF1 Putative homeodomain transcription factor 1 
PPV Positive predictive value 
Pre-POINT Primary Oral Insulin Trial 
PTPN22 Protein tyrosine phosphatase, non-receptor type 22 
RNA Ribonucleic acid 
RU Relative unit 
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 
SLC30A8 Solute carrier family 30 member 8 
SNAIL Slow or Nonprogressive Autoimmunity to the Islets of Langerhans 
SNP Single-nucleotide polymorphism 
T1D Type 1 diabetes 
T1DAL Inducing Remission in New-Onset Type 1 Diabetes with Alefacept Study 
TCR T-cell receptor 
TEDDY The Environmental Determinants of Diabetes in the Young 
Th17 T helper 17 
TRIGR Trial to Reduce IDDM in the Genetically at Risk 
UPR Unfolded protein response 
VDJ VDJ recombination, a mechanism of somatic recombination in developing 
lymphocytes during which T- or B-cell receptor gene segments are randomly 
recombined; variable (V), diverse (D), joining (J) segments 
VIGR Viruses in the Genetically at Risk 
VNTR Variable number tandem repeat 
ZnT8 Zinc transporter 8 
ZnT8A Autoantibodies to zinc transporter 8 
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INTRODUCTION 
 
Type 1 diabetes is a chronic autoimmune-mediated endocrine disorder characterized by the 
progressive loss of insulin-producing beta cells in the pancreas. When a critical proportion of beta 
cells is destroyed, the patient becomes permanently insulin-deficient and reliant on exogenous insulin 
treatment. 
 A rapid rise in the incidence of type 1 diabetes in developed countries over the past decades has 
created the need for novel means of preventing or delaying the onset of clinical type 1 diabetes (1). 
The increase in the incidence has been reported to be especially rapid in young children, which has 
raised suspicions of the role of aggressive autoimmune responses and the failure of self-tolerance 
mechanisms in children (2). Type 1 diabetes causes an excessive burden on affected individuals and 
their families and puts a strain on the healthcare system and society. Children with type 1 diabetes 
have increased mortality and risk of cardiovascular comorbidity compared with the general pediatric 
population (3, 4). Therefore, it is obvious that studies on the etiology, pathogenesis, and prediction 
and prevention of type 1 diabetes are urgently needed. 
 Type 1 diabetes is a heterogeneous disease (5). The disease begins with an asymptomatic period 
of highly variable duration during which autoantibodies against beta-cell structures usually appear 
into the circulation of prediabetic individuals and can be interpreted as a sign of ongoing beta-cell 
damage (6). Towards the advanced stages of the process, disturbances in glucose metabolism become 
more common as the beta-cell destruction proceeds. 
 However, not all genetically susceptible children with islet autoantibodies progress to clinical 
disease (7). At present, the most reliable and attainable strategies to identify individuals at risk for 
type 1 diabetes are based on screening for type 1 diabetes-associated HLA genotypes and preclinical 
islet autoantibody profiles (8). Despite substantial research efforts, screening for genetic and 
autoantibody markers has remained a rather poor tool for predicting the onset of clinical disease if no 
metabolic assessments are performed. The heterogeneous duration of the prediabetic phase suggests 
that, in addition to genetic factors, environmental elements modify the pace of the disease 
progression. 
 This thesis aims at improving the early prediction of type 1 diabetes and the timing of its onset 
by characterizing genetic, immunological, and demographic factors associated with both rapid and 
slow progression to type 1 diabetes and by identifying dynamics of the most common islet 
autoantibodies during the first 15 years in HLA-predisposed children recruited from the general 
population.  
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REVIEW OF THE LITERATURE 
 
 
HISTORY AND CLASSIFICATION OF DIABETES 
 
Diabetes mellitus comprises a heterogeneous group of metabolic diseases with the common 
characteristic of hyperglycemia. Depending on the form of diabetes, the hyperglycemia is caused by 
defective insulin secretion, impaired insulin action on target tissues, or both. The classical symptoms 
of hyperglycemia include increased urination, thirst, weight loss, and fatigue. Untreated diabetes can 
lead to acute life-threatening complications, most importantly diabetic ketoacidosis. In long-term 
diabetes, secondary complications often arise (9). Patients with diabetes have increased risk of 
cardiovascular diseases and increased mortality (3, 4). Although several forms of diabetes exist, most 
cases can be classified into one of two main etiopathogenic categories, type 1 or type 2 diabetes (9). 
 Type 1 diabetes is a chronic endocrine disorder usually diagnosed in children and adolescents, 
but it can develop at any age. The disease is characterized by immune-mediated destruction of insulin-
producing beta cells in the pancreatic islets of Langerhans, eventually resulting in almost total 
deficiency of endogenous insulin production (9). 
 Throughout history, type 1 diabetes has been recognized as a condition in which the affected 
person urinates excessively and loses weight, with the urine having the sweet taste of honey or sugar 
(10). Descriptively, the term diabetes originated from the Greek word ‘diabetes’, which means ‘to 
siphon’ or ‘to pass through’, referring to increased urination (11). Before the discovery of exogenous 
insulin therapy, the life expectancy of a patient with type 1 diabetes was poor, and the disease was 
generally considered deadly. 
 In 1889, an observation was made that the removal of the pancreas from dogs caused fatal 
diabetes, which indicated for the first time the role of the pancreas in diabetes (12). The islets of 
Langerhans were first discovered already in 1869 by Paul Langerhans, who noted that two types of 
cell populations exist in the pancreas, the first secreting the regular pancreatic juice and the other 
having an unidentified function (13). Later, in 1907, these cell clusters of unknown properties were 
given the name islets of Langerhans, and, eventually in 1921, experiments on pancreatic extracts of 
dogs resulted in the discovery of insulin and the successful treatment of the first type 1 diabetes 
patient with insulin (14). The heterogeneity in the etiopathogenesis of diabetes was not, however, 
recognized until in 1951. The observation that not all patients with diabetes were insulin-deficient led 
to the categorical discrimination between insulin-dependent type 1 and non-insulin-dependent type 2 
diabetes (15). The association of autoimmunity with type 1 diabetes was discovered in the 1970s, 
when the first diabetes-associated autoantibodies, islet cell antibodies, were described (16). Since 
then, the discovery of autoimmunity behind type 1 diabetes has paved the way for a series of 
fundamental advances in the study of the disease pathogenesis, many of which are introduced in the 
following sections. 
 
 
EPIDEMIOLOGY OF TYPE 1 DIABETES 
 
Globally, over 1.1 million children and adolescents under the age of 20 years have been diagnosed 
with type 1 diabetes and the disease incidence continues to rise at an annual rate of 3.4%, calling for 
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effective preventive measures (1, 17). Type 1 diabetes was a relatively rare disease until the 1950s, 
after which the incidence started to increase in many countries at the same time (18). The increase in 
the incidence has been especially rapid among children under the age of 5 years and in countries that 
previously had a low incidence (19). Finland has the highest incidence of type 1 diabetes in the world 
(1). Overall, the incidence is high in developed countries, and low in low-income countries with a 
poor standard of living. The increase in the incidence rate has been similar in boys and girls in the 
age groups 0–4 and 5–9 years, but in the age group 10–14 years the rate has been higher in boys than 
in girls (1). 
 In the 1990s, the incidence of type 1 diabetes in Finland was estimated to increase to 50/100 
000 by 2010 (19, 20). However, the highest incidence was observed already in 2006, reaching 65/100 
000 new cases per year (21). By the end of 2011, the incidence rate of type 1 diabetes in the Nordic 
countries had reached a phase of plateau, showing no subsequent increases (1, 21, 22). Interestingly, 
some studies have reported cyclic variation in the incidence of type 1 diabetes, but the evidence for 
this phenomenon is inconsistent (1). 
 The high incidence of type 1 diabetes in young children calls for innovative means for 
preventing or delaying the onset of the clinical disease. Genetic factors alone do not explain the rapid 
increase in type 1 diabetes, and thus, environmental etiologies or epigenetic factors are likely to 
contribute to the disease pathogenesis. This is also evident from studies on type 1 diabetes among 
monozygotic twins and immigrants (23–25). The decreasing age at the diagnosis of type 1 diabetes 
has raised questions of whether this is due to more aggressive autoimmune responses, dysregulation 
of immunological maturation, or defects in the mechanisms sustaining self-tolerance (2). 
  
 
THE IMMUNE SYSTEM 
 
Innate immunity 
 
The mammalian immune response undergoes three phases in the following order: the immediate 
innate immune response, the induced innate defenses, and the adaptive immune responses. 
Accordingly, the innate immune system forms the first line of defense against invading microbial 
pathogens in the human body. 
 The primary role of the innate immune system is to localize the site of infection and to keep the 
infection from spreading until an adaptive immune response is established. The immediate innate 
immunity comprises relatively simple mechanisms that are identical to any given pathogen and are 
constantly prepared to fight an invading microbe. 
 First, the physical and chemical barriers on epithelial and mucosal surfaces resist microbial 
colonization and invasion through several mechanisms (26). Second, the complement system consists 
of a range of plasma proteins involved in three pathways of cleavage reactions that facilitate the lysis 
or phagocytosis of invading pathogens (27). 
 Innate immune cells express multiple receptor systems that recognize diverse microbial 
structures. Based on the wide repertoire of receptors, such as pattern recognition receptors, these cells 
mediate rapid elimination of pathogens through phagocytosis, but induce also longer 
proinflammatory responses (28). Activation of cytokine production leads to recruitment of immune 
cells to the infection site, and promotes the initiation of the adaptive immune response by guiding 
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antigen-presenting cells (APCs) to lymphoid tissues (29). If the innate immune mechanisms fail to 
eradicate the infection, the recruitment of the adaptive immune system has already started. 
 
Adaptive immunity 
 
Whereas the innate immune response remains identical from one pathogen to another, the adaptive 
immune system communicates through an exquisite antigen-epitope recognition system and is 
capable of conducting highly specific and targeted responses to nearly any given pathogen. This 
ability results from a virtually indefinite repertoire of antigen-specific lymphocyte receptors unique 
to each lymphocyte and generated through random recombination of receptor gene segments and 
combinations of variable protein chains; heavy and light chains in the case of immunoglobulins and 
two chains (mostly α and β chains) in the case of T-cell receptors (TCRs). The adaptive immune 
response is characterized by high antigen-specificity and sensitivity achieved through the selection 
and amplification of the most antigen-specific lymphocyte clones in the process of clonal expansion. 
 
Cell-mediated immunity 
 
Cell-mediated immunity comprises adaptive immune responses that require cell-to-cell contact and 
involve T cells. Humoral immunity refers to immune responses that are mediated through the actions 
of immunoglobulins, produced by B cells. Naïve T and B cells awaiting activation are strictly 
organized into particular zones in the lymphoid tissues. This organization is regulated by chemokines 
and facilitates the interaction of naïve lymphocytes with APCs and with each other (30). 
 Activation of naïve T lymphocytes requires antigen presentation by APCs in a peptide-human 
leukocyte antigen (HLA) complex (31). The main APCs are dendritic cells, B lymphocytes, and 
macrophages. After primary activation, the T cells undergo clonal expansion and evolve into effector 
cells that are capable of efficiently invading the pathogen. The type of effector function that the T 
cell gains during clonal expansion is determined by the surrounding cytokine environment. Effector 
T cells orchestrate virtually the entire entity of effector mechanisms in the innate and adaptive 
immune response (32, 33). After acquiring effector function, the T cell can react to any cell that 
presents their cognate antigen independently of costimulation. 
 The effector functions of T cells are mediated by the actions of cytokines and the binding of 
membrane-associated effector molecules to their specific receptors. Cytotoxic CD8 T cells release 
prestored cytotoxins into the target cell and secrete interferon-γ (IFN-γ) that inhibits viral replication. 
IFN-γ causes hyperexpression of HLA class I molecules on the surface of virus-infected cells (34). 
Another event mediating function of cytotoxic T cells might be the binding of membrane-bound Fas 
ligand to Fas on the target cell, which induces apoptosis. 
 The predominant TCR consists of two protein chains, the TCRα and TCRβ. TCRs are 
structurally highly variable molecules that are cell surface-bound and unable to bind unprocessed 
antigens. Instead, they recognize the combination ligand of a peptide-self HLA complex. Each TCR 
is restricted to a specific peptide-HLA combination. In addition, T cells respond to this complex only 
if the same APC bears costimulatory molecule B7 on its surface to pair with CD28 molecule on the 
T cell (35). This double requirement for T-cell activation prevents the naïve T cells from turning 
autoreactive towards self-tissues, which do not express the required costimulatory molecules. 
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 Two classes of HLA molecules exist, defined by their binding to either costimulatory molecule 
CD8 or CD4 on the T cell. Accordingly, the two functional classes of α-β T cells are HLA-restricted. 
Only CD8-positive T cells bind to peptides presented on a peptide-HLA class I complex, while only 
CD4-positive T cells bind to peptide-HLA class II complex (35). 
 
Humoral immunity 
 
B cells are responsible for the production of antibodies, which function in immune defense via several 
mechanisms. These include neutralization of pathogens by blocking their ability to bind to host 
receptors and the activation of the classical pathway of the complement system. Immunoglobulins 
(Igs) are found in both soluble and membrane-bound forms as B-cell receptors (BCRs) on the B-cell 
surface. 
 Several functionally different antibody isotypes exist, namely the classes IgG, IgM, IgA, and 
IgE. The effector action of a certain isotype is defined by the structure of the Ig Fc region (non-
antigen binding site), which binds to Fc receptors on immune cells (36). However, the overall Ig 
structure is similar for all isotypes. Igs are Y-shaped molecules that comprise two identical heavy 
chains and two identical light chains. Each chain exhibits a constant (C) region and a variable (V) 
region, the latter of which contributes to the antigen-binding site. Each Ig molecule contains two 
antigen-binding sites, which promotes higher avidity of antigen binding and enables cross-linking of 
antigens (37). The BCR is unique to each B cell, and this variability is achieved through the process 
of VDJ recombination. Gene segments of the Ig V region are randomly combined to produce a unique 
nucleotide sequence that can be successfully translated into a protein (38). 
 Naïve B cells reside in the secondary lymphoid tissues awaiting activation. Although some 
thymus-independent non-peptide antigens can induce antibody production in the absence of T cells, 
most Ig production is T-cell-dependent. Therefore, B-cell activation requires binding of the specific 
antigen to the BCR and additional B-cell interaction with the cognate CD4 helper T cell in a process 
called linked recognition (39). B cells are APCs and present their antigens to CD4 helper T cells on 
a peptide-HLA class II complex. 
 After activation, a proportion of B cells become short-lived plasmablasts, while the rest move 
to the germinal center of the secondary lymphoid tissue to undergo somatic hypermutation and Ig 
class switching. In the germinal center reaction, the proliferation and clonal expansion of B cells is 
controlled by follicular CD4 helper T cells and relies on T-cell stimulation by cytokine release and 
through the binding of the CD40 ligand (T cells) to CD40 (B cells). During somatic hypermutation, 
the Ig genes in B cells undergo random point mutations across the Ig V region, resulting in antibody 
affinity maturation. Consequently, B cells producing the highest affinity antibodies become selected 
for survival and transform into long-lived antibody-secreting plasma cells or memory B cells. Ig class 
switching results from recombination of the Ig gene C region, which leads to an increased range of 
the functional properties of antibodies reacting to the same antigen specificity (40). 
 During infection the T-cell-dependent Ig production begins with IgM class antibodies, 
thereafter rapidly spreading to other Ig isotypes. The first-produced IgM class antibodies are of low 
affinity, but are efficient in the activation of the complement system. Natural antibodies produced in 
the absence of infection are of IgM class. IgG class antibodies, in turn, exhibit higher affinity to 
antigens and persist long after acute infection. IgA and IgE are especially important in immune 
defenses below epithelial body surfaces. 
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Immunological memory 
 
A unique feature of the adaptive immune system is immunological memory against encountered and 
successfully eradicated pathogens. After primary infection, subsets of memory B and T cells persist 
upon cytokine survival signals (41, 42). Upon re-encounter with the same antigen, these cells are able 
to utilize their immunological memory to provide aid to naïve lymphocytes. As a result, secondary 
and later infections by the same antigen rapidly lead to production of high affinity antibodies and 
efficient elimination of the pathogen. 
 
Mucosal immune system 
 
The constant exposure to foreign antigens in mucosal tissues, including the intestinal mucosa, sets a 
challenge for the immune system to initiate appropriate adaptive immune responses to pathogens, 
while remaining unresponsive towards food antigens and commensal microbes. This is achieved by 
several functional characteristics that distinguish the mucosal immune system from other lymphoid 
tissues (reviewed in 43). Once oral tolerance to a certain antigen is acquired, it ideally leads to 
suppression of all systemic immune responses to this antigen (43). Because of the need to balance 
between protective immunity and tolerance, the intestinal mucosa is virtually always in a state of 
physiological inflammation. The final selection between tolerance and elimination is determined by 
the degree of inflammation in the environment of APCs before antigen presentation to naïve T cells 
(44). 
 
Central and peripheral tolerance 
 
Cells of lymphoid lineage, including B and T cells, are derived from multipotent hematopoietic stem 
cells. B lymphocytes mature in fetal liver and after birth in bone marrow, while T lymphocytes 
originate from fetal liver and bone marrow, but undergo maturation in the thymus. 
 Both BCRs and TCRs are generated in a highly similar process of VDJ recombination. In B 
cells, the heavy chain is rearranged first, then the light chain, and if a complete BCR is formed, the 
immature B cells undergo tolerance to self-antigens (45). Many autoantigens are highly tissue-
specific and are not available in the bone marrow or in the circulation. Thus, high numbers of 
immature self-reactive B cells are released into the circulation, and if activated, they must be 
eliminated or inactivated. The mechanisms of peripheral tolerance include deletion, anergy, and 
survival. First, autoreactive B cells that encounter a strongly cross-linking antigen without the 
presence of infection undergo directly clonal deletion and apoptosis. Second, under exposure to high 
amounts of antigen, the B cells become unresponsive. Third, immature B cells compete for entry into 
the B-cell follicles of the spleen, where the follicle provides signals for B-cell survival. In this process, 
the B-cell-activating factor belonging to the TNF family (BAFF) plays a crucial role. 
 The precursors of T cells migrate from the bone marrow to the thymus, where their development 
is directed to one of multiple T-cell lineages (46). In maturing thymocytes, the β-chain of the TCR 
undergoes rearrangement first, whereafter the α-chain is rearranged, and the thymocyte begins 
expressing both CD4 and CD8 costimulatory molecules. The double-positive thymocytes that have 
carried out successful TCR rearrangement enter the phase of positive selection. Cells whose receptors 
respond to self-peptide–self-HLA complex become selected and mature to either CD4 or CD8 single-
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positive cells. These thymocytes then undergo negative selection during which too autoreactive cells 
are deleted. Negative selection is orchestrated by bone marrow-originated APCs and autoimmune 
regulator (AIRE) -expressing cells in thymic medulla. Mature T cells resulting from positive and 
negative selection are HLA-restricted (CD4- or CD8-positive) and tolerant towards autoantigens (47). 
Since not all autoantigens are expressed in the thymus, a proportion of autoreactive T cells is released 
into the periphery. This population escaping central tolerance is controlled by mechanisms of 
peripheral tolerance, including activation-induced cell death, anergy, and tolerance-inducing signals 
mediated by the lack of costimulatory signaling in the absence of infection. 
 
Autoimmunity 
 
Since autoreactive lymphocytes are always present in the immunological repertoire, mechanisms of 
peripheral tolerance are necessary to control responses to autoantigens (48). This is ensured by 
populations of FOXP3 regulatory T cells and induced regulatory T cells that are able to suppress 
activated weakly autoreactive cells. Lymphocytes are also per se prone to apoptosis, causing the 
immune response to favor self-restricting. 
 Should the tolerance mechanisms fail, autoreactive lymphocytes may respond to self-antigens. 
By definition, autoimmunity is mediated by components of the adaptive immune system that cause 
self-tissue damage such as autoreactive lymphocytes, cytokines, and autoantibodies. Although self-
reactive T cells are the main mediators in this process, B cells are also pivotal by providing continuous 
support to T cells and by enabling epitope spreading over the course of the immune response (49). 
 Genetic factors, particularly HLA class II molecules, but also several polymorphisms and 
mutations of other genes have been associated with many autoimmune conditions. However, the 
dilemma that many genetically susceptible individuals remain unaffected by autoimmune diseases 
has highlighted the contribution of environmental factors to autoimmunity. Molecular mimicry has 
been proposed to play a role in autoimmunity. According to this hypothesis, drugs, toxins, or foreign 
pathogens containing highly similar molecules to self-structures might induce autoimmune responses. 
Pathogens might promote autoimmunity by causing local inflammation and nonspecific tissue 
damage, triggering the so-called bystander activation of autoreactive lymphocytes (50). 
 
 
PATHOGENESIS OF TYPE 1 DIABETES 
 
The prediabetic disease process 
 
Symptomatic type 1 diabetes is preceded by an asymptomatic period, during which autoantibodies 
against several islet antigens can be detected in the circulation of prediabetic individuals (6). The 
length of this period has been observed to vary from only a few months to more than two decades 
(6). The highly variable duration of the prediabetic process suggests that individual genetic, 
immunological, or environmental factors might modify the pace of the disease progression. 
 The prediabetic disease process often starts early in life, with the autoantibody seroconversions 
peaking already during the first or second year of life (51, 52). This indicates that the triggering events 
of islet autoimmunity and type 1 diabetes occur in infancy or during the fetal period in such cases. 
The disease may also begin at an older age or in adulthood, but the mechanisms leading to adult-onset 
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type 1 diabetes are not completely understood and may differ from those causing juvenile diabetes. 
This thesis focuses on beta-cell autoimmunity in children and adolescents. 
 A model has been proposed to illustrate the early stages of type 1 diabetes (Figure 1). In this 
model based on increased genetic risk, stage 1 is defined as the appearance of islet autoantibodies, 
stage 2 as dysglycemia, and stage 3 as symptomatic type 1 diabetes (53). The asymptomatic phase of 
type 1 diabetes has been proposed to be given the nomenclature ’Autoimmune Beta Cell Disorder’ 
(ABCD) to emphasize the current view that type 1 diabetes is primarily an immune-mediated disease 
and only secondarily a metabolic disease (54). 
 Beta-cell destruction in type 1 diabetes is considered to be a primarily T-cell-mediated process. 
Islet autoantibodies are considered to merely reflect the disease activity rather than being active 
players in the pathogenesis. As markers of islet autoimmunity, however, they are suitable for disease 
prediction. The most commonly used autoantibodies for this purpose are islet cell antibodies (ICA), 
insulin autoantibodies (IAA), autoantibodies to glutamic acid decarboxylase (GADA), autoantibodies 
to protein tyrosine phosphatase family member islet antigen-2 (IA-2A), and autoantibodies to zinc 
transporter 8 (ZnT8A). The characteristics of these autoantibodies are introduced in the following 
sections. 
 The appearance of islet autoantibodies does not indicate the extent of beta-cell destruction (55). 
However, some evidence has supported a more active role for humoral beta-cell autoimmunity in the 
disease process (56). Also other views on the disease pathogenesis have recently been challenged. 
Traditionally, it has been believed that 85-95% of beta cells are destroyed at the onset of symptomatic 
type 1 diabetes and that the rest of the beta cells are permanently lost during a couple of years after 
diagnosis. Studies on pancreatic islets have, however, indicated that in some patients the remaining 
proportion of beta cells is significantly higher (57). This has raised questions of whether the severe 
symptoms of hyperglycemia often observed in overt type 1 diabetes originate from mechanisms other 
than explicit beta-cell destruction such as cellular stress or dysfunction, inflammation, or other 
immunological mechanisms. This idea is supported by the considerable heterogeneity in residual 
beta-cell function among patients with long-duration type 1 diabetes (58, 59). 
 Considering the pace of the progression from the prediabetic phase to clinical type 1 diabetes, 
it has been proposed that rapid progression might derive from a congenital defect in the regulation of 
beta-cell mass, and that individuals with higher beta-cell mass in the early years might present with 
slower disease progression (57). The human beta-cell mass is established by the age of 5 years, while 
beta-cell proliferation peaks during the first two years of life, and beta-cell replication in infancy is a 
substantial determinant of beta-cell mass in later life (60, 61). 
 According to the so-called ”stress test hypothesis”, the duration of the prediabetic period might 
be defined by three aspects: 1) the original quantity of beta-cell mass during early life, 2) the 
aggressiveness of beta-cell loss during the prediabetic process, determined by the functional capacity 
of beta cells, the ability of beta cells to survive the immune attack, and the individual genetic, 
epigenetic, immunological, or environmental factors capable of modifying the pace of the disease 
progression, and 3) the critical beta-cell mass that is no longer able to maintain sufficient insulin 
production and drives the disease process over the edge towards the manifestation of symptomatic 
type 1 diabetes (57). 
 An overview of the current understanding of the pathogenesis of type 1 diabetes is presented in 
the following sections. 
 
 
 
Figure 1. Stages of progression to type 1 diabetes and the factors determining the progression rate in the light of the ”stress test” hypothesis. 
Immunological dysregulation is an early phenomenon operating already at the beginning of Stage 1. Modified from (53) and (57). 
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Cell-mediated autoimmunity in type 1 diabetes 
 
Type 1 diabetes is considered to be a T-cell-mediated disease. This is supported by several findings. 
First, T cells, predominantly CD8 T cells, are found in insulitic lesions of the pancreatic islets (62, 
63). Second, hyperexpression of HLA class I molecules in beta cells positive for insulitis suggests 
direct peptide presentation of beta-cell autoantigens to infiltrating cytotoxic T cells (62–66). Third, 
several studies have demonstrated the presence of self-reactive T lymphocytes in patients with type 
1 diabetes (67–70). Finally, the administration of immunomodulatory therapy affecting the function 
of T cells has delayed the disease progression in clinical trials (71, 72). 
 Genetically, the strongest risk for type 1 diabetes is associated with HLA class II genes. 
Therefore, it might be expected that the autoimmune response is initially driven by a peptide antigen, 
and that CD4 T cells are involved in the process. Rather than through direct contact with the beta 
cells, CD4 T cells might cause beta-cell damage by cytokine secretion, by supporting autoantibody 
production, and by promoting the function of cytotoxic T cells (73). Yet, some beta cells of subjects 
with type 1 diabetes express HLA class II molecules, suggesting a direct interaction between beta 
cells and CD4 T cells in the affected islets (74). 
 Several alterations in CD4 T-cell subsets have been observed in patients with type 1 diabetes 
and prior to clinical disease (75–77). The frequency of follicular T helper cells is increased in children 
with multiple islet autoantibodies and impaired glucose tolerance (IGT) (77). Similarly, circulating 
CXCR5+PD-1hi peripheral T helper cells have been associated with progression to clinical disease 
(78). In the Type 1 Diabetes TrialNet study, distinct immune phenotypes of T and B cells were seen 
depending on the stage of disease progression (79). Also an attenuated cytokine response to IL-2, but 
an enhanced response to IL-6 in CD4 T cells might play a role (79–82). Changes in regulatory T-cell 
subsets might be related to more advanced stages of the disease process (83). 
 Recently, lymphocytes that expressed both BCRs and TCRs and the key lineage markers of T 
and B cells were discovered in the peripheral blood of patients with type 1 diabetes (84). Furthermore, 
some evidence has emerged for the role of neutrophils in the process. Reduced number of neutrophils 
in peripheral blood has been associated with worsening of the beta-cell function (85, 86). 
 
Insulitis, pancreatic size, and beta-cell properties 
 
Insulitis is a central phenomenon in the pathogenesis of type 1 diabetes. However, the proportion of 
simultaneously affected pancreatic islets at a given time is modest (87). Insulitis is more common in 
young children than adolescents, shows an inverse correlation with disease duration, and affects 
mostly pancreatic islets containing insulin (87–89). The criteria for insulitis have been defined as the 
infiltration of lymphocytes in the pancreatic islets of Langerhans with a count of at least 15 CD45 
cells within an islet and in at least three islets simultaneously (90). The insulitic lesion may contain 
both T and B lymphocytes, the cytotoxic CD8 T cells being the prevailing subset (89). Autoreactivity 
of the infiltrating CD8 T cells has been demonstrated (67). 
 A prominent feature of human type 1 diabetes is hyperexpression of HLA class I molecules in 
beta cells positive for insulitis (65, 66). Both the presence of insulitis and the hyperexpression of 
HLA class I molecules might indicate chronic islet inflammation (65). Signs of persistent enteroviral 
infection have, in fact, been detected in the pancreatic islets of living patients with type 1 diabetes 
(91). This suggests that CD8 T cells present in the insulitic lesion might recognize viral epitopes 
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derived from the infected beta cells of HLA class I molecules (67, 91). Furthermore, IFN-γ, a central 
cytokine in immune response against viral infections, has been shown to mediate the hallmarks of 
insulitis: HLA class I hyperexpression, beta-cell apoptosis, and endoplasmic reticulum (ER) stress in 
pancreatic islets (92). Heterogeneity in the features of insulitis exists since there are at least two 
distinct phenotypes of insulitis. They are characterized by either high or low frequency of CD20-
positive B cells in the insulitic lesion and are associated with a considerably different age at onset of 
clinical diabetes (64, 89, 93). 
 Considering the severe symptoms and deteriorated insulin secretion seen at diagnosis of type 1 
diabetes, insulitis findings present at diagnosis are relatively minor (87). Also the residual beta-cell 
mass and the proportion of surviving beta cells at diagnosis are higher than previously expected, 
suggesting that the severe hyperglycemia observed in many cases at diagnosis of diabetes might 
derive from mechanisms outside of direct beta-cell damage such as inflammation, cellular stress, or 
beta-cell dysfunction (94). Beta cells persist long after the onset of symptomatic disease and may be 
able to recover after damage or dysfunction (95). In several studies, type 1 diabetes cases have been 
described in which C-peptide production has been measurable after long disease duration, proposing 
an incomplete loss of beta cells (58, 59, 94). 
 How the surviving beta cells escape autoimmune destruction and whether their dysfunction is 
reversible are not yet fully understood. Most of the residual insulin secretion in type 1 diabetes might, 
in fact, derive from dedifferentiated beta cells or non-beta endocrine cells rather than from preserved 
beta cells (96–99). In any case, restoring the residual insulin production comprises a fascinating 
approach to prevention and treatment of type 1 diabetes. Apart from the honeymoon period shortly 
after diagnosis, there is no evidence of functional recovery of beta cells in established type 1 diabetes 
(94). Some remission of the beta cells might be possible close to the diagnosis (95). 
 Pancreatic size is diminished in type 1 diabetes (100). Interestingly, also autoantibody-negative 
first-degree relatives (FDRs) of patients with type 1 diabetes exhibit smaller pancreatic size than 
controls with no affected relatives (101). The appearance of islet autoantibodies does not imply the 
loss of beta-cell mass (55). 
 To summarize, insulitis as part of the pathogenesis of type 1 diabetes seems to be a chronic, 
and possibly heterogeneous condition that takes place in only a small fraction of pancreatic islets at 
a given time and continues years after onset of overt disease. However, as beta cells in type 1 diabetes 
seem to be preserved to a higher extent than previously thought, not all affected beta cells are 
necessarily under attack of the immune system. Beta-cell senescence may also play a role in the 
disease pathogenesis (102). 
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Humoral beta-cell autoimmunity 
 
Type 1 diabetes-associated autoantibodies 
 
Islet cell autoantibodies, ICA 
 
Islet cell antibodies (ICA) were the first described diabetes-associated autoantibodies (16, 103). They 
are analyzed by using a standardized immunofluorescence staining method on sections of frozen 
human pancreatic tissue (16). The ICA assay measures immunoglobulin (mostly IgG) binding on 
various structures of the pancreatic islets. Since the assay is labor-intensive and challenging to 
standardize and necessitates access to high-quality pancreatic tissue from organ donors, it has become 
tempting to replace ICA with biochemical autoantibodies for screening purposes. ICA are not beta 
cell-specific, but some of the reactivity is derived from other islet autoantibodies and also reactivity 
to unidentified antigens contributes to ICA reactivity (104, 105). The predictive characteristics of 
ICA have been extensively studied. Low ICA titers are widely detected in the general population and 
relatives of patients with type 1 diabetes with an increasing frequency in older subjects, suggesting 
that positivity for ICA in the absence of other autoantibodies represents non-progressive beta-cell 
autoimmunity (106, 107). In contrast, high ICA titers are associated with increased risk for type 1 
diabetes and are seen mostly in association with positivity for multiple biochemical autoantibodies 
(8, 108, 109). Positivity for ICA has been associated with female gender, the HLA-DR4-DQ8 
haplotype, and young age at disease onset (110). 
 
Autoantibodies against insulin, IAA 
 
Autoantibodies to insulin (IAA) were first described in 1983 in patients with recent-onset type 1 
diabetes (111). Among the islet autoantibodies, IAA appear often as the first or among the first 
autoantibodies (52, 112–114). In the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) 
study, seroconversions to IAA positivity peaked during the second year of life, while in The 
Environmental Determinants of Diabetes in the Young (TEDDY) study a peak was seen already 
during the first year (51, 52). Despite the early appearance during the disease process, IAA are rather 
unstable (112, 114, 115). Positivity for IAA has been associated with the HLA-DR4-DQ8 haplotype 
mediating increased risk for type 1 diabetes (116–118). Also several non-HLA gene polymorphisms 
have been associated with IAA positivity, including the insulin-encoding INS gene variable number 
tandem repeat (VNTR) polymorphism and single-nucleotide polymorphisms (SNPs) in the INS 
(rs689) and lymphoid tyrosine phosphatase-encoding PTPN22 genes (rs2476601) predisposing to 
type 1 diabetes (110, 119–121). In contrast, the predisposing SNP in the IKAROS family zinc finger 
4 (IKZF4) gene (rs1701704) has been inversely associated with IAA positivity (120). In young 
children, IAA have high sensitivity for predicting clinical type 1 diabetes (7, 112). High initial IAA 
titers increase the risk of progression to clinical disease (8, 51, 108). Recently, autoantibodies against 
a posttranslationally modified neoautoantigen, oxidized insulin, have been reported to improve the 
prediction of type 1 diabetes compared with autoantibodies against native human insulin (122). 
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Autoantibodies against glutamic acid decarboxylase, GADA 
 
The enzyme glutamic acid decarboxylase (GAD) catalyzes the synthesis of the neuroinhibitory 
transmitter gamma-aminobutyric acid (GABA) from glutamate and is a major autoantigen in type 1 
diabetes. Within the beta cell, the 65 kD isoform of GAD is localized in synaptic-like microvesicles. 
Autoantibodies against GAD (GADA) were first recognized as autoantibodies to a 64 kD cytosolic 
protein that was later identified as the 65 kD GAD protein (123, 124). There are two isoforms of the 
GAD protein with molecular weights of 65 and 67 kD, but only the former is expressed in the pancreas 
(125). Positivity for GADA has been associated with female gender and the HLA-DR3-DQ2 
haplotype predisposing to type 1 diabetes (110, 117, 126, 127). Polymorphisms in the IKZF4-ERBB3 
region (rs1701704, rs2292239) have been reported to affect the rate of beta-cell damage specifically 
among children with GADA as the primary autoantibody, and the predisposing BACH2 gene SNP 
(rs3757247) increases the risk of developing positivity for GADA only (128, 129). GADA are not 
specific for pancreatic islets and have been indicated to be associated with autoimmunity in general 
(118). Unlike high IAA or IA-2A titers, GADA titers do not increase the risk of type 1 diabetes among 
children with persistent islet autoantibodies (130). Also among siblings of affected children, GADA 
titers are not related to increased risk for type 1 diabetes, although the risk is increased in the presence 
of high levels of ICA, IAA, and IA-2A (131). At the diagnosis of type 1 diabetes, 65–68% of Finnish 
pediatric patients aged 0.01–16.0 years test positive for GADA (132, 133). After the diagnosis, 
GADA levels remain elevated longer than those of other islet autoantibodies (134). 
 
Autoantibodies against N-terminally truncated glutamic acid decarboxylase, truncated GADA 
 
A proportion of individuals with autoantibodies against the full-length GAD, comprising amino acid 
residues 1–585, do not progress to clinical type 1 diabetes. Therefore, it has become necessary to find 
more specific GADA assays. Autoantibodies against N-terminally truncated GAD, covering amino 
acids 96–585, have similar sensitivity, but are associated with a higher risk of type 1 diabetes than 
the full-length GADA among GADA-positive FDRs of patients with type 1 diabetes (135). This 
suggests that the truncated GADA might be beneficial in identifying participants for future 
intervention trials aimed at preventing type 1 diabetes. Among patients with adult-onset diabetes, 
truncated GADA positivity is associated with a clinical phenotype of autoimmune diabetes and 
predicts the need for insulin treatment (136). The initial GAD response is directed mostly to the M- 
and C-terminal epitopes of the GAD protein in progressors to type 1 diabetes, whereas immune 
responses to the N-terminal epitope do not increase the disease risk (137, 138). Epitope spreading 
during the GAD-specific autoimmune response has been demonstrated to occur from the middle 
region to both ends of the protein (139, 140). 
 
Autoantibodies against islet antigen-2, IA-2A 
 
Islet antigen-2 (IA-2) autoantibodies represent antibody reactivity against the intracellular part of the 
transmembrane protein islet cell antigen 512, which is a member of the family of protein tyrosine 
phosphatases. Islet antigen-2 was first identified as a protein fragment of molecular weight 40 kD, 
which among two other 50 kD and a 37 kD fragments resulted from proteolytic trypsin-mediated 
digestion of GAD (64 kD islet cell protein) (141–143). The 37 kD fragment was observed to be 
Review of the literature 
 25 
derived from a closely related transmembrane protein tyrosine phosphatase IA-2β (phogrin), which 
is also a major autoantigen in beta-cell autoimmunity and shares homology with the cytoplasmic 
domain of IA-2, but IA-2 is the primary autoantigen associated with type 1 diabetes (144, 145). 
 During islet autoimmunity IA-2A are often the last or among the last autoantibodies, but rarely 
the first autoantibody to appear (51, 112, 146). They are the most specific autoantibodies for 
predicting type 1 diabetes and are associated with a high risk of progression to clinical disease (112, 
147, 148). The disease risk associated with IA-2A is higher than that of GADA or IAA (7, 149). Early 
appearance of IA-2A in the prediabetic process is also associated with accelerated disease progression 
(150, 151). The appearance of IA-2A positivity has been associated with the DQB1*03:02/x genotype 
(x=other than DQB1*02 allele) (126, 132), and high IA-2A levels with the HLA-DR4 haplotype (118, 
152). High IA-2A levels increase the disease risk among persistently autoantibody-positive children 
(130). In young multipositive children, high IA-2A levels predict progression to clinical disease 
(153). In Finnish children between 0.01 and 16.0 years of age, the prevalence of IA-2A at diagnosis 
of type 1 diabetes is 75–79% (132, 133). 
 
Autoantibodies against zinc transporter 8, ZnT8A 
 
The cation efflux transporter zinc transporter 8 (ZnT8) is the most recently discovered autoantigen in 
patients with type 1 diabetes (154). The ZnT8 is primarily located in the islets of Langerhans, with 
the highest expression in beta cells, where it serves as the most abundant zinc transporter, participates 
in the regulation of zinc accumulation into insulin secretory granules, and is involved in insulin 
secretion (155, 156). Hexamers containing six insulin molecules together with two Zn2+ ions are 
stored in secretory vesicles in the beta cell (156). The ZnT8 molecule is a 369 amino acid polyepitopic 
transmembrane protein that contains cytoplasmic C- and N-terminal domains (154). 
 The ZnT8 protein is encoded by the SLC30A8 gene, which has been shown to affect insulin 
production (157). A SNP in the SLC30A8 gene that results in a modification in the protein amino acid 
sequence at position 325 has been associated with both type 2 (158) and type 1 diabetes (159). The 
ZnT8 autoantigen has three variants at amino acid position 325 determined by the SLC30A8 
polymorphism: ZnT8-R (arginine), ZnT8-W (tryptophan), and ZnT8-Q (glutamine) (160). 
Accordingly, ZnT8A against the C-terminal are amino acid-specific, and this epitope specificity is 
defined by the SLC30A8 genotype (161, 162). 
 At diagnosis of type 1 diabetes, ZnT8A positivity has been inversely associated with the HLA-
DR3-DQ2 haplotype and the DR3-DQ2/DR4-DQ8 genotype predisposing to type 1 diabetes (163–
165). However, the negative association of the DQ2 haplotype with ZnT8A is restricted to ZnT8WA 
(tryptophan) and ZnT8QA (glutamine), but not ZnT8RA (arginine) (165). Both DQ8 (without DQ2) 
and DQ6.4 (without DQ8 or DQ2) haplotypes have been associated with ZnT8A regardless of the 
amino acid variant (165). The differences in the HLA associations might be related to distinct binding 
of DQ molecules to ZnT8 epitopes (166). The type 1 diabetes risk-associated HLA-DR3 and -DR401 
molecules bind to peptides derived from ZnT8 (167). An AGER gene polymorphism might also affect 
the frequency of ZnT8A positivity (164). 
 In type 1 diabetes, ZnT8 is a target antigen of IFN-γ-producing autoreactive T cells (167). A 
broad repertoire of ZnT8-derived peptides is recognized by CD8 T cells, which might suggest that 
epitope spreading along the ZnT8 protein occurs during the autoimmune response (168–170). 
Functional differences in ZnT8-specific T cells have also been found between patients with type 1 
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diabetes and non-diabetic individuals, and these autoreactive cells are abundant in the pancreas of 
subjects affected by type 1 diabetes (171). 
 In new-onset type 1 diabetes, ZnT8A are present in approximately 60–70% of patients (159). 
Accordingly, in Finnish children with type 1 diabetes at the age of 0.3–15.0 years the prevalence of 
ZnT8A at diagnosis is 63% (164). At diagnosis, ZnT8A positivity has been associated with reduced 
beta-cell function and higher rate of ketoacidosis, and after the diagnosis with higher insulin 
requirement (163). However, contradictory observations on the risk of ketoacidosis have also been 
reported in a study cohort comprising more recently born children (164). The combined measurement 
of ZnT8A with other biochemical autoantibodies improves the detection of islet autoimmunity (154, 
159, 172), although in the Finnish pediatric population tested at diagnosis the improvement was 
minimal (164). Altogether, ZnT8A have been considered to appear at an older age and in a later phase 
of the disease process than other islet autoantibodies, and are often detected together with ICA and 
IA-2A, but less frequently with simultaneous positivity for GADA or IAA at diagnosis (154, 159, 
163). After diagnosis, ZnT8A disappear more rapidly than GADA or IA-2A (154). ZnT8-targeted T-
cell responses are also attenuated shortly after diagnosis (170). 
 
Neoepitopes as targets of beta-cell autoimmunity 
 
An increasing body of evidence implies that neoepitopes formed by post-translational modification 
of self-proteins might be involved in the pathogenesis of type 1 diabetes as a target of autoreactive 
T-cell responses (173). In the future, such neoantigens might prove useful in the disease prediction. 
 
Spreading of the autoimmune response 
 
Epitope spreading is a frequent phenomenon during the prediabetic disease process and occurs 
already early in the process both within an autoantigen and from one autoantigen to another (139, 
144, 174). Whereas positivity for a single autoantibody does not confer any notable risk for type 1 
diabetes, the presence of two or more biochemically defined autoantibodies is associated with a 
highly increased risk (149). Epitope spreading to positivity for multiple autoantibodies develops 
usually within the first year after the initial seroconversion and rarely thereafter (146, 175). 
 
Epitope-specific humoral responses 
 
The disease risk associated with epitope-specific autoantibodies to the major autoantigens varies 
considerably. The middle and C-terminal epitopes of GAD are associated with increased risk for type 
1 diabetes, whereas the N-terminal GAD-epitope confers no risk for multipositivity or type 1 diabetes 
(176, 177). More specifically, the first 142 amino acids of GAD are not recognized by risk-associated 
autoantibodies (178). The initial GADA response is M-epitope-specific and spreads rapidly to the C-
terminal epitope, but rarely to the N-epitope (137, 139, 179). High GADA titers are associated with 
broader epitope reactivity (140). Autoantibody responses to the full-length GAD compared with the 
N-terminally truncated GAD are more common among healthy individuals than people with type 1 
diabetes, which might result from reduced presentation of two or more conformational epitopes by 
the N-terminally truncated GAD (180). Most IA-2A identify the cytoplasmic part of the IA-2 protein, 
whereas no reactivity has been detected towards the transmembrane or extracellular parts (181, 182). 
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In young children, IA-2A towards the juxtamembrane epitopes tend to appear first, before 
autoantibodies against the protein tyrosine phosphatase epitopes, and this type of response is 
characteristic of children who later progress to type 1 diabetes (183). The mature autoimmune 
response against ZnT8 occurs mostly against the C-terminal epitopes of the antigen (154). Patients 
with type 1 diabetes have single amino acid-specific autoantibodies against the ZnT8-R and ZnT8-
W variants, the latter of which might have higher affinity for their specific autoantigen than the former 
(162). However, ZnT8A comprise also a variety of responses to epitopes unaffected by the amino 
acid in position 325 (161). 
 
Isotype-specific humoral responses 
 
During the prediabetic period also switching of the immunoglobulin class within the same 
autoantigen takes place. At the diagnosis of type 1 diabetes, IAA are primarily of the IgG1 subclass 
and to a lesser extent IgG4 and IgG2 subclasses (184). In young children, the IAA-related risk for 
type 1 diabetes is mostly associated with the IgG1 subclass, followed by IgG4, IgG3, and IgG2 (185). 
Strong IgG1 and IgG3 subclass IAA responses increase the risk of type 1 diabetes, while weak or 
lacking IgG3 responses might mediate some degree of protection against the clinical disease (186). 
Similarly, GADA are mostly of the IgG1 subclass in both patients with type 1 diabetes and individuals 
at high disease risk (148, 187). Type 1 diabetes has been associated with IgG1, IgG2, and IgG3 
subclass GADA, while a broad early response to IgG3 and IgG4 might mediate a protective effect 
against overt disease (137). Also IgG2 and IgG4 subclass GADA responses tend to be more common 
among non-progressors than progressors, although no significant differences in the distributions have 
been reported (138). In the case of IA-2A, the humoral immune response comprises mainly IgG1 
subclass in both type 1 diabetes patients and prediabetic individuals (187). Non-diabetic children 
positive for IA-2A present more often with IgE class IA-2A and have higher titers of IgE class IA-
2A than those who develop clinical diabetes (183). Among children with recent-onset diabetes, those 
who test positive for IA-2A only out of three biochemical autoantibodies (IAA, GADA, IA-2A) 
demonstrate a broader IA-2 isotype-specific response and a stronger association with the high-risk 
HLA-(DR4)-DQB1*03:02 haplotype than those with all three biochemical autoantibodies (133). In 
conclusion, most diabetes-associated autoantibodies are composed mainly of IgG class, indicating 
that maturation of the humoral immune response has occurred. 
 
Autoantibody affinity 
 
In general, high-affinity antibodies are a sign of a mature humoral immune response. After 
encountering their specific antigen, B cells migrate to lymph nodes, where they undergo somatic 
hypermutation that allows them to produce high-affinity antibodies over the course of several months 
from the initial encounter with the antigen. In type 1 diabetes, high-affinity IAA increase the risk of 
clinical diabetes (188, 189). However, the affinity of IAA does not seem to affect the progression rate 
from seroconversion to clinical disease (190). Similarly, high affinity of GADA confers higher 
susceptibility to type 1 diabetes than low-affinity GADA (176). This may be related to the spreading 
of the autoimmune response because children positive for only GADA show lower affinity of GADA 
than those with multiple autoantibodies (176). High-affinity GADA is more common among children 
carrying the HLA-DR3 haplotype (176). 
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Transient autoantibodies  
 
Non-persistent positivity for islet autoantibodies has been considered to be a relatively uncommon 
phenomenon and has not shown any correlation with the identified genetic risk factors (115, 191, 
192). However, in children with increased HLA susceptibility to type 1 diabetes, transient positivity 
for IAA occurs frequently during the first two years of life (112). Persistent IAA has been associated 
with a higher risk of type 1 diabetes than fluctuating IAA (8, 130, 193), and there has been some 
evidence that transient autoantibodies might reflect the pace of the disease progression. In the 
BABYDIAB study, a lower proportion of primarily IAA-positive multipositive children who became 
IAA-negative had progressed to clinical diabetes in 10 years than children who remained IAA-
positive (194). In contrast, transient GADA positivity in the presence of persistent IAA and IA-2A 
positivity has been associated with more rapid disease progression than stable GADA (195). 
Reversion of multiple autoantibody positivity occurs rarely, but is associated with a reduced risk of 
progression to type 1 diabetes (196). 
 
Are autoantibodies only bystanders in the disease process? 
 
Finally, it has been under debate whether the humoral autoimmunity in the pathogenesis of type 1 
diabetes is only secondary to T-cell-mediated autoimmunity. Islet antigen-specific B cells are central 
in the development of islet autoimmunity and are likely to provide support to T cells in the process 
of beta-cell destruction. Accordingly, the involvement of autoreactive B cells indicates the failure of 
silencing mechanisms of immunological tolerance. The loss of anergic B-cell populations has, in fact, 
been associated with islet autoimmunity and progression to type 1 diabetes, proposing that events 
disrupting the B-cell anergy might cause deviation towards islet autoimmunity among individuals at 
genetic risk (197). Moreover, several disturbances of B-cell responses have been associated with islet 
autoimmunity and clinical diabetes in the TrialNet study, including a decrease in the frequency of 
anergic B cells in autoantibody-positive individuals, and decreased B-cell responses towards the 
progression to clinical disease (79). Most importantly, selective depletion of B cells in the rituximab 
trial resulted in delayed disease progression in newly diagnosed patients with type 1 diabetes (56). 
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ETIOLOGY OF TYPE 1 DIABETES 
 
Genetics 
 
Human leukocyte antigen (HLA) 
 
HLA structure and function 
 
HLA molecules are glycoproteins located on the cell surface that present peptide antigens derived 
from microbial pathogens and host tissues for recognition to T lymphocytes. HLA class I molecules 
are expressed in all nucleated cells, but expression of HLA class II molecules is limited to APCs. 
 Multiple genes encode HLA molecules, leading to a highly individualized repertoire of HLA 
molecules with different antigen-binding properties. The main HLA-encoding genes are located on 
the short arm of chromosome 6. In this region, there are three pairs of genes encoding HLA class II 
α- and β-chains, the HLA-DR, -DQ, and -DP, and three genes encoding class I α-chain, the HLA-A, -
B, and -C. The HLA-encoding genes are highly polymorphic with multiple variants of each gene 
found within a population, except for the non-polymorphic β-chain of HLA class I molecules, β2-
microglobulin, which is encoded outside the HLA region on chromosome 15. 
 Four types of HLA class II molecules can be formed from the three pairs of genes. The different 
HLA alleles, the DR and DQ loci in particular, are in strong linkage disequilibrium (LD) with each 
other. Haplotypes formed by the combinations of these alleles have been associated with several 
autoimmune conditions. 
 The HLA alleles differ in amino acid sequence, especially on the peptide-binding site and the 
regions exposed to cell surface that bind to TCRs (198). Therefore, each HLA molecule exhibits 
different binding specificity for peptide antigens and T-cell recognition is restricted to a specific HLA 
variant. This means that T cells are only able to recognize their TCR-specific antigen when it is bound 
to a particular HLA molecule. 
 The HLA gene polymorphisms determine the range of peptides bound by HLA molecules and 
the binding of the HLA-peptide complex to a certain TCR. This extensive variability enables a broad 
range of antigen recognition against invading pathogens and creates highly personalized immune 
responses — each individual responds differently to a given antigen. 
 
HLA class II effects on type 1 diabetes 
 
The inherited risk for type 1 diabetes is mostly determined by the HLA class II genes, mediating 
approximately 40–50% of the genetic risk for type 1 diabetes (199). Polymorphisms in HLA-DRB1, 
DQA1, and DQB1 genes confer susceptibility to type 1 diabetes. Most of the disease risk mediated 
by these genes in populations of European origin is determined by three amino acid positions (200). 
A strong LD connects these genes since the alleles of different loci are inherited together as certain 
haplotypes more often than expected given their frequencies in the population. The combination of 
two inherited haplotypes, one from the mother and the other from the father, determines an 
individual’s HLA-mediated risk for type 1 diabetes. 
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 The haplotypes formed by combinations of the HLA class II genes can be classified according 
to the risk they confer for type 1 diabetes, ranging from high risk to strong protection (201). The 
disease risk mediated by some common haplotypes is shown in Table 1. The highest risk is mediated 
through a heterozygous genotype comprising the two major risk-associated serologically defined 
haplotypes, the DR3-DQ2 (DRB1*03:01-DQA1*05(:01)-DQB1*02) on one chromosome and the 
DR4-DQ8 [DRB*04:01/02/04/05/08-DQA1*03(:01)-DQB1*03:02(/04)] on the other (202). In 
Finland, the DR4-DQ8 is the most common haplotype conferring increased risk for type 1 diabetes, 
followed by the DR3-DQ2 (203). Due to the enhanced contribution of environmental factors to the 
pathogenesis of type 1 diabetes, the HLA associations behind the disease process are changing and 
an increasing proportion of individuals with “lower” HLA-mediated disease risk are progressing to 
clinical type 1 diabetes (204). 
 
Table 1. Classification of genetic risk for type 1 diabetes mediated by some common HLA class II 
haplotypes (A) and genotype risk categories for type 1 diabetes defined by the combination of HLA 
class II haplotypes (B). Modified from (201). 
 
A 
Haplotype Odds Ratio Risk 
DRB1*04:01-DQA1*03-DQB1*03:02 10.1 S 
DRB1*04:05-DQA1*03-DQB1*03:02 3.0 S 
DRB1*04:04-DQA1*03-DQB1*03:02 2.8 s 
(DR3)-DQA1*05-DQB1*02 2.8 s 
DRB1*04:02-DQA1*03-DQB1*03:02 1.8 S 
(DR13)-DQB1*06:04 1.1 N 
(DR9)-DQA1*03-DQB1*03:03 1.0 N 
(DR8)-DQB1*04 1.0 N 
(DR16)-DQB1*05:02 0.8 N 
(DR7)-DQA1*02:01 0.6 N 
(DR1/10)-DQB1*05:01 0.6 N 
(DR4)-DQA1*03-DQB1*03:01 0.5 N 
DRB1*04:03-DQA1*03-DQB1*03:02 0.4 p 
(DR13)-DQB1*06:09 0.4 N 
(DR13)-DQB1*06:03 0.2 p 
(DR11/12/13)-DQA1*05-DQB1*03:01 0.2 p 
(DR7)-DQA1*02:01-DQB1*03:03 0.08 P 
(DR15)-DQB1*06:01 0.07 P 
(DR15)-DQB1*06:02 0.03 P 
(DR14)-DQB1*05:03 0.03 P 
 
B 
Genotype risk category Haplotype risk code combination 
High risk S/s, s/s (if DR3-DQ2/DR4-DQ8 genotype) 
Moderately increased risk S/s, s/s (not DR3-DQ2/DR4-DQ8), S/S, S/N 
Slightly increased risk s/N, S/p 
Neutral N/N, S/P, s/P, s/p 
Slightly decreased risk p/N 
Strongly decreased risk P/N, p/p, P/p, P/P 
 
S=strong susceptibility, s=weak susceptibility, N=neutral, p=weak protection, P=strong protection  
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HLA class I effects on type 1 diabetes 
 
Apart from HLA class II DR/DQ region determinants, also HLA class I genes and other loci outside 
the HLA region have been associated with increased risk for type 1 diabetes (205, 206). In the Finnish 
population, HLA-B*39:06 allele increases the risk for type 1 diabetes among individuals with the 
(DR8)-DQB1*04 haplotype (207). The HLA class I alleles affect also the pace of disease progression, 
as described in the following sections. 
 
Genetic factors outside the HLA region 
 
Non-HLA gene associations with type 1 diabetes 
 
At present, more than 60 non-HLA gene loci have been confirmed to affect the risk of type 1 diabetes, 
and these loci together with HLA genes have been estimated to be responsible for over 80% of the 
heritability of the disease (208, 209). Large-sample genome-wide association studies (GWAS) have 
contributed to the discovery of multiple new non-HLA risk loci for type 1 diabetes (210–220). 
However, since the GWAS include only relatively common SNPs in the population, excluding rare 
disease variants, they are at best able to identify only a limited fraction of the genetic variants that 
mediate the risk for type 1 diabetes. Therefore, a 200 000 SNP ImmunoChip array was developed 
that provides a powerful tool for the detection of rare gene variants associated with the risk of 
immune-mediated diseases. Several findings from the ImmunoChip analyses on type 1 diabetes have 
been published (221–230). The unexplained proportion of the heritability of type 1 diabetes has been 
suggested to result from the effect of unidentified non-HLA genes, structural modification of gene 
material, or epistatic interactions between genes. Epigenetic factors may also play a role. 
 
Insulin gene (INS) 
 
After the HLA region, the insulin gene (INS) locus on chromosome 11p15 comprises the second most 
important genetic risk association with type 1 diabetes. Originally, the susceptibility locus for type 1 
diabetes within the INS gene was pinpointed to a VNTR region, which is characterized by three 
classes of alleles according to the number of repeats (231). The highest risk for type 1 diabetes is 
associated with the shortest repeats (class I alleles). Later on, two INS SNPs, –23HphI (rs689) and 
+1140A/C (rs3842753), have been consistently associated with type 1 diabetes in several studies 
(232). In populations of Caucasian origin, the rs689 SNP is found in complete LD with the VNTR 
region such that the predisposing SNP allele A is linked to short class I VNTR alleles, while the non-
predisposing SNP allele T is linked to long class III VNTR alleles (233). The former (risk-conferring) 
genotype has been associated with higher insulin expression in the human pancreas, but lower 
expression in the thymus, whereas the latter (non-predisposing) genotype shows the opposite 
association. Accordingly, the INS polymorphisms might affect the development of central tolerance 
to insulin by regulating the abundance of insulin miRNA and protein expression in the thymus (234, 
235). Also, another type 1 diabetes-associated SNP, -2221MspI (rs3842729), is situated within the 
INS gene. In the case of this SNP, the predisposing allele C is in LD with the VTNR class I and 
subclass IIIB alleles, whereas the non-predisposing allele T is associated with VNTR subclass IIIA 
(236). 
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 The predisposing INS SNP rs689 has been associated with the appearance of IAA as the primary 
autoantibody, but not with the pace of progression to clinical disease after seroconversion (117, 128). 
The association with the appearance of humoral islet autoimmunity is restricted to individuals with 
initial IAA positivity and has not been seen for those with GADA as the primary autoantibody (128). 
 
Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) 
 
The PTPN22 gene is located on chromosome 1p13 and encodes the lymphoid tyrosine phosphatase 
(LYP), which functions to prevent spontaneous T-cell activation and possesses the ability to inhibit 
the function of TCRs. The association between PTPN22 and type 1 diabetes is mediated through a 
gain-of-function SNP (rs2476601) at amino acid position 620 that causes a change in the amino acid 
sequence from arginine to tryptophan (237). However, the exact mechanism behind the increased 
susceptibility for type 1 diabetes and other autoimmune diseases remains open. The altered function 
of immune cell signaling might affect thymic negative selection or impair the function of regulatory 
T cells, which would allow autoreactive T cells to act unguarded. According to recent evidence, LYP 
together with another type 1 diabetes-linked protein tyrosine phosphatase is induced following the 
activation of naïve T cells, and by controlling the JAK-STAT pathway might be involved in the 
determination of how activated or memory T cells interpret and respond to cytokine signals (238). In 
addition, the PTPN22 risk allele A has been linked to an increased frequency of circulating regulatory 
T cells (239). The PTPN22 SNP predisposing to type 1 diabetes has shown an association with both 
the appearance of islet autoantibodies and progression from seroconversion to clinical disease (240), 
but no associations with specific autoantibody signatures have been observed. 
 
Familial type 1 diabetes 
 
Although most cases of pediatric type 1 diabetes are sporadic, having an FDR affected by type 1 
diabetes increases the risk of type 1 diabetes 8–15-fold and an affected second-degree relative 2-fold 
compared with the general population (241, 242). The risk of type 1 diabetes is higher in children 
with a father affected by type 1 diabetes than in children with an affected mother (241). 
 
Epigenetic factors 
 
In brief, the epigenome modulates the accessibility of DNA for transcription factors that control the 
level of gene expression in response to environmental interactions. Epigenetic regulation is essential 
for the integration of endogenous and exogenous signals to ensure appropriate gene expression. The 
epigenome comprises modifications of gene expression that do not involve changes in the DNA 
sequence, but can be inherited. These mechanisms include e.g. DNA methylation, post-translational 
histone modifications, gene silencing, regulation of gene expression by non-coding RNAs, and X 
chromosome inactivation (243). Type 1 diabetes-linked DNA methylation variable positions have 
been reported among monozygotic twins discordant for type 1 diabetes, including hypomethylation 
of the risk-associated HLA-DQB1 gene and the GAD2 gene, which encodes the autoantigen GAD 
(244). Variation of DNA methylation in the promoter region of the INS gene has also been reported 
(245). Some changes have been found in the patterns of histone modification and RNA interference 
between patients with type 1 diabetes and non-diabetic controls (245). Longitudinal differences in 
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DNA methylation profiles were observed in cases with type 1 diabetes prior to diagnosis in the 
Diabetes Autoimmunity Study in the Young (DAISY) (246). 
 
Environmental risk factors 
 
Microbial etiology 
 
Hygiene and biodiversity hypotheses 
 
Originally, the hygiene hypothesis suggested that reduced microbial contacts in infancy might 
increase the susceptibility to allergic or immune-mediated diseases. Several infections have been 
inversely associated with the risk of allergic conditions (247). Early microbial exposure might be 
pivotal for the education of the immune system in infancy (248). However, the hygiene hypothesis 
might not be entirely true since some studies have provided contradictory evidence, including the 
association of early life infections with islet autoimmunity (249–252). Instead, the role of exposure 
to commensal microbes in the environment has become of interest. According to the biodiversity 
hypothesis, the human microbiota might be unfavorably altered in the urban living environment, and 
this might increase the risk of allergic and immune-mediated diseases (253). In fact, having an indoor 
dog as a pet in infancy has been shown to decrease the risk of beta-cell autoimmunity (248). 
 
Viral infections 
 
Seasonal pathogens, especially viruses, have been proposed to play a role in the pathogenesis of type 
1 diabetes. The strongest evidence for an association with type 1 diabetes exists for enteroviruses, in 
particular group B coxsackieviruses, but some studies have supported a role for many other viruses, 
including rotaviruses (254, 255). Moreover, early cytomegalovirus infection might delay the onset of 
clinical diabetes (256). During the present coronavirus disease 2019 (COVID-19) pandemic concerns 
have been raised about the comorbidity between the severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) infection and type 1 diabetes, especially as the infection might induce direct beta-
cell damage or dysfunction (257). 
 Currently, the primary hypothesis is that enteroviruses cause an acute infection of the pancreatic 
beta cells. Failure to eradicate the virus might lead to persistent chronic low-grade infection, resulting 
in beta-cell destruction and type 1 diabetes (258). This is supported by several findings. Increased 
frequencies of enteroviral RNA have been detected in both stools and blood before the onset of islet 
autoimmunity (259, 260). Coxsackie B viruses show tropism to human beta cells, and enteroviruses 
are found in the pancreatic islets of most patients with type 1 diabetes (91, 261). The main receptor 
for group B coxsackieviruses is expressed in the pancreatic islets (261, 262). In epidemiological 
studies, the association between enteroviruses and type 1 diabetes has been confirmed in a meta-
analysis (263). A systematic analysis of the specific enterovirus types revealed that the highest risk 
was associated with coxsackievirus B1 infections (264). Also, prospective intestinal virome analyses 
in HLA-predisposed children have suggested that a chronic enteroviral infection is associated with 
the development of islet autoimmunity (265). Interestingly, the coxsackievirus B1 infections have 
been associated with the IAA-driven endotype of islet autoimmunity, but not with the GADA-first 
endotype, indicating potential heterogeneity in the triggers of the disease process (266). According 
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to the so-called polio hypothesis, the diabetogenic effect of enteroviruses is intensified in populations 
with a decreased rate of enteroviral infections such as in Finland (267). However, the convincing 
association between enteroviruses and type 1 diabetes might not be causal. To examine potential 
causality, a vaccine to prevent acute enteroviral infections and type 1 diabetes is under investigation 
and is among the most enticing strategies for the primary prevention of type 1 diabetes (258). 
 
Gut microbiota 
 
Since genetic factors alone do not explain the rapid increase of type 1 diabetes in young children, the 
immediate living environment, microbial contacts, and the effect of gut microbiome on the immune 
system have become fascinating candidates for playing a role in the pathogenesis of type 1 diabetes. 
 Early childhood is a unique period in several respects. First, during the early years the child’s 
immune system undergoes fundamental education through numerous microbial contacts and 
infections. This is necessary in order to gain sufficient immunological memory and tolerance. Second, 
alongside the immunological development, the gut microbiome is stabilized by three years of age 
(268). Thereafter, the composition of the gut microbiome is similar to that of adults. Several factors 
modify the composition of the gut microbiome in infancy, including delivery mode, breastfeeding, 
introduction of solid foods, and use of antibiotics (269). The establishment of the gut microbiome is 
tightly related to the maturation of the immune system and might modulate intestinal immune 
responses (270). Third, simultaneously with these events, the first diabetes-associated autoantibodies 
usually appear. The use of antibiotics during the first four years is, however, not associated with islet 
autoimmunity (271). 
 Changes in the gut microbiome precede the appearance of islet autoimmunity. These include 
an increased relative abundance of the Bacteroidetes species and decreased abundance of the 
Firmicutes species and changes indicating a gut environment that favors inflammation (272, 273). In 
the prospective TEDDY study, children who progressed to type 1 diabetes demonstrated increased 
levels of Bifidobacterium pseudocatenulatum, Roseburia hominis, and Alistipes shahii in their 
intestinal microbiome (274). Intestinal impermeability is increased in children with signs of islet 
autoimmunity (275), and intestinal barrier function is decreased in type 1 diabetes (276). 
 It has been proposed that a chronic or repetitive dysbiosis of the intestinal microbiome might 
cause failure of the mechanisms sustaining self-tolerance and potentially lead to gut-initiated systemic 
immune responses. However, also favorable changes in the gut microbiota may occur since an 
increase in butyrate-producing bacteria could mediate a protective effect against islet autoimmunity 
(277). Early intake of oral probiotics has also shown a protective effect against type 1 diabetes among 
children with the high-risk HLA-DR3/DR4 genotype (278). Altogether, these findings raise questions 
of whether changes in the gut microbiota and type 1 diabetes are linked causally. 
 
Gut mycobiota 
 
Fungi are present on all barriers of the human body, including the gut mucosa. Although knowledge 
of the role of fungi in health and disease is currently limited, the mycobiota might modify the function 
of the immune system and alter the composition of bacterial microbiota and virome, thereby 
modulating intestinal homeostasis (279). Fungal and bacterial dysbiosis and intestinal inflammation 
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appear to be associated with the development of type 1 diabetes in children with signs of beta-cell 
autoimmunity (280). 
 
Gut virome 
 
Virome sequencing techniques have enabled screening for all viruses simultaneously. In the DIPP 
study, no prominent changes were found in the gut virome prior to the signs of islet autoimmunity 
(281). However, an imbalance within the Bacteroides genus showed a potential association with islet 
autoimmunity, and a possible connection existed between Bacteroides dorei and the bacteriophage 
CrAssphage (282). The Australian Viruses in the Genetically at Risk (VIGR) study reported 
enrichment of enterovirus A species in the gut of children positive for islet autoantibodies (283). In 
the TEDDY study, a prolonged enterovirus B infection was associated with islet autoimmunity, 
although no association with the development of type 1 diabetes was found (265). In a study observing 
HLA-predisposed Finnish and Estonian children from birth, the gut virome in islet autoantibody-
negative children showed higher diversity and higher abundance of Circoviridae-derived sequences 
than in autoantibody-positive children (284). The intestinal viruses might be capable of affecting the 
intestinal bacterial composition, thereby causing disturbance of intestinal homeostasis. The 
alterations in the gut virome linked to islet autoimmunity potentially may contribute to the 
development of type 1 diabetes. 
 
Dietary factors 
 
During the past decades the Western lifestyle, including the diet and eating habits, has changed 
fundamentally. Increased processing of foods, supplementation of foods, and awareness about the 
food’s microbial composition have led to questions about whether dietary factors are behind the 
rapidly increasing incidence of type 1 diabetes. 
 Several aspects of the diet have been considered as potential contributors to islet autoimmunity 
and type 1 diabetes. The focus has been mainly on early diet in infancy, but also factors related to 
maternal diet during pregnancy and later food consumption in childhood have been studied. 
 Short breastfeeding has been suggested to increase the risk of islet autoimmunity. A meta-
analysis showed a weak protective effect of breastfeeding against islet autoimmunity (285). Breastfed 
infants demonstrated a decreased risk for type 1 diabetes in a study combining two large Scandinavian 
birth cohorts compared with infants who had never been breastfed (286). During the introduction of 
gluten-containing cereals simultaneous breastfeeding was associated with protection against type 1 
diabetes (287). 
 Early introduction of cow’s milk proteins has also been investigated. In the Trial to Reduce 
IDDM in the Genetically at Risk (TRIGR) study, weaning to an extensively hydrolyzed cow’s milk 
formula compared with a conventional formula did not reduce the risk of type 1 diabetes (288), 
although a smaller pilot study suggested a protective effect of weaning to a hydrolyzed formula 
against islet autoimmunity (289). However, high consumption of cow’s milk later in childhood has 
been linked to increased risk of islet autoimmunity and type 1 diabetes, and genetic factors might 
modify this risk (290–292). 
 The risk of islet autoimmunity is potentially increased in association with both early (<4 months 
of age) and late (>6 to 9 months of age) introduction of solid foods, especially gluten (293–296). 
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However, also high intake of oats has been linked to increased risk of islet autoimmunity and type 1 
diabetes (297). 
 Vitamin D may contribute to the development of type 1 diabetes. Nevertheless, the findings 
have been highly contradictory and the role of vitamin D in type 1 diabetes remains unclear (298). 
Higher serum 25-hydroxyvitamin D levels were associated with lower risk of islet autoimmunity in 
the TEDDY study (299). In a Norwegian study, increased levels of 25-hydroxyvitamin D in cord 
blood decreased the risk of type 1 diabetes depending on the vitamin D receptor genotype (300). 
However, in HLA-susceptible children in the DIPP study, no differences were seen in cord blood 25-
hydroxyvitamin D concentrations between children who developed clinical diabetes or islet 
autoantibodies and those with no signs of beta-cell autoimmunity (301). Nor were any differences 
observed in the circulating concentrations of 25-hydroxyvitamin D between those who progressed to 
overt type 1 diabetes and matched controls in a longitudinal follow-up of DIPP participants (302). In 
the TRIGR ancillary study, serum 25-hydroxyvitamin D concentrations decreased months before the 
appearance of islet autoantibodies in children who later developed multiple autoantibodies or clinical 
type 1 diabetes (303). This was, however, considered to reflect the effects of vitamin D on the immune 
system, rather than a causal relationship between low vitamin D levels and type 1 diabetes. 
 Furthermore, a higher intake of omega-3 fatty acids, especially docosapentaenoic acid, has been 
inversely associated with the risk of islet autoimmunity (304). However, neither vitamin D nor 
omega-3 fatty acid supplementation during pregnancy have been shown to affect the risk of islet 
autoimmunity in offspring (305). Among other vitamins, high levels of plasma ascorbic acid might 
decrease the risk of islet autoimmunity (306). Also, the intake of probiotics during the first four weeks 
of life has been associated with a decreased risk of islet autoimmunity in infants carrying the high-
risk HLA-DR3-DQ2/DR4-DQ8 genotype (278). However, in a Finnish randomized controlled trial 
probiotic administration in infancy had no effect on the development of type 1 diabetes (307). 
Advanced glycation end-products and their receptors have been implicated in the early stages of islet 
autoimmunity (308). 
 
Beta-cell stress 
 
According to the accelerator hypothesis, insulin resistance or increased insulin demand caused by 
various factors, including rapid weight gain, increased height velocity, high body mass index (BMI), 
obesity, glucose overload, puberty, stressful life events, traumatic injuries, infections, steroid 
treatment, or psychological stress, may induce beta-cell stress and contribute to the pathogenesis of 
type 1 diabetes (309). 
 Childhood obesity has been linked to increased risk of later type 1 diabetes in several studies, 
including a meta-analysis (298, 310). Also high birthweight has been associated with increased risk 
of type 1 diabetes in a meta-analysis (311). Rapid weight gain in early life increases the risk of islet 
autoimmunity (312, 313). In the TEDDY study, a higher rate of weight gain during the slow growth 
phase after infancy increased the risk of progression from islet autoimmunity to clinical diabetes 
specifically among children with GADA as the primary autoantibody (313). Furthermore, high BMI 
might provoke the progression of islet autoimmunity to clinical diabetes (314). 
 Psychological stress is not to be overlooked. Children of parents who experienced a stressful 
life event during the child’s first years or children who themselves encountered a serious life event 
have been reported to be at increased risk of type 1 diabetes (315, 316). 
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 According to the overload hypothesis, environmental factors that cause excessive stress to beta 
cells might render them susceptible to immune destruction and apoptosis. Stress-inducing cytokine 
signals, viral infections, or metabolic overload may lead to impaired ER function and defective 
protein folding in beta cells, i.e. a cellular stress response known as the unfolded protein response 
(UPR). This might result in the release of improperly folded and potentially immunogenic peptide 
structures from the beta cell (317). 
 
 
HETEROGENEITY IN TYPE 1 DIABETES 
 
Observations on the rate of beta-cell destruction 
 
The duration of the prediabetic period is highly variable, ranging from a couple of months to more 
than two decades (6). A notable increase in the pace of disease progression in recent years has raised 
concerns of whether the mechanisms that normally guard self-tolerance have weakened at the 
population level (2, 131, 148, 318). The age at diagnosis of type 1 diabetes has decreased, suggesting 
earlier and more aggressive autoimmune responses in children (2). In newly diagnosed patients with 
type 1 diabetes, the amount of residual beta-cell function is highly heterogeneous, indicating that the 
rate of functional beta-cell loss is also extremely variable (319). 
 
IAA vs. GADA-first endotypes 
 
Among the biochemically defined autoantibodies, IAA or GADA is usually the first to appear (151). 
The disease process beginning with either IAA or GADA shows different genetic and etiological 
associations and characteristics of islet autoimmunity. This suggests heterogeneity in the triggers of 
beta-cell autoimmunity. 
 As the primary autoantibody, IAA peak during the second year, whereas GADA usually appear 
later as the first autoantibody, at approximately 3–5 years of age, with a more even and broader profile 
(52, 117, 320). As the second autoantibody, GADA tend to appear soon after IAA (117). Initial IAA 
positivity has been associated with homozygosity for the HLA-DR4-DQ8 haplotype, while GADA as 
the primary autoantibody has been linked to homozygosity for the HLA-DR3-DQ2 haplotype (117, 
126, 127, 320). Coxsackievirus B1 infections have been observed to be associated with the initiation 
of beta-cell autoimmunity in those with an IAA-initiated disease process, whereas no such association 
has been seen in those with initial GADA positivity (266). This implies that a diabetogenic Coxsackie 
B infection may be the trigger of beta-cell autoimmunity in the former cases. 
 
Heterogeneity in cellular responses 
 
Cytokine expression profiles in the peripheral blood of patients with newly diagnosed type 1 diabetes 
show notable differences in response to stimulation by different autoantigens (64). At diagnosis of 
type 1 diabetes, proinflammatory T-cell autoreactivity is more frequent in children and more often 
targeted to insulin and proinsulin peptides than in adult patients (321). In insulitis, two types of 
inflamed islets can be found, distinguished by the abundance of CD20-positive B cells in the insulitic 
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lesion (64). Several subtypes of type 1 diabetes also seem to exist depending on the level of the innate 
inflammatory activity (322). There is also disease stage-dependent variation in the immune 
phenotypes of T and B cells, indicating heterogeneity in cellular responses in type 1 diabetes (79). 
 
Heterogeneity in metabolic condition at diagnosis 
The metabolic status at diagnosis of type 1 diabetes is highly heterogeneous. In the TrialNet study, 
positivity for only one autoantibody, mostly GADA, was associated with insulin resistance and higher 
C-peptide levels relative to multiple autoantibody positivity (319). In the Finnish Pediatric Diabetes 
Register, more severe metabolic disturbance was seen among children with sporadic type 1 diabetes 
than in children from families with at least one member affected by type 1 diabetes (323). In the same 
study, children with a father affected by type 1 diabetes showed higher frequency of diabetic 
ketoacidosis and increased weight loss at diagnosis compared with offspring of mothers with diabetes 
(323). At diagnosis, girls presented with more severe metabolic deterioration than boys (324). 
Positivity for ZnT8A at diagnosis has been linked to older age and poorer metabolic state, including 
higher frequency of ketoacidosis (163). In general, age at diagnosis seems to have a substantial impact 
on the severity of type 1 diabetes (reviewed in 325). 
 
PREDICTION AND PREVENTION OF TYPE 1 DIABETES 
 
Prediction of type 1 diabetes 
 
General aspects of disease prediction 
 
The ability to precisely predict type 1 diabetes would enable cost-effective screening for risk of type 
1 diabetes in the general population and facilitate the optimal design of intervention trials aimed at 
preventing or delaying the onset of clinical diabetes. 
 The focus on the prediction of type 1 diabetes has been on identifying risk individuals from the 
general population based on HLA risk genotypes or FDRs of individuals affected by type 1 diabetes 
and on measuring islet autoantibodies and metabolic markers of dysglycemia in such individuals. 
However, the disease process has proven to be highly heterogeneous (5). This has led to the consensus 
that the underlying causes of type 1 diabetes are complex and multifactorial and that novel biomarkers 
in addition to the traditional ones are needed for elaborate and correctly timed disease prediction. 
 The individuals at high disease risk can already be identified relatively reliably based on HLA 
risk genotypes and prediabetic autoantibody profiles. However, the factors determining the pace of 
the disease progression, the metabolic condition at diagnosis, and the disease progression after 
diagnosis are not yet completely understood. The goal of disease prediction is not only to gain 
knowledge of the natural history of type 1 diabetes, but to identify the heterogeneous subpopulations 
of at-risk individuals and to define the stages of disease progression. This might enable prevention 
trials suitable for both the disease stage and endotype to be conducted. 
 Although at present the screening for HLA risk genotypes and islet autoantibodies comprises 
the most reliable and easily accessible tools for the prediction of type 1 diabetes, autoantibodies only 
become measurable at a stage at which the immunological tolerance has already been exceeded and 
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the autoimmune response is ongoing. Thus, in the future it is crucial to generate biomarkers that are 
applicable before the signs of humoral autoimmunity emerge or that act as direct markers of beta-cell 
damage and/or dysfunction. 
 However, the prediabetic period per se provides a unique time frame for conducting secondary 
prevention trials. At this stage, it might still be possible to revert or halt the disease progression. 
Therefore, it is important to stratify the disease risk associated with the heterogeneous patterns of 
preclinical islet autoimmunity and to elucidate the role of autoantibody dynamics in detailed staging 
of the disease process. In this respect, prospective follow-up studies starting from birth or during the 
fetal period are essential since they might provide unique insights into the temporal events that occur 
at various stages of the disease process. Also, in primary prevention trials the islet autoantibodies 
comprise a valuable endpoint marker for initiated disease activity. 
 
Predictive characteristics of islet autoantibodies 
 
Islet autoantibodies have proven useful in the prediction of type 1 diabetes in children at increased 
genetic risk (326), in young FDRs of patients with type 1 diabetes (318), and in the pediatric general 
population (6). The most important findings in prospective studies of islet autoimmunity include the 
observation that beta-cell autoimmunity begins very early in life, with autoantibody seroconversions 
peaking during the first two years (51, 52). Young age at autoantibody appearance increases the risk 
of type 1 diabetes (8, 51, 52, 112). Another important finding has been the association of positivity 
for multiple autoantibodies with an extremely high risk of disease progression, with about 70% of 
multipositive children with HLA-DR/DQ risk genotypes and/or FDRs affected by type 1 diabetes 
progressing to clinical diabetes in 10 years (7, 149). Early and fast development of multipositivity is 
especially predictive of high disease risk (51, 149, 175). 
 As discussed, the prediabetic period is heterogeneous both in duration and in the context of the 
primary autoantigen (6, 117). The HLA genotype affects both the number and quality of islet 
autoantibodies during this period (327). The order of autoantibody appearance affects the disease risk 
(146). Furthermore, autoantibody titer and affinity and different autoantibody combinations increase 
the prognostic value of autoantibody testing when screening for risk of type 1 diabetes (8, 109, 188). 
Especially, rapid increase in autoantibody titers after seroconversion is predictive of fast progression 
to clinical disease (51). Also, the combination of persistent ICA and IAA positivity and high titers of 
ICA and IAA at seroconversion may predict rapid progression to overt disease (8, 51, 107, 108). 
 Although at present the screening for HLA risk haplotypes and islet autoantibodies comprises 
the most applicable tools for the evaluation of the risk for type 1 diabetes, autoantibodies are not very 
useful in predicting the timing of the clinical diagnosis. Other biomarkers might prove more precise 
in the prediction of the pace of the disease process. Moreover, there is still a need for improved 
understanding of the natural dynamics of islet autoantibodies in childhood to better discriminate non-
progressive immunological activity from true progressive autoimmunity. 
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Factors related to progression rate 
 
HLA gene effects on disease progression 
 
Although HLA class II genes are strongly involved in the initiation of beta-cell autoimmunity, other 
genetic factors are likely to modify the rate of beta-cell destruction after the establishment of beta-
cell autoimmunity (Table 2). Recent findings have strongly indicated that the HLA class II effect on 
disease progression is attenuated after the appearance of islet autoantibodies, but certain HLA class I 
alleles might modulate the rate of beta-cell destruction thereafter (201, 328, 329). 
 HLA class I allele B*39 promotes disease progression after the appearance of the second 
autoantibody, and this risk-increasing effect is strongly enhanced among children carrying the high-
risk HLA-DR3/DR4 genotype (329). In the same study, the HLA-A*03 allele was found to mediate a 
protective effect against disease progression in children without the high-risk HLA-DR3/DR4 
genotype (329). In another study, no effect of the HLA-B*39 on disease progression was seen, but the 
HLA-B*18 allele was associated with more rapid progression to clinical disease in children carrying 
the HLA-DQ2 haplotype (328). HLA-A*24 favored progression in HLA-DQ8 carriers (328). 
 Among FDRs of patients with type 1 diabetes, the HLA-A*24 allele was reported to mediate 
accelerated progression from multiple autoantibody positivity to clinical diabetes, but this association 
was detected only among relatives with the HLA-DQ8 haplotype testing positive for IA-2A and/or 
ZnT8A (330). The HLA-B*18 allele mediated more rapid progression to clinical disease in HLA-DQ2 
carriers positive for both GADA and IAA, but no effect was observed for the HLA-B*39 allele (330). 
The disease-promoting HLA-A*24 allele has been associated with attenuated islet autoantibody 
responses (331, 332). Also, the HLA class II haplotype DRB1*15:01-DQA1*01:02-DQB1*06:02 has 
been shown to mediate a protective effect against disease progression in autoantibody-positive 
relatives of patients with type 1 diabetes at all stages of the disease process (333). 
 
Non-HLA gene effects on disease progression 
 
The effect of the predisposing SNP (rs689) in the INS gene is restricted to the early stages of islet 
autoimmunity (240). However, the predisposing SNP (rs2476601) in the PTPN22 gene affects the 
progression rate to clinical disease also after the onset of humoral beta-cell autoimmunity (240). A 
predisposing SNP (rs3757247) in the BACH2 gene affects the pace of disease progression specifically 
in children with IAA as the primary autoantibody (128). Similarly, predisposing SNPs (rs1701704, 
rs2292239) in the IKZF4-ERBB3 region modify the progression rate only in children with GADA as 
the primary autoantibody (128). Among other non-HLA polymorphisms, the predisposing SNP 
(rs45450798) in the PTPN2 gene affects the rate of beta-cell damage after seroconversion regardless 
of the primary autoantibody (128). 
 In the TEDDY study, a genetic risk score predicted the pace of disease progression (334). Also, 
another genetic risk score predicted the progression rate successfully among participants in the 
TrialNet study (222). In the DAISY study, a genetic risk score combining HLA and non-HLA genes 
improved the prediction of progression from islet autoimmunity to type 1 diabetes in children 
recruited from the general population (335). In the BABYDIAB study, several differences were found 
in the distributions of non-HLA genotypes between rapid and slow progressors to clinical type 1 
diabetes (150). Furthermore, the predisposing SNP in the SLC30A8 gene encoding ZnT8 might affect 
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the age at disease presentation, and accordingly, might modify the rate of disease progression (336). 
Progression to clinical disease is faster in ZnT8A-positive children homozygous for the SLC30A8 
SNP (rs1326634) alleles (159). 
 
Autoantibody characteristics associated with progression rate 
 
Several studies have reported findings on autoantibody characteristics related to the pace of disease 
progression. Development of multiple autoantibodies at a young age enhances the risk of progression 
to type 1 diabetes in the next 15 years (149). High initial levels of IAA increase the risk of rapid 
progression (51). In young children with multiple autoantibodies, characteristics that predict faster 
progression to clinical diabetes include young age and higher levels of IAA and IA-2A (153). 
Especially the appearance of IA-2A as the first biochemical autoantibody increases the risk of 
accelerated disease progression (117). 
 In the BABYDIAB study characterizing rapid and slow progressors to type 1 diabetes among 
multipositive individuals, the development of IA-2A was delayed among slow progressors (150). In 
the DAISY study, slow progressors were characterized by later onset of islet autoimmunity, less 
frequent positivity for IAA, and lower levels of autoantibodies, especially IAA, than rapid progressors 
(337). Also, the development of multiple autoantibodies was delayed among slow progressors (337). 
In a combined analysis of five prospective cohorts that attempted to identify the characteristics of 
slow progressors, GADA dominated as the most frequent autoantibody in the first sample positive 
for multiple autoantibodies among multipositive children who remained disease-free for over 10 years 
after initial seroconversion (338). Furthermore, in children with multiple autoantibodies recruited to 
the Type 1 Diabetes TrialNet, GADA positivity indicated reduced risk of progression to diabetes, 
while children positive for IA-2A were at increased risk (339). 
 Considering the IAA vs. GADA-first endotypes, the simultaneous appearance of two other 
autoantibodies with primary GADA positivity was reported to promote disease progression (340). 
However, no similar effect was observed in the case of primary IAA positivity (340). In children with 
IAA as the first autoantibody, IA-2A as the second reactivity predicted rapid disease progression, 
while no accelerating effect of GADA as the secondary autoantibody was seen after primary IAA 
positivity (340). In the DIPP study, no differences were found in the delay from seroconversion to 
diagnosis between children with either IAA or GADA as the primary autoantibody, but the disease 
progression was accelerated among children with IA-2A as the primary autoantibody and delayed 
among those with ZnT8A as the primary autoantibody (151). Early appearance of ZnT8A in the 
disease process has been associated with delayed disease progression (338). 
 In a subset of multipositive individuals, the loss of IAA positivity has been associated with a 
decreased rate of progression to clinical type 1 diabetes after 10 years of follow-up compared with 
persistent IAA positivity (194). In contrast, transient GADA positivity has been linked to more rapid 
progression in the presence of stable IAA and IA-2A (195). 
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Table 2. Factors related to progression rate to type 1 diabetes in the literature. 
 
Characteristic associated with 
progression rate to T1D 
Effect on disease progression after 
appearance of islet autoimmunity 
Reference 
HLA class II haplotype DRB1*15:01-
DQA1*01:02-DQB1*06:02 
Protective effect in autoantibody-positive 
FDRs of patients with T1D 
333 
HLA class I B*39 allele Promotes progression after appearance of 
secondary autoantibody, effect enhanced 
in individuals with HLA-DR3/DR4 genotype 
329 
HLA class I B*39 allele No effect 328, 330 
HLA class I A*03 allele Protective effect among individuals without 
the HLA-DR3/DR4 genotype 
329 
HLA class I B*18 allele Rapid progression in HLA-DQ2 carriers 328 
HLA class I B*18 allele Accelerated progression from multiple 
autoantibody positivity to T1D diagnosis in 
GADA and/or IAA-positive FDRs of T1D 
patients with the HLA-DQ2 haplotype 
330 
HLA class I A*24 allele Favors progression in HLA-DQ8 carriers 328 
HLA class I A*24 allele Accelerated progression from multiple 
autoantibody positivity to clinical T1D in IA-
2A and/or ZnT8A-positive FDRs of T1D 
patients with the HLA-DQ8 haplotype 
330 
INS gene SNP (rs689) No effect 128, 240 
PTPN22 gene SNP (rs2476601) Promotes progression to clinical diabetes 240 
PTPN2 gene SNP (rs45450798) Promotes progression to clinical diabetes 128 
IKZF4 gene SNP (rs1701704) Promotes progression to clinical diabetes in 
individuals with GADA as the first 
autoantibody 
128 
ERBB3 gene SNP (rs2292239) Promotes progression to clinical diabetes in 
individuals with GADA as the first 
autoantibody 
128 
BACH2 gene SNP (rs3757247) Promotes progression to clinical diabetes in 
individuals with IAA as the first 
autoantibody 
128 
SLC30A8 Younger age at disease onset 336 
SLC30A8 gene SNP (rs1326634) 
homozygosity in ZnT8A-positive 
children 
Increases the risk of rapid progression 159 
Genetic risk score combining HLA 
and non-HLA genes 
Successfully predicted progression 335 
Genetic risk score including 
predisposing non-HLA SNPs 
Discriminative differences in distributions of 
non-HLA SNPs between rapid and slow 
progressors 
150 
Genetic risk score including 
predisposing non-HLA SNPs and 
HLA class I and class II alleles 
Successfully predicted progression 222, 334 
Multiple autoantibodies at a young 
age 
Increases the risk of rapid progression 149, 153 
IA-2A as the first autoantibody Rapid progression 117, 151 
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Delayed development of IA-2A Slower progression 150 
High initial level of IA-2A Increases the risk of progression 153 
High initial level of IAA Increases the risk of progression 51, 153 
Lower initial level of IAA and other 
biochemical autoantibodies 
Slow progression 337 
Simultaneous appearance of two 
other autoantibodies in children with 
GADA as the primary autoantibody 
Accelerated progression 340 
ZnT8A as the first autoantibody Delayed progression 151 
Older age at appearance of islet 
autoimmunity 
Slow progression 337 
Slower development of multiple 
autoantibodies 
Slow progression 337 
GADA positivity in the first sample 
with multiple autoantibodies in 
multipositive children 
Delayed progression 338 
GADA positivity in children with two 
autoantibodies 
Reduced risk of progression 339 
IA-2A positivity in children with two 
autoantibodies  
Increased risk of progression 339 
Transient IAA positivity Lower rate of progression 194 
Transient GADA positivity Accelerated progression in individuals with 
persistent IAA and IA-2A positivity 
195 
Higher BMI SDS Accelerated progression 153 
Reduced first-phase insulin response Accelerated progression 153 
Insulin resistance  No effect 153 
 
T1D = type 1 diabetes. SDS = standard deviation score. 
 
Early signs and biomarkers 
 
Dysregulation of glucose metabolism 
 
During the prediabetic disease process signs of metabolic dysregulation can be observed as the beta-
cell damage proceeds (53). Reduced first-phase insulin response (FPIR) in the intravenous glucose 
tolerance test predicts progression to clinical diabetes in multipositive children (153). The FPIR 
declines rapidly during the last two years before symptomatic diabetes, but decreased responses may 
be observed as early as 4–6 years before diagnosis (341, 342). 
 Increasing levels of glycated hemoglobin (HbA1c) might improve the estimation of the timing 
of type 1 diabetes diagnosis. In the DAISY study, increasing HbA1c levels predicted increased risk 
of type 1 diabetes independently of random plasma glucose levels or the number of autoantibodies 
(343). In the TrialNet study, increased HbA1c values predicted the onset of clinical disease in the 
following years (344). In the DIPP series, an increase in HbA1c levels affected both the risk of 
diabetes and the delay from the observed rise in HbA1c to diagnosis (345). A consistent increase in 
HbA1c values was observed in progressors during the last two years before diagnosis. 
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 During the oral glucose tolerance test (OGTT) both decreased early and increased late C-
peptide responses indicate increased risk for type 1 diabetes (346). Similarly, impaired fasting glucose 
and IGT in OGTT predict progression to overt disease (347). Randomly obtained plasma glucose 
measurements might also provide a useful tool for disease prediction, although in the DAISY study 
an increase in random plasma glucose values predicted type 1 diabetes only marginally (HR 1.4) 
compared with an HR of 6.0 in the DIPP study (343, 347). Furthermore, continuous glucose 
monitoring has revealed increased glycemic variability in children with islet autoantibodies and 
predicts progression to clinical diabetes in prediabetic children (348). 
 How the preclinical changes in glucose metabolism relate temporally to the dynamics of islet 
autoantibodies is not completely understood. In the TrialNet study, the development of dysglycemia 
was associated with IA-2A titers (349). Moreover, insulin-like growth factors (IGFs) are involved in 
the regulation of glucose metabolism and might play a role in type 1 diabetes. Decreasing levels of 
especially IGF-1 have been observed preclinically in multipositive children and those who later 
progress to type 1 diabetes, and after the diagnosis the IGF-1 titers seem to decrease alongside the 
declining beta-cell function (350). 
 
Proteomics 
 
Studies on proteomics, metabolomics, and transcriptomics may provide information on the 
pathogenesis of type 1 diabetes before the appearance of humoral islet autoimmunity and might reveal 
novel biomarkers for the prediction of type 1 diabetes. Some of the recent findings in these fields are 
introduced below. 
 In general, age has a strong influence on the formation of the serum proteome (351). Among 
children progressing towards clinical type 1 diabetes, studies on the serum proteome have revealed 
an increase in the amount of proteins usually seen during acute inflammation, complement activation, 
and adaptive immune responses (352). Serum apolipoproteins M and C-IV have been reported to 
differ in levels between autoantibody-positive and -negative individuals (353). In children who later 
progress to type 1 diabetes, the expression of proteins involved in oxidative stress responses is 
increased already before autoantibody seroconversion compared with healthy controls (354). 
 
Metabolomics 
 
Metabolomic profiles might reflect changes in immunologic or metabolic status during the 
pathogenesis of type 1 diabetes. Dysregulation of lipid and amino acid metabolism in the fetal period 
might contribute to the process since several changes have been found in the cord blood lipidome of 
children who progress to diabetes at a young age, including reduced levels of choline-containing 
phospholipids (355, 356). A study on plasma metabolites in early infancy revealed that progression 
to clinical diabetes was associated with increased levels of methionine, but decreased abundance of 
amino acids, sugar metabolites, and fatty acids, including catabolites derived from microbial origin 
(357). The signs of humoral islet autoimmunity appeared to be associated with decreased glutamic 
and aspartic acids (357). In infancy, several plasma metabolites, including sphingomyelins, 
unsaturated phosphatidylcholines, phosphatidylethanolamines, glucosylceramides, and phospholipid 
ethers, have been inversely associated with the risk of developing multiple autoantibodies, whereas 
dicarboxylic acids might increase this risk (358). In the longitudinal TEDDY study, several changes 
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in plasma metabolites, including reduced plasma proline and branched-chain amino acids, preceded 
the appearance of the first islet autoantibody, and especially GABA showed an association with the 
IAA-first endotype (359). Furthermore, a longitudinal analysis of peripheral blood mononuclear cell 
metabolomics revealed that dysregulation of lipid metabolism in these cells was associated with 
progression to type 1 diabetes (360). 
 
Transcriptomics 
 
An analysis of transcriptomic profiles in the whole blood of children with signs of islet autoimmunity 
revealed dynamic changes in gene expression in pathways involved in the immune system (361). 
Gene expression profiles indicating immunological activation have been observed even prior to the 
signs of humoral beta-cell autoimmunity. Both in the Finnish DIPP study and in the German 
BABYDIET study, a type I interferon-inducible gene set was found to be transiently increased in 
expression before the appearance of islet autoantibodies in children with increased genetic risk for 
type 1 diabetes (362, 363). A recent study demonstrated a diminished amount of sulfatide in isolated 
pancreatic islets of patients with type 1 diabetes compared with healthy controls, indicating reduced 
expression of enzymes participating in sphingolipid metabolism (364). Changes in peripheral blood 
lymphocyte expression profiles may also prove useful in the assessment of risk for type 1 diabetes 
(365). 
 
T-cell biomarkers 
 
Although several mechanisms involving both innate and adaptive immune responses are likely to 
contribute to the pathogenesis of type 1 diabetes, the evidence so far refers to T cells as the primary 
mediators (73). Certain T-cell subsets might be useful as biomarkers of treatment efficacy in clinical 
trials (71, 366). Follicular and peripheral T helper cells are increased in number before and at 
diagnosis of type 1 diabetes and might prove useful as biomarkers for disease prediction (75, 77, 78). 
Also functional deficiencies, altered cytokine signaling, and changes in transcriptional profiles of 
FOXP3 regulatory T cells have been associated with type 1 diabetes and might provide another 
promising approach for the prediction of type 1 diabetes (80, 82, 367–369). 
 
Prevention of type 1 diabetes 
 
The globally rising incidence of type 1 diabetes calls for effective preventive measures (1). No cure 
for type 1 diabetes will probably be found before successful prevention. The timeline for prevention 
of type 1 diabetes can be staged into four categories: 1) primary prevention before onset of islet 
autoimmunity, 2) secondary prevention before diagnosis of type 1 diabetes, 3) tertiary prevention in 
newly diagnosed patients to preserve residual β-cell function, 4) and late prevention of secondary 
complications in established type 1 diabetes and attempts to revive lost β-cell function. 
 The JDRF’s global vision is to discover a primary prevention approach safe enough to be 
administered to the general childhood population without the evaluation of disease risk (370). A lead 
candidate for such a measure would be a preventive vaccine for early immunization (370). 
 To date, prevention trials carried out in human populations have demonstrated only limited 
success in achieving their goal (371). Some past and ongoing trials are summarized in Table 3. The 
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most promising results have been achieved in studies of teplizumab (71), rituximab (56), alefacept 
(72), abatacept (366), and anti-thymocyte globulin (372). Also, a transient benefit after the 
administration of oral insulin was seen in a subgroup of individuals with high IAA levels in the 
Diabetes Prevention Trial-Type 1 trial (373). 
 The main obstacles to successful prevention of type 1 diabetes derive from the incomplete 
understanding of disease heterogeneity and pathomechanisms and the lack of biomarkers for cost-
effective screening. Improved biomarkers are needed to target appropriate interventions to suitable 
populations (371). Some beneficial effects in the past trials may not have been observed due to 
suboptimal study design (371). Considering the optimal selection of the study population, the disease 
stage, and the applied intervention in prevention trials, the dilemma exists that in the early stages of 
the disease process more effective interventions may be used, but the disease prediction is poorer and 
a larger population is predisposed to potential side effects of the treatment. In contrast, in later stages, 
the disease prediction is more precise, but applicable interventions are less effective due to the already 
advanced disease process (374). 
 Consideration of these aspects in future trial design might improve the probability of observing 
a beneficial effect. The use of combination therapies targeting multiple facets of the disease 
pathogenesis might generate better results than a single-target therapy alone. The key to achieving 
sufficient resources for carrying out successful prevention trials is an active collaboration globally. 
Shorter and more affordable pilot studies should be encouraged to identify the best intervention 
candidates for larger clinical trials (371). The primary focus in intervention trials should, however, 
always be on clinically meaningful improvements. Even mild preservation of the beta-cell function 
is a victory for patients living with type 1 diabetes. 
 
Ethical issues on disease prediction and prevention 
 
Delay of onset of type 1 diabetes might have meaningful positive effects on the social, emotional, 
mental, and physical development of young patients en route to type 1 diabetes. Delayed onset of the 
clinical disease could provide young individuals more disease-free time in their teenage years, during 
which the compliance to treatment is often poor due to challenges of insulin therapy, and glycemic 
control is often affected by this (375). Life expectancy is the lowest among patients who have been 
diagnosed at a young age, emphasizing the importance of at least delaying the onset of type 1 diabetes 
(3, 4). Young age at diagnosis might also increase the lifetime risk of secondary complications due 
to the longer disease duration (3). 
 Children participating in prospective follow-up studies are diagnosed at an earlier and 
metabolically less severe stage of the disease pathogenesis than the background population, probably 
due to the increased education of the families about the symptoms of type 1 diabetes (376). Increased 
awareness of the symptoms in general might promote earlier contact with healthcare. 
 On the other hand, the screening for risk of type 1 diabetes raises a range of ethical concerns. 
Awareness of the disease risk might cause anxiety and psychological discomfort in study participants 
and their families (377). However, enrollment in follow-up studies might also decrease parental stress 
and improve quality of life and glycemic control in participants affected by type 1 diabetes (378, 
379). In general, parents prefer to be informed about the high risk of type 1 diabetes in their offspring, 
even if no preventive measure is available (380). In prospective studies, screening for genetic risk of 
newborn infants occurs often in the days immediately following birth, which is a sensitive period for 
Review of the literature 
 47 
mothers psychologically, especially concerning the wellbeing and health of their babies. Increased 
maternal anxiety is a common response to the information that the child is at genetic risk of diabetes 
(381). However, the increased anxiety usually dissipates over time (377). 
 As an essential part of screening and prevention strategies in follow-up studies, a 
communication protocol might be considered to avoid misunderstandings and potential psychological 
harm to study participants and their families. This also requires good communication skills and 
emotional sensitivity of the study personnel to detect any ethical concerns that may arise. Behavior 
rating scales for the assessment of parental attitudes might prove helpful in targeting parent education 
efforts in studies screening for risk of type 1 diabetes in pediatric populations (382). 
 
 
Table 3. Some previous and ongoing trials aimed at preventing type 1 diabetes. 
 
Study Intervention Stage Outcome achieved 
TRIGR Hydrolyzed casein formula Primary No 
BABYDIET Gluten-free diet during first year  Primary No 
DIPP Intranasal insulin Secondary No 
DPT-1 Oral insulin Secondary Transient benefit in 
subgroup with high 
IAA levels 
DPT-1 Parenteral insulin Secondary No 
Belgian Diabetes 
Registry 
Subcutaneous insulin Secondary No 
INIT-II Intranasal insulin Secondary Ongoing 
TrialNet Oral insulin Secondary No 
Pre-POINT Oral/intranasal insulin Primary Yes (immune 
response to insulin) 
DIAPREV-IT Alum-GAD (Diamyd ®) Secondary No 
DIAPREV-IT2 Alum-GAD + Vitamin D3 2000 IU/d Secondary Ongoing 
TrialNet Teplizumab (anti-CD3 monoclonal 
antibody) 
Secondary Yes 
TrialNet Abatacept Tertiary Yes 
TrialNet NIP Docosa-hexaenoic acid Primary No 
ENDIT Nicotinamide (vitamin B3) Secondary No 
DENIS Nicotinamide Secondary No 
TrialNet, AIDA Canakinumab Tertiary No 
TrialNet GAD vaccine Tertiary No 
TrialNet Mycophenolate mofetil/daclizumab Tertiary No 
TrialNet Rituximab Tertiary No long-term effect 
DEFEND-1 Otelixizumab Tertiary No 
T1DAL Alefacept Tertiary Yes 
TrialNet Anti-thymocyte globulin Tertiary Yes 
TrialNet Hydroxychloroquine Secondary Ongoing 
University of 
Buffalo, USA 
Etanercept Tertiary Yes (pilot) 
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AIMS OF THE STUDY 
 
This thesis focuses on assessing the dynamics of islet autoantibodies in childhood, from birth up to 
15 years of age, and on identifying the demographic, genetic, and immunological characteristics of 
rapid and slow progression to clinical type 1 diabetes in children with increased HLA-conferred risk 
for type 1 diabetes recruited from the general population. 
 
The main aims of the thesis were as follows: 
 
1. To determine the genetic, immunological, and demographic characteristics of rapid disease 
progression from seroconversion to autoantibody positivity. 
 
2. To determine the genetic, immunological, and demographic characteristics of slow disease 
progression from seroconversion to autoantibody positivity. 
 
3. To assess the seroconversion dynamics of individual islet autoantibodies during prospective 
follow-up from birth up to 15 years of age. 
 
4. To evaluate the predictive value of autoantibody testing for clinical type 1 diabetes and to 
describe systematically for the first time the role of ZnT8A in this context. 
 
5. To examine the role of primary autoantibodies in disease progression. 
 
6. To assess the role of inverse seroconversions and autoantibody fluctuations in disease 
progression. 
 
7. To examine the value of ICA in the prediction of type 1 diabetes. 
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SUBJECTS AND METHODS 
 
Study subjects 
 
Type 1 Diabetes Prediction and Prevention (DIPP) Study 
 
The DIPP study is a prospective Finnish general population-based birth cohort study carried out in 
the university hospitals of Turku, Oulu, and Tampere. The DIPP study aims at monitoring the signs 
of humoral islet autoimmunity and progression to clinical type 1 diabetes among individuals with 
increased HLA-conferred risk for type 1 diabetes and at identifying measures for preventing or 
delaying the manifestation of clinical type 1 diabetes in at-risk individuals. The recruitment was 
launched in Turku University Hospital in 1994, in Oulu University Hospital in 1995, and in Tampere 
University Hospital in 1997 and is ongoing. 
 Newborn infants born in the participating hospitals are screened for HLA risk genotypes from 
cord blood. Families with an infant carrying an eligible genotype are invited to participate in the study 
follow-up starting from the age of 3 months (383). Islet autoantibodies are analyzed as markers of 
beta-cell autoimmunity from venous blood samples obtained at regular clinical visits. In Oulu and 
Tampere, the children are seen at the ages of 3, 6, 12, 18, and 24 months and annually thereafter, and 
in Turku every 3 months up to the age of 2 years and thereafter every 6 months. Children testing 
positive for autoantibodies are invited to visits every 3 months. According to the DIPP study design, 
the visits continue up to the diagnosis of type 1 diabetes or to the age of 15 years. Children with 
multiple autoantibodies may continue in the follow-up after the age of 15 years. Efforts are made to 
minimize the dropout rate during the follow-up. Infants with severe congenital abnormalities or 
disease are excluded from the study. Families with no common language (i.e. Finnish, Swedish, or 
English) with the study personnel are also excluded. 
 The current DIPP study cohorts were recruited in 1994–2003. At the time, the three hospitals 
together covered a population of approximately 1.2 million (24% of the total population in Finland), 
and the number of annual births in these hospitals was around 11 000 (20% of the total number of 
annual births in Finland). Between 1994 and 1998, more than 90% of the babies born annually in 
these hospitals took part in the HLA screening (383). Thereafter, the proportion decreased gradually 
to an estimated 80%. By the end of July 1997, written informed consent had been obtained for 12 170 
newborns, all of whom underwent HLA screening (112). By the end of July 2003, altogether 75 813 
infants had attended the HLA screening (8). 
 
Publication I 
 
In Study I, the first 1006 children (53% boys) recruited to the DIPP study in 1994–1997 were followed 
from birth up to 15.5 years of age for the development of islet autoantibodies and for progression to 
clinical type 1 diabetes (Table 4). Follow-up visits after the age of 14.5 years were considered as the 
final study visits. Venous blood samples obtained before the age of 15.5 years were included in the 
detailed autoantibody analyses. Altogether 542 children (55.8%) completed the 15-year follow-up. 
In Study I, all available samples from the 1006 children were analyzed for ICA, IAA, GADA, IA-
2A, and ZnT8A. 
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 By the age of 15.5 years, 35 children (3.5%) had progressed to type 1 diabetes. Among the 
progressors, two had their first autoantibody-positive sample at diagnosis and were therefore 
excluded from the autoantibody analyses. Both children had dropped out from the active follow-up 
several years before the diagnosis (3.6 and 10.4 years). Autoantibody data at diagnosis were available 
for 34 progressors. In Study I, autoantibody titers were compared between progressors and multiple 
autoantibody-positive controls matched for the closest date of birth (+/- 3 months), DIPP study center, 
HLA risk genotype, and sex. 
 
Publications II and III 
 
To identify the characteristics of rapid and slow progression from seroconversion to type 1 diabetes, 
7410 HLA-predisposed children (52.6% boys) recruited to the DIPP study between November 1994 
and July 2003 were followed from birth until the end of December 2015 (Table 4). The children in 
the study cohort had attended the DIPP follow-up visits for at least one year before the end of 2003 
or had been diagnosed with type 1 diabetes before the age of one year by the end of 2003. The first 
1006 children included in Study I were also included in Studies II and III. 
 Among the 7410 children, 13 (0.2%) had developed clinical type 1 diabetes without any 
detectable autoantibody positivity and were therefore excluded from the autoantibody analyses. 
Twelve of the 13 children had a long time (3–12 years) since the last autoantibody sampling before 
diagnosis, which might have contributed to the absence of detectable autoantibodies. Fourteen 
children (0.2%) had their first autoantibody-positive sample at the diagnosis of type 1 diabetes. Since 
the delay from seroconversion to diagnosis could not be defined in these children, they were excluded 
from the autoantibody analyses in Studies II and III. 
 
Methods 
 
Genetic screening 
 
Analyses of HLA genotypes 
 
Screening for the major type 1 diabetes-risk associated HLA-DR/DQ haplotypes from cord blood was 
performed by using polymerase chain reaction (PCR) amplification, followed by time-resolved 
fluorometry with lanthanide-labeled allele sequence-specific oligonucleotide probes, as previously 
described (384, 385). The risk conferred by some of the HLA class II genotypes is shown in Table 1. 
 
Analyses of non-HLA genotypes 
 
Non-HLA SNPs in Studies II and III were analyzed by using the Sequenom (San Diego, California, 
USA) platform at the Genome Center of Eastern Finland, University of Eastern Finland, Kuopio, 
Finland. The SNP marker analysis was considered successful if the proportion of failed SNP analyses 
remained below 10% (386). According to the original research setting, SNP markers were analyzed 
from DIPP study participants who had tested positive for ICA and for at least one additional 
biochemical autoantibody (IAA, GADA, and/or IA-2A) and from their autoantibody-negative 
controls (two controls per case) matched for the closest date of birth, sex, and study center (128). 
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Non-HLA SNPs predisposing to type 1 diabetes were selected for the current analysis by using 
ImmunoBase, a web-based resource providing information on the genetics of immune-mediated 
diseases in man (www.immunobase.org, formerly www.t1database.org). In Study II, predisposing 
SNPs of 25 non-HLA genes were analyzed to assess their potential association with rapid disease 
progression (Table 5). In Study III, additional SNPs were included and altogether 45 non-HLA SNPs 
were investigated for associations with delay from seroconversion to diagnosis among progressors, 
age at seroconversion, age at diagnosis of type 1 diabetes, delay from single to multiple autoantibody 
positivity, and disease-free time from seroconversion in children with confirmed autoantibody 
positivity (Table 5). 
 
 
Table 4. DIPP study cohorts in Studies I–III. Continuous variables are medians (range). *One 
progressor was excluded from the autoantibody analyses in Study III since only one autoantibody-
positive sample was available at the age of 3 months. In this case, maternal autoantibody positivity 
could not be excluded. 
 
 Publication I 
DIPP cohort (n=1006) 
Publications II and III 
DIPP cohort (n=7410) 
DIPP study center Turku, Oulu Turku, Oulu, Tampere 
Recruitment Born between November 
1994 and July 1997 
Followed for ≥one year or 
progressed to T1D before 
the age of one year by the 
end of 2003 
Follow-up period in the current study Until the age of 15.5 years Until 31 December 2015 
Timing of study visits Every 3–12 months from 
birth 
Every 3–12 months from 
birth 
Clinical characteristic 
Sex, boys 533 (53.0%) 3895 (52.6%) 
High-risk HLA-DQB1*02/*03:02 genotype 252 (25.0%) 1575 (21.3%) 
Progression to type 1 diabetes 35 (3.5%) Study II 248 (3.3%) 
Study III 247 (3.3%)* 
Follow-up time from birth including 
progressors, years 
14.9 (1.9–15.5) 16.2 (0.9–21.1) 
Follow-up time from birth excluding 
progressors, years 
15.0 (1.2–15.5) NA 
Age at diagnosis of type 1 diabetes, years 8.0 (2.1–14.2) 7.6 (0.9–18.0) 
Age at seroconversion, years 7.4 (0.3–15.1) 5.0 (0.2–15.1) 
Time from seroconversion to diagnosis, 
years 
3.8 (0.1–11.1) 4.0 (0.02–17.0) 
 Subjects and methods  
 52 
Table 5. Investigated non-HLA SNPs in Studies II and III. 
 
Chromosome SNP Gene Minor / 
major allele 
Risk genotype Reference Study 
1p13.2 rs2476601 PTPN22 A/G AA, AG 237 II, III 
11p15.5 rs689 INS T/A AA 211 II, III 
10p15.1 rs12722495 IL2RA G/A AA, AG 216 II, III 
10p15.1 rs2104286 IL2RA G/A AA, AG 386 II, III 
12q13.2 rs1701704 IKZF4 C/A CC, AC 214 II, III 
12q13.2 rs2292239 ERBB3 A/C AA, AC 210 II, III 
1q31.2 rs2816316 RGS1 G/T TT 216 II, III 
2q33.2 rs3087243 CTLA4 A/G GG, AG 210 II, III 
4q27 rs17388568 ADAD1/IL2 A/G AA, AG 210 II, III 
18q11.2 rs45450798 PTPN2 C/G GG, CG 216 II, III 
2q24.2 rs1990760 IFIH1 C/T TT, CT 210 II, III 
6q15 rs3757247 BACH2 A/G AA, AG (only GADA+) 129, **212 II, III 
12q24.1 rs3184504 SH2B3 A/G (T/C) AA, AG (TT, CT) 210 II, III 
15q25.1 rs3825932 CTSH C/T TT 212 II, III 
16p13.1 rs12708716 CLEC16A G/A AA, AG 210 II, III 
19q13.4 rs601338 FUT2 A/G AA (non-secretor) 220 II, III 
1p31.1 (non-
confirmed) 
rs630115 LOC646538 A/G GG, AG ***217, 386 II, III 
15q14 rs17574546 RASGRP1 C/A CC, AC 213 II, III 
10p11.2 rs2666236 NRP1 A/G (T/C) AA, AG (TT, CT) 210 II, III 
2q32.2 rs7574865 STAT4 T/G TT, GT 213 II, III 
18q22.2 rs763361 CD226 T/C TT, CT 210 II, III 
1q32.1 rs3024505 IL10 T/C CC, CT 208 II, III 
3p21.3 rs11711054 CCR3-CCR5 G/A GG, AG 208, 216 II, III 
12p13.3 rs3764021 CLEC2D T/C (A/G) CC (GG) 210 II, III 
6q23.3 rs6920220 TNFAIP3 A/G AA, AG 221 II 
16p13 rs2903692 KIAA0350 
/CLEC16A 
A/G GG, AG 217 III 
Chr 10 rs11594656 IL2RA/CD25 A/T TT, AT 210 III 
11p15.5 rs3842729 INS C/T CC 236 III 
Chr 8 rs13266634 SLC30A8 C/T CC, TT homozygotes 
(ZnT8A+) 
159 III 
12q24 rs17696736 NAA25 G/A GG, AG 210 III 
Chr 2 rs2111485 IFIH1 A/G GG, AG 218, 221 III 
Chr 7 rs6965571 GIMAP5 A/G GG, AG 387 III 
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Chr 7 rs2286899 GIMAP5 C/T TT, CT* 387 III 
Chr 7 rs10361 GIMAP5 C/G GG, CG* 387 III 
Chr 7 rs2293174 GIMAP4 C/A AA, AC* 387 III 
Chr 7 rs2373816 GIMAP4 G/A GG, AG* 387 III 
Chr 3 rs4402960 IGF2BP2 G/T GG risk genotype 
for T2D* 
388 III 
4q27 rs4505848 KIAA1109/IL2 A/G susceptible locus 208 III 
Chr 10 rs41295061 IL2RA C/A CC, AC 221 III 
12p13.31 rs4763879 CD69 G/A AA, AG 208 III 
1p13.2 rs6679677 PHTF1 C/A AA, AC  210 III 
2q12.1 rs917997 IL18RAP A/G GG, AG 216 III 
2p13 rs6546909 DQX1 T/A AA, AT 210 III 
2q11 rs9653442 AFF3- 
LOC150577 
G/A (C/T) GG, AG (CC, CT) 210 III 
10p15.1 rs11258747 PRKCQ T/G TT 208 III 
13q32 rs9585056 GPR183/EBI2 C/T CC, CT 219 III 
 
*No association with type 1 diabetes reported. **Association with type 1 diabetes reported for 
another BACH2 gene SNP (rs11755527) in high linkage disequilibrium with the investigated 
rs3757247 SNP (r2=0.94). ***Association with type 1 diabetes reported for another LOC646538 gene 
SNP (rs672797) in complete linkage disequilibrium with the investigated rs630115 SNP (r2=1). 
 
 
Autoantibody analyses 
 
The analyses of type 1 diabetes-associated autoantibodies were carried out in the Research 
Laboratory, Department of Pediatrics, University of Oulu, Oulu, Finland, except in the case of 
ZnT8A, which were analyzed in the PEDIA Laboratory, University of Helsinki, Helsinki, Finland. 
The primary screening in the DIPP study was ICA-based from 1994 to 2002. Three biochemical 
autoantibodies, IAA, GADA, and IA-2A, were analyzed from all earlier and subsequent samples of 
study participants who tested positive for ICA or were diagnosed with clinical type 1 diabetes. All 
samples from participants born in 2003 onwards were analyzed directly for ICA, IAA, GADA, and 
IA-2A. Furthermore, all samples obtained from the first 1006 DIPP children born in 1994–1997 were 
analyzed directly for ICA, IAA, GADA, and IA-2A, and subsequently also for ZnT8A. 
 ICA were analyzed by using a standardized indirect immunofluorescence method on sections 
of frozen human blood group O donor pancreas (16). The ICA titers were expressed in JDF units 
(JDFU). The detection limit for ICA positivity was 2.5 JDFU. The biochemical autoantibodies IAA, 
GADA, IA-2A, and ZnT8A were analyzed by using specific radiobinding assays, as previously 
described (154, 164, 389–391). Autoantibody titers of the biochemical autoantibodies were expressed 
in relative units (RU), reflecting the specific binding of autoantibodies to their antigens. The RU were 
based on a standard curve run on each assay plate by using the MultiCalc software (PerkinElmer Life 
Sciences-Wallac, Inc., Turku, Finland). Cut-off values for autoantibody positivity were set at the 99th 
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percentile levels in 370–374 non-diabetic Finnish children (IAA, 3.48 RU; GADA 5.36 RU; IA-2A, 
0.43 RU; ZnT8A, 0.61 RU). Before analyses, all serum samples were stored at –70°C. All samples 
with autoantibody titers between the 97th and 99.5th percentile values of the reference population were 
reanalyzed to confirm the result. 
 According to the results of the Diabetes Autoantibody Standardization Program (DASP) and 
the Islet Autoantibody Standardization Program (IASP) between 2010 and 2016, the sensitivities of 
the IAA, GADA, IA-2A, and ZnT8A radiobinding assays were 36–62%, 64–88%, 62–72%, and 62–
70%, respectively. The corresponding specificities were 94–98%, 94–99%, 93–100%, and 99–100%. 
 
Definitions 
 
In Studies I and III, confirmed autoantibody positivity was defined as positivity for at least one 
autoantibody in at least two consecutive samples before diagnosis of type 1 diabetes. In Study II, 
confirmed seroconversion was defined as positivity for at least one autoantibody in at least two 
samples, and also five children who had been diagnosed with classical type 1 diabetes, but had tested 
autoantibody-positive in only one sample before the diagnosis were considered as autoantibody-
positive progressors. 
 The date of seroconversion to autoantibody positivity was defined as the date of draw of the 
first autoantibody-positive sample. Multipositivity was defined as positivity for two or more 
autoantibodies in the same sample. Primary autoantibody was defined as the first-appearing single 
autoantibody. Autoantibody titers in all studies were compared among individuals positive for the 
specific autoantibody reactivity. Inverse seroconversion was defined as becoming permanently 
autoantibody-negative after testing autoantibody-positive. Fluctuating autoantibody positivity was 
defined as one or more autoantibody-negative samples between positive samples. In the DIPP study, 
infants with transplacentally transferred maternal autoantibodies were excluded from the 
autoantibody analyses if no de novo synthesis of islet autoantibodies was detected. Progressors were 
defined as participants who were diagnosed with type 1 diabetes. 
 Type 1 diabetes was diagnosed according to the World Health Organization criteria (392). 
Whenever possible, the date of diagnosis of type 1 diabetes was verified by using the data of the 
Finnish Pediatric Diabetes Register, which covers over 90% of children under the age of 16 years 
diagnosed with type 1 diabetes in Finland since 2002. An autoantibody sample was considered to be 
obtained at the time of diagnosis if it was drawn within two weeks before or after the date of diagnosis. 
In the DIPP study, information on the affected FDRs of the study children was attained by using 
structured questionnaires completed by the parents shortly after the birth of the index child. 
 Progression to type 1 diabetes was considered to be rapid if type 1 diabetes was diagnosed 
within 1.5 years (18 months) from seroconversion to autoantibody positivity. The rationale for this 
definition was to identify approximately one-fifth of the study population with the most rapid disease 
progression. Although there was no biological evidence to support the selected cut-off, this definition 
was chosen based on practical aspects, for instance, that the individuals with aggressive islet 
autoimmunity would likely comprise one of the main target groups for future preventive 
interventions. In this regard, we considered that it takes a couple of months to confirm autoantibody 
positivity, exclude clinical type 1 diabetes, and recruit the child to a clinical trial. On the other hand, 
if a preventive treatment is successful, the effect will become apparent in a short period of time. 
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 Disease progression was considered as slow in cases where the delay from seroconversion to 
diagnosis lasted for at least 7.26 years (87 months). This cut-off was set at the 75th percentile value 
of the delay to diagnosis observed among progressors in the DIPP study cohort. Again, no biological 
evidence supports the selected cut-off, but this definition provided a favorable setting to investigate 
the factors related to a considerably longer delay from seroconversion to diagnosis than seen among 
most progressors in the DIPP study cohort. As the definitions of rapid and slow progression were 
partly data-driven, the generalizability of the results might be limited. 
 In Study III, multipositive non-progressors were defined as participants with multiple 
autoantibodies who had been monitored for at least 7.26 years after seroconversion to autoantibody 
positivity, but had remained unaffected by type 1 diabetes by 31 December 2015 (n=198). 
 
Data management and statistical methods 
 
IBM SPSS predictive analytics software for Macintosh (versions 22.0 and 25.0, IBM Corp., Armonk, 
NY, USA) was applied for statistical analyses. The confidence interval (CI) was set at 95% and the 
statistical significance at P<0.05 (two-tailed). To test statistical differences, cross-tabulation, 
Pearson’s χ2 test, Fisher’s exact test, the Mann-Whitney U test, and the Kruskall-Wallis test were 
used, when applicable. Sensitivity and specificity values were calculated as previously described 
(393). Survival distributions were analyzed by using the log-rank test (Kaplan-Meier analysis). In 
Study I, survival tables were created by applying the GraphPad Prism 8 Software for Mac Os X. In 
Study II, Cox regression analyses were applied to identify independent variables predictive of rapid 
progression to type 1 diabetes. 
 In the SNP association analyses, the high possibility of false-positive associations caused by 
multiple statistical testing was taken into consideration. In Study II, the P-values of the multiple 
comparisons were corrected by using the Bonferroni correction. In Study III, the false discovery rate 
was controlled by using the Benjamini-Hochberg step-up procedure applying the cumulative 
minimum principle (R Software for Statistical Computing for Macintosh, version 3.3.3, R 
Foundation, Vienna, Austria) (394). Corrections for multiple comparisons were not applied in the 
data analysis in Study I due to the overly conservative nature of the Bonferroni correction. The 
observed associations were, however, interpreted cautiously. 
 
Ethical considerations 
 
The DIPP study protocol was approved by the local ethics committees of the participating hospitals. 
The study has been carried out in accordance with the principles of the Declaration of Helsinki as 
revised in 2008. The legal guardians of the newborn infants gave written informed consent for HLA 
screening and for participation in the DIPP study follow-up.  
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RESULTS 
 
Dynamics of islet autoantibodies from birth up to 15 years of age 
 
In Study I, the 1006 HLA-predisposed children, including progressors to type 1 diabetes, were 
followed from birth over a median time of 14.9 years (range 1.9–15.5 years) (Table 4). In total, 542 
participants (55.8%) completed the 15-year follow-up. By 15.5 years of age, type 1 diabetes was 
diagnosed in 35 children (3.5%), and confirmed seroconversion to autoantibody positivity was 
detected in 275 children (27.3%), including 32 progressors. 
 
Age-related dynamics of islet autoantibodies 
 
Over the first 15 years, there were marked differences in the age-related behavior of individual 
autoantibodies. The overall seroconversion rate accelerated towards puberty, mostly due to low-titer 
ICA seroconversions. The cumulative proportions of all autoantibodies increased up to 15 years of 
age (Table 6). There was no difference in the overall seroconversion rate between boys and girls with 
increasing age (Table 7). To examine the dynamics of islet autoantibodies, we calculated 
seroconversion rates of each autoantibody reactivity in four age periods (Table 6). The low-titer ICA 
seroconversion rate increased continuously, while the seroconversion rates of biochemically defined 
autoantibodies and high-titer ICA decreased with advancing age. In children under the age of 3 years, 
IAA prevailed as the most common autoantibody, but after 3 years of age, ICA exceeded IAA as the 
predominant autoantibody (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Development of ICA, 
IAA, GADA, IA-2A, and ZnT8A 
by 15.5 years of age. 
 
Reproduced with permission from 
J Clin Endocrinol Metab.
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Table 6. Cumulative frequencies of autoantibodies by the age of 15.5 years, median age at seroconversion, and seroconversion rates in four age 
periods (0–1.99, 2–4.99, 5–9.99, and 10–15.5 years) among the 1006 HLA-susceptible children in Study I. 
JDFU=Juvenile Diabetes Foundation units. Reproduced with permission from J Clin Endocrinol Metab. 
 
Autoantibody type Cumulative frequency of 
autoantibody positivity at 
15.5 years (%) 
Median age at 
seroconversion, years 
(range) 
Seroconversions per 100 follow-up years 
0–1.99 years 2–4.99 years 5–9.99 years 10–15.5 years 
ICA, ≥2.5 JDFU 245 (24.4) 8.1 (0.5–15.1) 1.2 1.5 2.3 2.8 
ICA, ≥10 JDFU 72 (7.2) 4.2 (0.5–14.5) 1.1 0.6 0.5 0.4 
IAA 69 (6.9) 2.5 (0.5–14.0) 1.4 0.6 0.4 0.2 
GADA 69 (6.9) 5.0 (0.8–12.9) 0.9 0.6 0.6 0.3 
IA-2A 42 (4.2) 4.1 (1.0–12.1) 0.5 0.6 0.3 0.1 
ZnT8A 48 (4.8) 3.1 (0.3–15.0) 0.8 0.6 0.3 0.1 
At least 1 autoantibody 275 (27.3) 7.4 (0.3–15.1) 2.0 1.8 2.5 2.7 
At least 1 autoantibody, ICA ≥10 JDFU 126 (12.5) 4.0 (0.3–14.5) 2.0 1.2 0.9 0.5 
At least 1 biochemical autoantibody 113 (11.2) 4.0 (0.3–14.0) 1.7 1.1 0.9 0.5 
Multiple (≥2) autoantibodies 71 (7.1) 4.0 (0.8–14.4) 1.1 0.6 0.5 0.4 
Multiple biochemical autoantibodies 50 (5.0) 3.0 (0.8–12.1) 1.0 0.5 0.3 0.1 
 
Table 7. Seroconversion rate to autoantibody positivity in boys vs. girls in the age periods of 0–4.99, 5–9.99, and 10–15.5 years. 
 
Sex Cumulative frequency of autoantibody 
positivity at 15.5 years 
P-
value 
Age at seroconversion, years P-
value 
Seroconversions per 100 follow-up years P-
value 
 N (%)  Median (range)  0–4.99 years 5–9.99 years 10–15.5 years  
 With ICA        
Boys 146 (27.4) 
0.97 
7.3 (0.3–15.0) 
0.96 
1.0 1.3 1.5 
0.92 Girls 129 (27.3) 7.4 (0.3–15.1) 0.9 1.2 1.2 
 Without ICA        
Boys 70 (13.1) 
0.04 
5.0 (0.3–14.0) 
0.10 
0.7 0.6 0.4 
0.22 Girls 43 (9.1) 3.5 (0.3–12.0) 0.6 0.3 0.1 
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Development of multipositivity 
 
The cumulative proportion of multipositive children grew steadily up to 15 years of age, but only four 
children turned positive for multiple biochemical autoantibodies after the age of 10 years (Figure 3). 
 
Figure 3. Development of multiple autoantibodies by the age of 15.5 years with and without ICA in 
the analysis. Reproduced with permission from J Clin Endocrinol Metab. 
 
 
Effect of HLA genotype on islet autoimmunity 
By 15 years of age, 8.3% of children with the high-risk HLA-DQB1*02/*03:02 genotype and 1.9% 
of those with moderate-risk HLA-DQB1*03:02/x (x≠*02, *03:01, *06:02) genotypes had progressed 
to type 1 diabetes. At 15 years, the proportions of children in the HLA risk groups remained virtually 
unaltered, with 136 children (25.1%) in the high-risk and 406 children (74.9%) in the moderate-risk 
HLA group (Table 4). The high-risk genotype increased the risk of islet autoimmunity compared with 
moderate-risk genotypes (36% vs. 24%; P<0.001; screening without ICA 18% vs. 9%; P<0.001). 
Among the seroconverted children, the high-risk HLA genotype was associated with an increased 
frequency of IAA (33% vs. 21%; P=0.03), GADA (36% vs. 20%; P=0.003), and multiple 
autoantibodies (35% vs. 21%; P=0.01; screening without ICA 29% vs. 13%; P=0.002), but was not 
significantly associated with positivity for ICA (90% vs. 89%; P=0.70), IA-2A (21% vs. 13%; 
P=0.07), or ZnT8A (23% vs. 15%; P=0.08) compared with moderate-risk genotypes. 
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Primary autoantibodies in different age groups 
 
The primary autoantibody profiles at initial seroconversion showed unique characteristics in different 
age groups. In young children, IAA and ZnT8A appeared commonly as the first autoantibody, but at 
preschool age IA-2A- and GADA-initiated islet autoimmunity became common. ICA as the single 
first autoantibody increased towards puberty (Figure 4). Multipositive seroconversions occurred most 
frequently in the youngest age groups. The primary ICA seroconversion rate accelerated continuously 
up to the age of 15 years, but primary seroconversions positive for biochemical autoantibodies peaked 
already at a young age. The only exception was seen in the case of primary GADA seroconversion 
rate, which continued to remain stable throughout childhood (Table 8). 
 
Primary autoantibodies at seroconversion in progressors and non-progressors 
 
Consistently with the age-associated profiles, the primary autoantibodies at seroconversion showed 
conspicuous differences between progressors and non-progressors (Table 9). In progressors, the 
primary autoantibody was in most cases either IAA or ZnT8A among those who were not 
multipositive at seroconversion, whereas in multipositive non-progressors it was mostly GADA. 
Accordingly, GADA as the single first autoantibody was rarely seen among progressors. This was 
considered to reflect the fact that ICA might overlap with positivity for the biochemical 
autoantibodies. Therefore, the analysis was also carried out without ICA. However, even when ICA 
was excluded from the analysis, primary GADA positivity remained rare among progressors, but was 
associated with multipositive non-progressors (Table 9). Notably, ICA as the single primary 
autoantibody at seroconversion implied non-progressive autoimmunity regardless of the ICA titer. 
 
Figure 4. Autoantibody profiles at initial seroconversion in the age groups 0–2 (N=41, a), 2–5 (N=51, b), 5–
10 (N=97, c), and 10–15.5 (N=86, d) years. *P<0.05 compared with all other groups, †P<0.05 a vs. b, a vs. c, 
a vs. d, b vs. c, b vs. d, ‡P<0.05 a vs. b, a vs. c, a vs. d, b vs. c, §P<0.05 a vs. c, a vs. d. Reproduced with 
permission from J Clin Endocrinol Metab.  
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Table 8. Autoantibodies at primary seroconversion and the rates of primary seroconversions positive 
for each autoantibody in four age periods with ICA (A) and without ICA (B) in the analysis. 
 
A 
With ICA N (% of primary seroconversions in the age period)b 
Autoantibody positivity 0–1.99 years 2–4.99 years 5–9.99 years 10–15.5 years 
ICA 10 (24.4) 25 (49.0) 75 (77.3) 76 (88.4) 
IAA 24 (58.5) 14 (27.5) 10 (10.4) 2 (2.3) 
GADA 8 (19.5) 11 (21.6) 15 (15.5) 9 (10.5) 
IA-2A 1 (2.4) 3 (5.9) 3 (3.1) 1 (1.2) 
ZnT8Aa 11 (35.5) 9 (18.4) 2 (3.0) 0 (0.0) 
Multiple (≥2) AABs 9 (22.0) 5 (9.8) 7 (7.2) 2 (2.3) 
Multiple biochemical AABs  7 (17.1) 5 (9.8) 1 (1.0) 0 (0.0) 
 Primary seroconversions per 100 follow-up years* 
 0–1.99 years 2–4.99 years 5–9.99 years 10–15.5 years 
ICA 0.5 0.9 1.9 2.4 
IAA 1.2 0.5 0.3 0.1 
GADA 0.4 0.4 0.4 0.3 
IA-2A 0.0 0.1 0.1 0.0 
ZnT8A 0.5 0.3 0.1 0.0 
Multiple (≥2) AABs 0.4 0.2 0.2 0.1 
Multiple biochemical AABs  0.3 0.2 0.0 0.0 
 
B 
Without ICA N (% of primary seroconversions in the age period)d 
Autoantibody positivity 0–1.99 years 2–4.99 years 5–9.99 years 10–15.5 years 
IAA 24 (70.6) 14 (46.7) 12 (35.3) 3 (20.0) 
GADA 8 (23.5) 11 (36.7) 18 (52.9) 10 (66.7) 
IA-2A 1 (2.9) 4 (13.3) 3 (8.8) 1 (6.7) 
ZnT8Ac 11 (45.8) 9 (32.1) 3 (11.5) 1 (20.0) 
Multiple biochemical AABs  7 (20.6) 5 (16.7) 1 (2.9) 0 (0.0) 
 Primary seroconversions per 100 follow-up years* 
 0–1.99 years 2–4.99 years 5–9.99 years 10–15.5 years 
IAA 1.2 0.5 0.3 0.1 
GADA 0.4 0.4 0.5 0.3 
IA-2A 0.0 0.1 0.1 0.0 
ZnT8A 0.5 0.3 0.1 0.0 
Multiple biochemical AABs 0.3 0.2 0.0 0.0 
 
aZnT8A data available at primary seroconversion for 159 children. 
bPrimary seroconversions in the age period 0–1.99 years, n=41; 2–4.99 years, n=51; 5–9.99 years, 
n=97; 10–15.5 years, n=86. 
cZnT8A data available at primary biochemical autoantibody seroconversion for 83 children. 
dPrimary seroconversions without ICA in the age period 0–1.99 years, n=34; 2–4.99 years, n=30; 5–
9.99 years, n=34; 10–15.5 years, n=15. 
*Primary seroconversions positive for autoantibody reactivity per 100 follow-up years. 
AAB=autoantibody. Reproduced with permission from J Clin Endocrinol Metab. 
 
Table 9. Primary autoantibody signatures in progressors, multipositive non-progressors, and single autoantibody-positive non-progressors with 
and without ICA in the analysis. 
 
Primary autoantibodies Total Progressors Multipositive non-progressors Single AAB-positive 
non-progressors 
P* P† P‡ P§ 
 
With ICA n=275 n=32 n=39 n=204     
 N (%)        
Only ICAa 172 (62.5) 1 (3.1) 8 (20.5) 163 (79.9) NS *** *** *** 
Only IAAa 35 (12.7) 6 (18.8) 9 (23.1) 20 (9.8) NS *** ** ** 
Only GADAa 28 (10.2) 0 (0) 13 (33.3) 15 (7.4) ** NS *** NS 
Only IA-2Aa 2 (0.7) 0 (0) 0 (0) 2 (1.0) NA NA NA NS 
Only ZnT8Aa,b 15 (5.5) 7 (21.9) 4 (10.3) 4 (2.0) ** *** NS *** 
Multiple autoantibodies 23 (8.4) 18 (56.3) 5 (12.8) 0 (0) *** NA NA *** 
Without ICA n=113 n=32 n=19 n=62     
 N (%)        
Only IAAa 41 (36.3) 8 (25.0) 5 (26.3) 28 (45.2) NS NS NS NS 
Only GADAa 37 (32.7) 3 (9.4) 9 (47.4) 25 (40.3) * * NS * 
Only IA-2Aa 5 (4.4) 2 (6.3) 0 (0) 3 (4.8) NS NS NS NS 
Only ZnT8Aa,c 17 (15.0) 8 (25.0) 3 (15.8) 6 (9.7) NS * NS * 
Multiple autoantibodies 13 (11.5) 11 (34.4) 2 (10.5) 0 (0) NS NA NA *** 
 
P*= Progressors vs. multipositive non-progressors 
P†= Progressors vs. single autoantibody-positive non-progressors 
P‡= Multipositive vs. single autoantibody-positive non-progressors 
P§= Progressors vs. all non-progressors 
aMultipositive individuals were excluded from the comparisons of single autoantibody-positive signatures between the groups. 
bZnT8A data available at seroconversion for 27 progressors, 35 multipositive non-progressors, and 97 single autoantibody-positive non-progressors. Among 
these children, 12 progressors and 30 multipositive non-progressors had only one autoantibody at initial seroconversion. 
cZnT8A data available at biochemical autoantibody seroconversion for 28 progressors, 18 multipositive non-progressors, and 37 single autoantibody-positive 
non-progressors. Among these children, 18 progressors and 16 multipositive non-progressors had only one biochemical autoantibody at initial seroconversion. 
*P<0.05 
**P<0.01 
***P<0.001 
NS=non-significant. Reproduced with permission from J Clin Endocrinol Metab.
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Inverse seroconversions and fluctuating autoantibodies 
 
Among the islet autoantibodies, IAA experienced most frequently an inverse seroconversion and 
demonstrated most often fluctuations in autoantibody positivity (Table 10). Inverse seroconversions 
of IAA, IA-2A, and ICA were less common among progressors than non-progressors. No reversions 
or fluctuations of ICA occurred in progressors. None of the children with multiple biochemical 
autoantibodies reverted back to complete autoantibody negativity, but one of these children tested 
positive for only ICA in the last available sample. 
 
 
Table 10. Inverse seroconversions and autoantibody fluctuations in Study I. 
 
 Total* 
(n=275) 
Progressors 
(n=32) 
Autoantibody-positive non-
progressors (n=243) 
P-value 
 N (%)  
Inverse seroconversions 124 (45.1) 13 (40.6) 111 (45.7) NS 
Fluctuating AABs 110 (40.0) 12 (37.5) 98 (40.3) NS 
Multiple fluctuations of the 
same reactivity 
49 (17.8) 8 (25.0) 41 (16.9) NS 
Inverse seroconversions 
and/or fluctuations 
180 (65.5) 21 (65.6) 159 (65.4) NS 
Inverse seroconversions and 
fluctuations 
54 (19.6) 4 (12.5) 50 (20.6) NS 
 
 N (%)a  
Inverse seroconversion     
 ICA 77 (31.4) 0 (0) 77 (36.2) <0.001 
 IAA 34 (49.3) 7 (25.9) 27 (64.3) 0.002 
 GADA 20 (29.0) 5 (20.0) 15 (34.1) NS 
 IA-2A 4 (9.3) 0 (0) 4 (22.2) 0.01 
 ZnT8A 9 (18.8) 3 (12.0) 6 (26.1) NS 
Fluctuating positivity     
 ICA 69 (28.2) 0 (0) 69 (32.4) <0.001 
 IAA 25 (36.2) 7 (25.9) 18 (42.9) NS 
 GADA 14 (20.3) 1 (4.0) 13 (29.5) 0.01 
 IA-2A 6 (14.0) 2 (8.0) 4 (22.2) NS 
 ZnT8A 8 (16.7) 6 (24.0) 2 (8.7) NS 
 
*Total number of seroconverters. 
aProportion of participants positive for the specific autoantibody reactivity. 
AAB=autoantibody. NS=non-significant. 
Reproduced with permission from J Clin Endocrinol Metab. 
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Effect of autoantibody titers on autoantibody persistence 
 
As IAA and ICA demonstrated the most unstable characteristics among the islet autoantibodies, we 
examined the effect of their titers on the rate of inverse seroconversions. For each child positive for 
IAA and/or ICA, the peak autoantibody titer of each reactivity was selected for analysis. The highest 
IAA titers were significantly higher among children with persistent IAA positivity than among those 
who became negative for IAA (median 34.6 vs. 11.0 RU; P<0.001). The peak ICA titers also reached 
higher levels among those who remained ICA-positive than among those who reverted back to ICA 
negativity (median 10.0 vs. 5.0 JDFU; P<0.001). 
 
Persistence of insulin autoantibodies and progression rate to type 1 diabetes 
 
We examined the association of autoantibody persistence with the pace of disease progression. 
Compared with progressors with persistent IAA positivity, those who became IAA-negative before 
diagnosis had a prolonged delay from seroconversion to diagnosis (8.2 vs. 3.4 years; P=0.01). At 
diagnosis, the proportion of IAA-positive children was higher among those with the high-risk HLA 
genotype than among those with moderate-risk genotypes (75% vs. 36%; P=0.02). Children who 
tested IAA-positive at diagnosis were diagnosed at a younger age than those who tested IAA-negative 
(median 6.6 vs. 11.7 years; P=0.02), although the age at seroconversion did not differ between these 
groups (1.2 vs. 1.0 years; P=0.42). No significant associations emerged between positivity for other 
islet autoantibodies and the age at diagnosis (data not shown). Data on autoantibodies at diagnosis of 
type 1 diabetes are shown in Table 11. 
 
 
Table 11. Autoantibody positivity and median titers for positive autoantibodies at diagnosis of type 
1 diabetes among the 34 progressors with available autoantibody samples at diagnosis. 
 
 Autoantibody type N (%) 
Autoantibody positivity ICA 33 (97.1) 
 IAA 20 (58.8) 
 GADA 22 (64.7) 
 IA-2A 29 (85.3) 
 ZnT8A 19 (65.5) 
 Multipositivity 33 (97.1) 
 Multiple biochemical autoantibodies 28 (82.4) 
  Median (range) 
Autoantibody titers ICA, JDFU 44.0 (3.0–640.0) 
 IAA, RU 18.9 (4.0–303.0) 
 GADA, RU 34.0 (5.9–165.7) 
 IA-2A, RU 91.1 (0.4–126.7) 
 ZnT8A, RU 4.3 (0.7–17.0) 
 
Reproduced with permission from J Clin Endocrinol Metab. 
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Dynamics of islet autoimmunity and season of birth 
 
In Study I, season of birth contributed to age-related characteristics of islet autoimmunity. 
Multipositivity for biochemical autoantibodies developed more often before the age of 2 years among 
children born in the winter, from December to February, than among those born in other seasons 
(67% vs. 25%; P=0.004). Multipositivity for biochemical autoantibodies tended to appear also at a 
younger age among children born in the winter than among those born in other seasons (median 1.5 
vs. 4.0 years; P=0.06). However, being born in the winter did not increase the frequency of 
progression to type 1 diabetes compared with being born in other seasons (4% vs. 3%; P=0.43). 
Inverse seroconversions to IAA showed a higher frequency among children born in the fall, from 
September to November, than among those born in other seasons (77% vs. 43%; P=0.03). However, 
these observations should be interpreted cautiously, as the number of participants in the comparisons 
was small and significant differences in the distributions may have arisen by chance. 
 
Comparison of progressors to multiple autoantibody-positive non-progressors 
 
As multipositivity is a strong predictor of type 1 diabetes within 15 years, we examined the profiles 
of progressors compared with multipositive non-progressors (149). Multipositivity within a year from 
seroconversion predicted strongly progression to clinical disease (Table 12). However, this difference 
did not reach statistical significance when ICA was excluded from the analysis. All progressors and 
multipositive non-progressors developed ICA positivity. 
 When ICA was omitted from the analysis, only a few differences were seen between the groups, 
but those that remained statistically significant included a higher frequency of the high-risk HLA 
genotype and younger age at ZnT8A positivity among the progressors than among the multipositive 
non-progressors. The progressors tested also significantly more often positive for IAA at 
seroconversion before the age of 5 years than the multipositive non-progressors. 
 No inverse seroconversions or fluctuations of ICA occurred among progressors, but the 
corresponding proportions among multipositive non-progressors were notable (Table 13). Without 
ICA in the analysis, IAA positivity disappeared more often among multipositive non-progressors than 
progressors. Furthermore, progressors and multipositive non-progressors demonstrated significant 
differences in the dynamics of autoantibody titers. Compared with matched multipositive controls, 
the titers of ICA, IA-2A, and ZnT8A started to increase in progressors already months before the 
diagnosis (Table 14).  
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Table 12. Clinical characteristics in progressors and multipositive non-progressors with ICA (A) and 
without ICA (B) in the analysis. 
RU=relative units. JDFU=Juvenile Diabetes Foundation units. *P<0.05, **P<0.01, ***P<0.001, 
NS=non-significant. Reproduced with permission from J Clin Endocrinol Metab. 
 
A 
  Progressors 
(n=32) 
Multipositive non-progressors 
(n=39) 
P-value 
 N (%)  
HLA genotype    
 High-risk HLA genotype 20 (62.5) 12 (30.8) ** 
Sex    
 Boys 18 (56.3) 28 (71.8) NS 
Affected FDRs at birth 5 (15.6) 2 (5.1) NS 
Period of seroconversion   NS 
 0–5 years 25 (78.1) 21 (53.8)  
 5–10 years 6 (18.8) 15 (38.5)  
 10–15.49 years 1 (3.1) 3 (7.7)  
AAB positivity at seroconversion    
 ICA 12 (37.5) 11 (28.2) NS 
 IAA 19 (59.4) 11 (28.2) ** 
 GADA 11 (34.4) 17 (43.6) NS 
 IA-2A 6 (18.8) 0 (0) ** 
 ZnT8A 12 (44.4) 6 (17.1) * 
 Multipositivity 18 (56.3) 5 (12.8) *** 
 Multipositivity without ICA 11 (34.4) 2 (5.1) ** 
AAB positivity during follow-up    
 ICA 32 (100) 39 (100) NA 
 IAA 27 (84.4) 21 (53.8) ** 
 GADA 25 (78.1) 27 (69.2) NS 
 IA-2A 24 (75.0) 16 (41.0) ** 
 ZnT8A 25 (78.1) 18 (46.2) ** 
 Multipositivity 32 (100) 39 (100) NA 
 Multipositivity within a year from 
seroconversion 
30 (93.8) 19 (48.7) *** 
 Multipositivity ≤5 years of age 25 (78.1) 14 (35.9) *** 
 Multipositivity without ICA 31 (96.9) 19 (48.7) *** 
  Median (range)   
Age at seroconversion, years 1.7 (0.3–10.6) 4.2 (0.3–12.9) ** 
 ICA 2.1 (0.8–10.6) 5.5 (1.0–14.4) *** 
 IAA 1.8 (0.5–10.3) 3.0 (0.8–12.0) NS 
 GADA 1.8 (0.8–9.9) 5.5 (0.8–12.9) * 
 IA-2A 4.0 (1.0–10.6) 5.0 (1.2–12.1) NS 
 ZnT8A 2.2 (0.3–10.7) 5.0 (0.3–15.0) * 
 Multipositivity 2.0 (0.8–10.6) 7.4 (1.0–14.4) *** 
 Multipositivity without ICA 2.5 (0.8–10.7) 4.0 (1.0–12.1) NS 
AAB titers at seroconversion    
 ICA, JDFU 13.5 (4.0–320.0) 5.0 (4.0–28.0) ** 
 IAA, RU 9.8 (5.0–56.1) 7.1 (4.1–19.0) * 
 GADA, RU 28.0 (6.5–176.3) 11.0 (5.7–65.7) NS 
 IA-2A, RU 12.6 (1.4–109.9) – NA 
 ZnT8A, RU 1.7 (0.7–2.8) 0.7 (0.7–7.5) NS 
Time from single to multiple 
autoantibody positivity, years 
0.5 (0.3-2.7) 1.5 (0.2-9.4) ** 
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B 
  Progressors 
(n=32) 
Non-progressors with multiple 
biochemical autoantibodies (n=19) 
P-value 
 N (%)  
HLA genotype    
 High-risk HLA genotype 20 (62.5) 6 (31.6) * 
Sex    
 Boys 18 (56.3) 13 (68.4) NS 
Affected FDRs at birth 5 (15.6) 1 (5.3) NS 
Period of seroconversion   NS 
 0–5 years 25 (78.1) 15 (78.9)  
 5–10 years 6 (18.8) 2 (10.5)  
 10–15.49 years 1 (3.1) 2 (10.5)  
Period of seroconversion   NS 
 0–2 years 17 (53.1) 8 (42.1)  
 2–5 years 8 (25.0) 7 (36.8)  
 5–10 years 6 (18.8) 2 (10.5)  
 10–15.49 years 1 (3.1) 2 (10.5)  
AAB positivity at seroconversion    
 IAA 19 (59.4) 6 (31.6) NS 
 GADA 11 (34.4) 11 (57.9) NS 
 IA-2A 6 (18.8) 0 (0) NS 
 ZnT8A 13 (46.4) 5 (27.8) NS 
 Multipositivity 11 (34.4) 2 (10.5) NS 
AAB positivity at seroconversion at 
age ≤5 years 
   
 IAA 18 (72.0) 6 (40.0) * 
 GADA 8 (32.0) 7 (46.7) NS 
 IA-2A 3 (12.0) 0 (0) NS 
 ZnT8A 11 (52.4) 5 (33.3) NS 
 Multipositivity 10 (40.0) 2 (13.3) NS 
AAB positivity during follow-up    
 IAA 27 (84.4) 13 (68.4) NS 
 GADA 25 (78.1) 18 (94.7) NS 
 IA-2A 24 (75.0) 15 (78.9) NS 
 ZnT8A 25 (78.1) 16 (84.2) NS 
 Multipositivity 31 (96.9) 19 (100) NS 
 Multipositivity within a year from 
seroconversion 
24 (77.4) 11 (57.9) NS 
 Multipositivity ≤5 years of age 23 (74.2) 12 (63.2) NS 
  Median (range)   
Age at seroconversion, years 1.6 (0.3–10.6) 2.5 (0.3–10.5) NS 
 IAA 1.8 (0.5–10.3) 1.6 (0.8–11.0) NS 
 GADA 1.8 (0.8–9.9) 3.9 (0.8–10.5) NS 
 IA-2A 4.0 (1.0–10.6) 5.4 (1.2–12.1) NS 
 ZnT8A 2.2 (0.3–10.7) 4.0 (0.3–15.0) * 
 Multipositivity 2.5 (0.8–10.7) 4.0 (1.0–12.1) NS 
AAB titers at seroconversion    
 IAA, RU 9.8 (5.0–56.1) 7.7 (4.1–8.8) NS 
 GADA, RU 28.0 (6.5–176.3) 31.3 (5.7–65.7) NS 
 IA-2A, RU 12.6 (1.4–109.9) – NA 
 ZnT8A, RU 1.5 (0.7–2.8) 0.7 (0.7–7.5) NS 
Time from single to multiple 
autoantibody positivity, years 
0.5 (0.1-4.0) 0.9 (0.2-7.4) NS 
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Table 13. Inverse seroconversions and fluctuations of autoantibodies in progressors and multipositive 
non-progressors with ICA (A) and without ICA (B) in the analysis. 
 
A 
  Progressors 
(n=32) 
Multipositive non-progressors (n=39) P-value 
  N (%)a   
Inverse seroconversions    
 ICA 0 (0) 8 (20.5) ** 
 IAA 7 (25.9) 11 (52.4) NS 
 GADA 5 (20.0) 4 (14.8) NS 
 IA-2A 0 (0) 2 (12.5) NS 
 ZnT8A 3 (12.0) 3 (16.7) NS 
Fluctuating autoantibodies    
 ICA 0 (0) 9 (23.1) ** 
 IAA 7 (25.9) 12 (57.1) * 
 GADA 1 (4.0) 6 (22.2) NS 
 IA-2A 2 (8.0) 3 (18.8) NS 
 ZnT8A 6 (24.0) 1 (5.6) NS 
 
B 
  Progressors 
(n=32) 
Non-progressors with multiple 
biochemical autoantibodies (n=19) 
P-value 
  N (%)a   
Inverse seroconversions    
 IAA 7 (25.9) 8 (61.5) * 
 GADA 5 (20.0) 1 (5.6) NS 
 IA-2A 0 (0) 1 (6.7) NS 
 ZnT8A 3 (12.0) 3 (18.8) NS 
Fluctuating autoantibodies    
 IAA 7 (25.9) 7 (53.8) NS 
 GADA 1 (4.0) 4 (22.2) NS 
 IA-2A 2 (8.3) 3 (20.0) NS 
 ZnT8A 6 (24.0) 1 (6.3) NS 
 
aProportion among those who tested positive for the autoantibody reactivity. 
*P<0.05 
**P<0.01 
***P<0.001 
NS=non-significant. 
Reproduced with permission from J Clin Endocrinol Metab. 
 
 
 
Table 14. Median autoantibody titers in progressors (n=20) and multipositive controls (non-progressors who developed multiple autoantibodies by 
the age of 15.5 years, n=20) matched for date of birth (+/- 3 months), DIPP study center, HLA risk genotype, and sex. 
 
  Progressors Multipositive controls P-value 
  Median (range)   
In the latest study sample available within a year from 
seroconversion 
   
 Age, years 2.6 (1.5–11.5) 2.7 (1.4–11.4) NS 
 ICA, JDFU 31.0 (0.0–130.0) 0.0 (0.0–640.0) *** 
 IAA, RU 7.8 (0.0–294.8) 5.3 (0.0–10.2) * 
 GADA, RU 8.8 (0.0–151.7) 0.1 (0.0–165.1) ** 
 IA-2A, RU 1.0 (0.1–122.3) 0.1 (0.0–18.7) ** 
 ZnT8A, RU 1.3 (0.1–5.1) 0.2 (0.0–37.9) ** 
In the latest study sample available 18–24 months before 
diagnosis of type 1 diabetes 
   
 Age, years 6.5 (0.5–12.5) 6.4 (0.6–12.5) NS 
 ICA, JDFU 66.5 (0.0–640.0) 2.5 (0.0–191.0) ** 
 IAA, RU 5.3 (0.0–76.9) 5.3 (0.4–30.3) NS 
 GADA, RU 10.0 (0.1–141.1) 0.2 (0.1–1489.5) NS 
 IA-2A, RU 77.9 (0.1–116.6) 0.1 (0.0–93.5) *** 
 ZnT8A, RU 3.2 (0.1–22.5) 0.3 (0.0–35.7) *** 
In the latest study sample available 6–12 months before 
diagnosis of type 1 diabetes 
   
 Age, years 7.6 (1.5–13.6) 7.6 (1.7–13.6) NS 
 ICA, JDFU 60.5 (4.0–640.0) 4.5 (0.0–380.0) *** 
 IAA, RU 4.9 (0.2–97.5) 4.1 (0.0–11.1) NS 
 GADA, RU 22.3 (0.1–146.1) 1.8 (0.1–173.7) NS 
 IA-2A, RU 72.7 (0.0–142.6) 0.1 (0.0–96.2) ** 
 ZnT8A, RU 2.9 (0.1–14.6) 0.2 (0.0–5.7) *** 
 
RU=relative units. JDFU=Juvenile Diabetes Foundation units. Reproduced with permission from J Clin Endocrinol Metab. 
*P<0.05 
**P<0.01 
***P<0.001 
NS=non-significant. 
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General observations on progression rate 
 
In Studies II and III, we aimed at identifying factors associated with the progression rate from 
seroconversion to type 1 diabetes. In the study cohort comprising 7410 HLA-predisposed children, 
the median duration of the prediabetic period was 4.0 (range 0.02–17.0) years. The distribution of the 
delay from seroconversion to diagnosis did not correlate with age at seroconversion (Spearman 
correlation coefficient 0.051; P=0.43), and there was no evidence of a naturally occurring cut-off 
between rapidly and slowly progressing forms of islet autoimmunity (Figure 5). 
 
Figure 5. Delay from seroconversion to diagnosis in relation to age at seroconversion in progressors 
with confirmed seroconversion (N=247). Reproduced with permission from J Clin Endocrinol Metab. 
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Characterization of rapid progression to type 1 diabetes 
 
Identifying the rapid progressors 
 
Of the 7410 children in Study II, altogether 1550 (20.9%) tested positive for at least one autoantibody 
in at least two samples by 31 December 2015. The median age at seroconversion was 5.0 (range 0.2–
15.1) years in the study population, and the children were followed for a median time of 16.2 (range 
0.9–21.1) years from birth (Table 4). Among the seroconverted children, 248 children (16.0%) 
developed clinical type 1 diabetes and among the progressors 42 children (16.9%) progressed to 
clinical diabetes within 1.5 years after initial seroconversion. These children were considered as rapid 
progressors, and the rest of the progressors (n=206, 83.1%) were defined as the group of slower 
progressors. The median duration of prediabetes was 0.51 (range 0.02–1.45) years among the rapid 
progressors and 5.37 (range 1.53–17.0) years among the slower progressors. 
 
Comparison of rapid progressors to slower progressors 
 
Between rapid and slower progressors, no significant differences emerged in the distributions of the 
high-risk HLA-DQB1*02/*03:02 genotype, sex, or age at seroconversion (Table 15). At 
seroconversion, the rapid progressors tested more often positive for multiple autoantibodies and 
presented with higher titers of ICA, IAA, and IA-2A than the slower progressors. However, there 
were no differences in positivity for any of the four autoantibodies between the groups at 
seroconversion, although IAA positivity tended to be more frequent among rapid progressors.  
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Table 15. Clinical characteristics of rapid and slower progressors. 
 
Characteristic Rapid progressors 
(n=42) 
Slower progressors 
(n=206) 
P-value 
 N (%)  
High-risk HLA-DQB1*02/*03:02 
genotype 
21 (50) 82 (40) NS 
Sex (boys) 25 (60) 117 (57) NS 
Autoantibody positivity at 
seroconversion 
   
 ICA 26 (62) 116 (56) NS 
 IAA 34 (81) 136 (66) NS 
 GADA 24 (57)  93 (45) NS 
 IA-2A 11 (26) 43 (21) NS 
 Multiple autoantibodies 30 (71) 113 (55) * 
Autoantibody seroconversion <1 or ≥7 
years of age 
17 (41) 37 (18) ** 
Distributions of non-HLA SNPs    
 FUT2 major allele G 
homozygositya 
13 (68) 19 (28) 0.03c 
 PTPN22 minor allele Ab 19 (46) 76 (38) NS 
  Median (range)  
Autoantibody titer at seroconversion    
 ICA, JDFU 34.5 (4–320) 10 (3–668) ** 
 IAA, RU 10.5 (4.3–66.2) 8.8 (3.5–81.0) * 
 GADA, RU 32.1 (5.6–310.4) 28.0 (5.8–189.5) NS 
 IA-2A, RU 52.5 (2.6–108.6) 16.4 (0.4–121.0) * 
Age at seroconversion, years 1.5 (0.3–13.8) 1.9 (0.3–12.0) NS 
Age at diagnosis, years 2.4 (0.9–14.6) 8.4 (2.1–18.0) NA 
Delay from seroconversion to 
diagnosis, years 
0.51 (0.02–1.45) 5.37 (1.53–17.0) NA 
Follow-up time, years 2.4 (0.9–14.6) 8.4 (2.1–18.0) NA 
 
RU=relative units. JDFU=Juvenile Diabetes Foundation units. 
aIn children with the high-risk HLA genotype. 
bData on the PTPN22 SNP genotype were available for 41 rapid progressors and 200 slower 
progressors. 
cBonferroni-corrected P-value. 
*P<0.05 
**P<0.01 
***P<0.001 
NS=non-significant. 
Reproduced with permission from Diabetologia. 
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Comparison of rapid progressors to autoantibody-positive non-progressors 
 
Among the 1550 autoantibody-positive children in Study II, 1302 (84.0%) remained disease-free by 
the end of December 2015. Compared with these non-progressors, the rapid progressors carried more 
frequently the high-risk HLA genotype and developed autoantibodies at a younger age, but there was 
no significant difference in the sex distribution between the groups (Table 16). At seroconversion, 
the rapid progressors tested more often positive for IAA, GADA, IA-2A, and multiple autoantibodies 
and demonstrated higher titers of all four autoantibodies (Table 16). The rapid progressors presented 
also more often with multiple biochemical autoantibodies at seroconversion (48% vs. 2%; P<0.001). 
However, the frequency of ICA positivity at seroconversion was higher among autoantibody-positive 
non-progressors than among rapid progressors (Table 16). This was probably related to the ICA-
based primary screening in the DIPP study. The sensitivities, specificities, and predictive values for 
predicting rapid progression of characteristics present at seroconversion are shown in Table 17. 
 
 
Table 16. Clinical characteristics of rapid progressors and autoantibody-positive non-progressors. 
 
Characteristic Rapid progressors 
(n=42) 
AAB-positive non-
progressors (n=1302) 
P-
value 
 N (%)  
High-risk HLA-DQB1*02/*03:02 genotype 21 (50) 319 (25) *** 
Sex (boys) 25 (60) 685 (53) NS 
Autoantibody positivity at seroconversion    
 ICA 26 (62) 1082 (83) *** 
 IAA 34 (81) 134 (10) *** 
 GADA 24 (57) 147 (11) *** 
 IA-2A 11 (26) 30 (2) *** 
 Multiple autoantibodies 30 (71) 70 (5) *** 
Distributions of non-HLA SNPs    
 FUT2 major allele G homozygositya 13 (68) 23 (31) NSc 
 PTPN22 minor allele Ab 19 (46) 167 (24) *c 
  Median (range)  
Autoantibody titer at seroconversion    
 ICA, JDFU 34.5 (4–320) 4 (3–512) *** 
 IAA, RU 10.5 (4.3–66.2) 6.9 (3.5–148.7) *** 
 GADA, RU 32.1 (5.6–310.4) 13.5 (5.4–342.1) * 
 IA-2A, RU 52.5 (2.6–108.6) 2.3 (0.5–88.9) *** 
Age at seroconversion, years 1.5 (0.3–13.8) 6.0 (0.2–15.1) *** 
Follow-up time, years 2.4 (0.9–14.6) 16.5 (12.4–21.1) NA 
 
aIn children with the high-risk HLA genotype. 
bData on the PTPN22 SNP genotype were available for 41 rapid progressors and 696 AAB-positive non-
progressors. 
cBonferroni-corrected P-value. 
RU=relative units. JDFU=Juvenile Diabetes Foundation units. NA=not available. AAB=autoantibody. 
*P<0.05, **P<0.01, ***P<0.001, NS=non-significant. 
Reproduced with permission from Diabetologia. 
 
Table 17. Sensitivities, specificities, positive (PPV) and negative predictive values (NPV), and odds ratios (ORs) for predicting rapid progression to 
type 1 diabetes of characteristics present at initial seroconversion (N=1550). Among the diabetes-associated autoantibodies at seroconversion, IAA 
had the highest sensitivity and IA-2A the highest specificity for predicting rapid progression. The 95% confidence intervals (CIs) are given in 
parentheses. The highest values in each column have been bolded. 
 
Characteristic at seroconversion Sensitivity, % Specificity, % PPV, % NPV, % OR (95% CI) P-value 
ICA positivity 62 (46–76) 21 (20–21) 2 (2–3) 95 (93–97) 0.42 (0.22, 0.79) 0.006 
IAA positivity 81 (66–91) 82 (82–82) 11 (9–13) 99 (99–100) 19.46 (8.91, 42.50) <0.001 
GADA positivity 57 (41–72) 84 (84–85) 9 (7–11) 99 (98–99) 7.04 (3.77, 13.18) <0.001 
IA-2A positivity 26 (15–41) 95 (95–96) 13 (7–21) 98 (98–98) 6.97 (3.37, 14.42) <0.001 
Multiple (≥2) autoantibodies 71 (56–84) 88 (87–88) 14 (11–17) 99 (99–100) 18.10 (9.11, 35.98) <0.001 
Multiple (≥2) biochemical autoantibodies 48 (33–63) 94 (93–94) 17 (12–24) 99 (98–99) 13.22 (6.98, 25.07) <0.001 
High-risk HLA genotype 50 (35–65) 73 (73–74) 5 (3–7) 98 (98–99) 2.76 (1.49, 5.11) <0.001 
Sex (boys) 41 (26–57) 53 (53–54) 2 (2–3) 97 (96–98) 0.77 (0.41, 1.44) 0.417 
FUT2 major allele G homozygositya 68 (45–86) 71 (68–73) 24 (16–30) 94 (90–98) 5.26 (1.88, 14.77) 0.001 
Age at seroconversion <1 year 41 (27–54) 82 (79–85) 32 (21–42) 87 (84–90) 3.11 (1.53, 6.33) 0.001 
Age at seroconversion <5 years  86 (71–94) 52 (51–52) 5 (4–5) 99 (98–100) 6.36 (2.66, 15.18) <0.001 
Age at seroconversion ≥7 years  14 (6–29) 64 (64–65) 1 (1–2) 96 (96–97) 0.30 (0.13, 0.72) 0.004 
ICA titer ≥10 JDFU at seroconversionb 77 (56–90) 89 (87–88) 12 (9–14) 99 (99–100) 23.83 (9.42, 60.31) <0.001 
ICA titer ≥20 JDFU at seroconversionb 65 (45–82) 96 (95–96) 25 (17–31) 99 (99–100) 41.63 (17.71, 97.83) <0.001 
IAA level ≥10 RU at seroconversionb 53 (36–69) 65 (63–67) 16 (11–21) 92 (89–95) 2.11 (1.03, 4.32) 0.039 
IAA level ≥20 RU at seroconversionb 27 (14–43) 87 (85–89) 20 (11–32) 90 (89–92) 2.34 (1.01, 5.41) 0.042 
IAA level ≥30 RU at seroconversionb 24 (12–38) 93 (92–95) 31 (16–49) 91 (89–92) 4.31 (1.71, 10.87) 0.001 
IA-2A level ≥50 RU at seroconversionb 55 (26–81) 78 (74–82) 27 (13–40) 92 (87–97) 4.28 (1.15, 15.84) 0.022 
 
aAmong participants with the high-risk HLA genotype. 
bAmong participants positive for the specific autoantibody reactivity. 
RU=relative units. JDFU=Juvenile Diabetes Foundation units.
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Double-peak distribution of age at seroconversion among rapid progressors 
 
Rapid progression to type 1 diabetes occurred in two age peaks (Figure 6). The first peak emerged 
already in early childhood before the age of 5 years and the second closer to puberty at the age of 8–
14 years. Most rapid progressors (n=36) belonged to the younger age group, but six children did not 
develop clinical diabetes until early puberty. No seroconversions between 5 and 7 years of age 
resulted in rapid disease progression. The double-peak distribution was exclusive for rapid 
progressors, not being seen for slower progressors. Compared with slower progressors, the rapid 
progressors became autoantibody-positive significantly more often before the age of one year or after 
the age of 7 years (Table 15). 
 Although the number of children in both subgroups of rapid progressors was modest, limiting 
the power of any statistical analyses, a comparison between the two subgroups revealed considerable 
differences in the autoantibody profiles among the rapid progressors at seroconversion. The young 
rapid progressors demonstrated a higher frequency of IAA positivity and higher titers of IAA than 
the older rapid progressors, whereas the older rapid progressors tested more often positive for GADA 
and had higher titers of GADA at seroconversion than the younger rapid progressors (Table 18). 
Although a higher number of the rapid progressors in the older subgroup turned out to be boys, the 
sex distribution remained non-significant. There were no statistically significant differences between 
the two subpopulations in the distribution of the high-risk HLA genotype, or the frequency of 
positivity for ICA, IA-2A, or multiple autoantibodies at initial seroconversion. Neither were the 
differences in the autoantibody profiles explained by the non-HLA SNPs analyzed in Study II (data 
not shown, except for the FUT2 (1,2-α-Fucosyltransferase) SNP in Table 18). 
 
 
Figure 6. Seroconversion age among rapid and slower progressors. Black bars, rapid progressors. 
White bars, slower progressors. Reproduced with permission from Diabetologia.  
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Table 18. Clinical characteristics of young and older rapid progressors.  
 
  Rapid progressors  
Characteristic Younga (n=36) Olderb (n=6) P-value 
  N (%)  
High-risk HLA-DQB1*02/*03:02 genotype 19 (53) 2 (33) NS 
Sex (boys) 20 (56) 5 (83) NS 
Autoantibody positivity at seroconversion    
 ICA 21 (58) 5 (83) NS 
 IAA 32 (89) 2 (33) ** 
 GADA 18 (50) 6 (100) * 
 IA-2A 9 (25) 2 (33) NS 
 Multiple autoantibodies 25 (69) 5 (83) NS 
FUT2 major allele G homozygosityc 11 (65) 2 (100) NS 
  Median (range)  
Autoantibody titer at seroconversion    
 ICA, JDFU 5 (0–320) 49 (0–85) NS 
 IAA, RU 9.5 (4.3–66.2) 1.4 (0.1–13.0) ** 
 GADA, RU 5.1 (0.1–310.4) 97.7 (5.6–158.5) ** 
 IA-2A, RU 0.11 (0.05–108.6) 0.12 (0.05–52.51) NS 
Age at seroconversion, years 1.4 (0.3–4.1) 9.0 (7.0–13.1) NA 
Age at diagnosis, years 2.1 (0.9–5.5) 9.7 (8.2–14.6) NA 
Delay from seroconversion to diagnosis, years 0.41 (0.02–1.45) 0.73 (0.59–1.19) NA 
 
 
RU=relative units. JDFU=Juvenile Diabetes Foundation units. 
aEarly childhood (<5 years old). 
bPrepuberty and puberty (>7 years old). 
cIn children with the high-risk HLA genotype. 
*P<0.05 
**P<0.01 
***P<0.001 
NS=non-significant. 
Reproduced with permission from Diabetologia. 
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Non-HLA SNPs and rapid progression to type 1 diabetes 
 
In Study II, we examined the potential associations between rapid disease progression and 25 non-
HLA SNPs predisposing to type 1 diabetes (Table 5). The distributions of the SNP genotypes were 
compared between the groups of rapid progressors, slower progressors, and autoantibody-positive 
non-progressors. Although several differences in the distributions were found between the groups, 
after Bonferroni correction for multiple testing the only differences that remained significant were 
seen among children carrying the high-risk HLA-DQB1*02/*03:02 genotype. Among such children, 
the rapid progressors carried more frequently the homozygous GG genotype in the FUT2 gene than 
the slower progressors (68% vs. 28%; OR 5.70 [95% CI 1.89, 17.17], corrected P-value, Pc=0.03). 
In addition, the rapid progressors tended to be more often homozygous for the FUT2 G allele than 
the autoantibody-positive non-progressors (68% vs. 31%; OR 4.90 [95% CI 1.66, 14.49], P=0.002, 
Pc=0.06). 
 Among progressors to type 1 diabetes, the delay from seroconversion to diagnosis was shorter 
among those homozygous for the FUT2 gene major allele G than among those who carried the AG 
or AA genotype (median 3.0 vs. 4.7 years; P=0.03). Furthermore, among children who carried the 
high-risk HLA genotype and tested autoantibody-positive before the age of 6 years, a higher 
proportion of those with the FUT2 GG genotype had progressed to clinical diabetes within 1.5 years 
after seroconversion than those carrying the FUT2 AG or AA genotype (34% vs. 8%; P=0.02). 
 Although the intention with the analysis of the non-HLA SNPs was to assess associations with 
the progression rate, we observed additionally that the autoantibody-positive non-progressors carried 
less frequently the minor allele A in the predisposing PTPN22 gene than either rapid progressors 
(46% vs. 24%; OR 2.74 [95% CI 1.45, 5.19], Pc=0.03) or slower progressors (38% vs. 24%; OR 1.93 
[95% CI 1.38, 2.70], Pc=0.002), indicating a role for the PTPN22 SNP in overall progression to type 
1 diabetes. 
 
Predictive characteristics of rapid progression in a multivariate analysis 
 
The predictive characteristics of rapid disease progression were studied by using the Cox proportional 
hazards models. The variables included in the analyses comprised sex, the high-risk HLA genotype, 
the presence of affected FDRs at birth of study participants, age at seroconversion, multipositivity at 
seroconversion, and positivity and titers for ICA, IAA, GADA, and IA-2A at seroconversion. 
Variables that predicted rapid progression to type 1 diabetes within 1.5 years after seroconversion 
were the high-risk HLA genotype, age at seroconversion, multipositivity at seroconversion, IAA 
positivity at seroconversion, and ICA titers at seroconversion (Table 19A). Having an FDR with type 
1 diabetes did not affect the risk of rapid progression. 
 Statistically significant variables found in the first model were included in a subsequent 
analysis. In the second step, age at seroconversion and titers of ICA were included as categorical 
variables. In the multivariate analysis, the variables identified as independent predictors of rapid 
progression at seroconversion were the high-risk HLA genotype, young age, positivity for multiple 
autoantibodies, IAA positivity, and ICA titer of >10 JDFU (Table 19B). In contrast, ICA positivity 
at seroconversion was inversely associated with the risk of rapid disease progression in both analyses, 
which might be explained by the addition of biochemical autoantibodies to the models. 
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Table 19. Predictive characteristics of rapid progression to type 1 diabetes in Cox proportional 
hazards models. The following variables were studied in the univariate analyses (A) and the 
multivariate analysis (B): sex, HLA-conferred disease risk, the presence of affected FDRs at birth of 
study participants, age at seroconversion, positivity for multiple autoantibodies at seroconversion, 
and positivity and titers of ICA, IAA, GADA, and IA-2A at seroconversion. The FUT2 and PTPN22 
SNPs were not included in the models due to missing values. 
 
A 
Variable HR (95% CI) P-value 
HLA-DQB1*02/*03:02 genotype 1.64 (1.27, 2.12) *** 
Sex (boys) 1.04 (0.81, 1.35) NS 
Affected FDRs 1.24 (0.82, 1.87) NS 
Age at seroconversion 0.82 (0.77, 0.87) *** 
Multiple (≥2) autoantibodies at seroconversion 4.32 (2.68, 6.99) *** 
ICA positivity at seroconversion 0.50 (0.35, 0.71) *** 
IAA positivity at seroconversion 2.05 (1.35, 3.11) *** 
GADA positivity at seroconversion 1.27 (0.84, 1.92) NS 
IA-2A positivity at seroconversion 0.96 (0.61, 1.50) NS 
ICA titers at seroconversion, JDFU 1.003 (1.001, 1.005) ** 
IAA level at seroconversion, RU 1.004 (0.995, 1.014) NS 
GADA level at seroconversion, RU 1.000 (0.996, 1.003) NS 
IA-2A level at seroconversion, RU 1.007 (0.999, 1.015) NS 
 
B 
Variable HR (95% CI) P-value 
HLA-DQB1*02/*03:02 genotype 1.58 (1.23, 2.04) *** 
Age at seroconversion  *** 
 0–4 years 5.29 (2.15, 13.05)  
 5–9 years 2.33 (0.89, 6.07)  
 ≥10 years 1.0  
Multiple (≥2) autoantibodies at seroconversion 4.70 (3.34, 6.61) *** 
ICA positivity at seroconversion 0.21 (0.12, 0.38) *** 
ICA titers at seroconversion  *** 
 ≤4 JDFU 1.0  
 5–10 JDFU 1.77 (0.99, 3.16)  
 >10 JDFU 3.79 (2.08, 6.90)  
IAA positivity at seroconversion 1.85 (1.31, 2.61) *** 
 
HR=hazard ratio. CI=confidence interval. JDFU=Juvenile Diabetes Foundation units. RU=relative 
units. 
*P<0.05 
**P<0.01 
***P<0.001 
NS=non-significant. 
Reproduced with permission from Diabetologia.  
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Characterization of slow progression to type 1 diabetes 
 
Identifying the slow progressors 
 
In Study III, 1528 (20.6%) of the 7410 HLA-susceptible children tested autoantibody-positive for at 
least one autoantibody in at least two consecutive samples by the end of 2015. Among them, 247 
children (16.2%) progressed to type 1 diabetes and had confirmed seroconversion before the 
diagnosis. One progressor was excluded from the autoantibody analyses in Study III based on only 
one autoantibody-positive sample at the age of 3 months. No cord blood sample was available for 
this child, and therefore, it could not be determined whether the autoantibodies were derived from de 
novo synthesis. 
 Among the 247 progressors, 62 children (25.1%) were slow progressors, in whom type 1 
diabetes was diagnosed at the earliest 7.26 years after the initial seroconversion. In contrast, there 
were 185 children (74.9%) with a delay from seroconversion to diagnosis of less than 7.26 years, and 
these children were defined as the group of other progressors. The median time from seroconversion 
to diagnosis was 8.7 (range 7.3–17.0) years in slow progressors and 3.0 (range 0.02–7.2) years in 
other progressors. In the whole study population, the median duration of the preclinical period was 
4.0 (range 0.02–17.0) years (Table 4).  
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Comparison of slow progressors to other progressors 
 
Compared with other progressors, the slow progressors tested less frequently positive for IA-2A and 
multiple autoantibodies at seroconversion, although no significant difference emerged between the 
groups in the frequency of positivity for multiple biochemical autoantibodies at seroconversion 
(Table 20). The titers of ICA and IAA at seroconversion were significantly lower among slow 
progressors than other progressors. In addition, the slow progressors progressed more slowly from 
single to multiple autoantibody positivity after seroconversion for a single autoantibody than the other 
progressors. 
 Between the two groups of progressors, there were no statistically significant differences in the 
distributions of the high-risk HLA genotype, sex, or the presence of FDRs with type 1 diabetes at 
birth of study children. No differences were found between the groups in the frequency of positivity 
for ICA, IAA, or GADA, or the titers of GADA and IA-2A at seroconversion (Table 20). Similar 
proportions of slow progressors and other progressors developed multipositivity by the time of 
diagnosis. 
Interestingly, there was significant variation in the season of birth between slow progressors 
and other progressors. Slow progressors showed higher frequency of being born in the fall (from 
September to November) than the other progressors (31% vs. 22%), whereas the other progressors 
tended to be born more often in the spring (from March to May; 31% vs. 15%; P=0.04) (Figure 7). 
No similar trend was observed among non-progressors who had developed multiple autoantibodies 
during the follow-up. 
 
Figure 7. Season of birth among the groups of slow progressors (n=62), other progressors (n=185), and 
multipositive non-progressors (n=198). 
*Slow progressors vs. other progressors. 
**Slow progressors vs. multipositive non-progressors, other progressors vs. multipositive non-progressors. 
Reproduced with permission from J Clin Endocrinol Metab.  
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Table 20. Clinical characteristics of slow progressors and other progressors. 
 
Clinical characteristic Slow progressors 
(n=62) 
Other progressors 
(n=185) 
P-value 
 N (%)  
High-risk HLA-DQB1*02/*03:02 genotype 24 (39) 78 (42) NS 
Sex (boys) 35 (57) 107 (58) NS 
Affected FDRs 4 (7) 24 (13) NS 
Autoantibody positivity at seroconversion    
 ICA 30 (48) 112 (61) NS 
 IAA 44 (71) 126 (68) NS 
 GADA 25 (40) 91 (49) NS 
 IA-2A 5 (8) 50 (27) ** 
 IAA without GADA 28 (45) 74 (40) NS 
 GADA without IAA 9 (15) 39 (21) NS 
 IAA and GADA 16 (26) 52 (28) NS 
 Multiple autoantibodies 27 (44) 117 (63) ** 
 Multiple biochemical autoantibodies 17 (27) 74 (40) NS 
 Multipositivity during follow-up 62 (100) 182 (98) NS 
 Median (range)  
Autoantibody titers at seroconversion    
 ICA, JDFU 7 (4–131) 15 (3–668) ** 
 IAA, RU 7.1 (3.5–40.3) 10.2 (3.6–81.0) ** 
 GADA, RU 21.0 (5.9–135.3) 32.9 (5.6–310.4) NS 
 IA-2A, RU 9.8 (0.4–57.3) 22.9 (0.6–121.0) NS 
Age at seroconversion, years 1.5 (0.6–7.5) 2.0 (0.3–13.8) NS 
Age at diagnosis, years 11.4 (8.6–18.0) 5.5 (0.9–17.4) NA 
Delay from seroconversion to diagnosis, 
years 
8.7 (7.3–17.0) 3.0 (0.02–7.2) NA 
Time from single to multiple autoantibody 
positivity, years 
1.5 (0.2–8.2) 0.5 (0.2–6.0) * 
Follow-up time from seroconversion, years 8.7 (7.3–17.0) 3.0 (0.02–7.2) NA 
 
RU=relative units. JDFU=Juvenile Diabetes Foundation units. 
*P<0.05 
**P<0.01 
***P<0.001 
NS=non-significant. 
Reproduced with permission from J Clin Endocrinol Metab. 
  
Results 
 81 
Identifying multipositive non-progressors 
 
Because more than 70% of multipositive children progress to clinical diabetes in 10 years, we 
hypothesized that the current multipositive non-progressors might eventually progress to type 1 
diabetes, but at a remarkably slow pace (149). Accordingly, comparisons of phenotypically diverse 
slow progressors and multipositive non-progressors might reveal mechanisms counteracting the 
disease progression. 
 The group of multipositive non-progressors in Study III comprised 198 individuals who had 
developed multiple autoantibodies, but remained disease-free during the follow-up period until the 
end of 2015 and had been followed up for at least a period of 7.26 years from seroconversion. The 
median follow-up time among the multipositive non-progressors was 12.8 (range 7.4–20.1) years. 
 
Comparison of slow progressors to multiple autoantibody-positive non-progressors 
 
As expected, there were multiple similarities between the groups, but the two groups also differed in 
several aspects. At seroconversion, the slow progressors were significantly younger than the 
multipositive non-progressors (median age 1.5 vs. 3.5 years; P<0.001) and demonstrated higher titers 
of ICA (median 7 vs. 5 JDFU; P=0.003). The slow progressors tested more often positive for IAA 
(71% vs. 34%; P<0.001) and multiple autoantibodies at seroconversion, with ICA (44% vs. 26%; 
P=0.008) or without ICA in the analysis (27% vs. 11%; P=0.002). 
 However, the two groups shared similar distributions of the high-risk HLA genotype (39% vs. 
29%; P=0.14), sex (boys 57% vs. 62%; P=0.43), and affected FDRs at birth (7% vs. 7%; P=1.00). At 
seroconversion, they demonstrated similar frequencies of positivity for ICA (48% vs. 56%; P=0.32), 
GADA (40% vs. 36%; P=0.53), and IA-2A (8% vs. 9%; P=0.80). Furthermore, the titers of IAA 
(median 7.1 vs. 7.0 RU; P=0.78), GADA (21.0 vs. 16.9 RU; P=0.52), and IA-2A (9.8 vs. 2.7 RU; 
P=0.88) at seroconversion did not differ between groups. 
 Notably, the multipositive non-progressors demonstrated higher frequency of GADA positivity 
at seroconversion without simultaneous IAA positivity than the slow progressors (28% vs. 15%; 
P=0.03). In contrast, the slow progressors tested more often positive for IAA at seroconversion 
without simultaneous GADA positivity than the multipositive non-progressors (45% vs. 26%; 
P=0.005). 
 
Autoantibody status at seroconversion 
 
In Study III, the majority of progressors (41.3%), including both slow (45.2%) and other progressors 
(40.0%), tested IAA-positive but GADA-negative at seroconversion (P=0.48 between progressors). 
However, this was true in a significantly smaller proportion of multipositive non-progressors (26%; 
P=0.005 compared with slow progressors, and P=0.004 compared with other progressors). 
 In contrast, nearly a third of the multipositive non-progressors (27.8%) tested GADA-positive 
at seroconversion without simultaneous IAA positivity, while the corresponding proportions among 
the slow and other progressors were only 14.5% and 21.1%, respectively (P=0.04 compared with all 
progressors; P=0.03 compared with slow progressors; and P=0.13 compared with other progressors). 
Compared with other progressors, this difference turned out to be statistically non-significant, which 
was probably related to the high proportion of multipositive individuals among the other progressors. 
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 In seroconverted non-progressors with only one autoantibody during follow-up, this 
autoantibody was predominantly ICA (79%). Both slow (43.5%) and other progressors (63.2%) tested 
multipositive at seroconversion more often than seroconverted non-progressors (5.5%; P<0.001). The 
autoantibody combinations at seroconversion are shown in Table 21. 
 
 
Table 21. Autoantibody combinations at seroconversion in the groups of slow progressors (n=62), 
other progressors (n=185), multipositive non-progressors (n=198), and single autoantibody-positive 
non-progressors (n=1039). 
 
 
AAB=autoantibody. NA=not available. Reproduced with permission from J Clin Endocrinol Metab. 
*Follow-up time ≥7.26 years from seroconversion to autoantibody positivity. 
 
 
Non-HLA SNPs and slow progression to type 1 diabetes 
 
We analyzed the potential associations between slow disease progression and the previously reported 
non-HLA SNPs predisposing to type 1 diabetes (Table 5). Multiple SNPs were associated with the 
delay from seroconversion to diagnosis (Table 22), but after corrections for multiple comparisons 
these associations did not reach statistical significance. Also, after corrections for multiple testing, no 
significant differences were observed in the non-HLA SNP distributions between the groups of slow 
progressors, other progressors, and multipositive non-progressors (Table 23). 
 Not surprisingly, the predisposing SNPs in the PTPN22, INS (rs689), and PHTF1 genes were 
associated with overall progression to type 1 diabetes and survived the corrections for multiple testing 
(Table 24). Also, the CC, CT genotype of the predisposing GPR183/EBI2 SNP tended to associate 
with overall progression to type 1 diabetes in the whole study population independently of 
seroconversion status (progressors 51% vs. non-progressors 41%; P=0.008, Pc=0.06).  
AAB combination Slow 
progressors 
Other 
progressors 
Multipositive 
non-progressors* 
Single AAB-positive 
non-progressors 
 N (%)    
Only ICA 8 (12.9) 13 (7.0) 67 (33.8) 933 (89.8) 
Only IAA 20 (32.3) 38 (20.5) 38 (19.2) 53 (5.1) 
Only GADA 7 (11.3) 15 (8.1) 38 (19.2) 45 (4.3) 
Only IA-2A 0 (0) 2 (1.1) 4 (2.0) 8 (0.8) 
ICA + IAA 8 (12.9) 21 (11.4) 11 (5.6) NA 
ICA + GADA 1 (1.6) 17 (9.2) 14 (7.1) NA 
ICA + IA-2A 1 (1.6) 5 (2.7) 4 (2.0) NA 
IAA + GADA 5 (8.1) 14 (7.6) 5 (2.5) NA 
IAA + IA-2A 0 (0) 4 (2.2) 2 (1.0) NA 
GADA + IA-2A 0 (0) 0 (0) 1 (0.5) NA 
ICA + IAA + GADA 8 (12.9) 17 (9.2) 7 (3.5) NA 
ICA + IAA + IA-2A 0 (0) 11 (5.9) 1 (0.5) NA 
ICA + GADA + IA-2A 1 (1.6) 7 (3.8) 2 (1.0) NA 
IAA + GADA + IA-2A 0 (0) 0 (0) 0 (0) NA 
All four antibodies 3 (4.8) 21 (11.4) 4 (2.0) NA 
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Table 22. Predisposing SNPs associated with the delay from seroconversion to diagnosis of type 1 
diabetes in progressors. NS=non-significant, Pc=corrected P-value by using the Benjamini-Hochberg 
step-up procedure to control the false discovery rate. 
 
 
Reproduced with permission from J Clin Endocrinol Metab.  
Gene SNP Genotype (n) Median (range) P-value Pc 
RGS1 rs2816316 TT (148) 4.6 (0.02–17.0) 0.03 NS 
  GT, GG (55) 3.5 (0.12–11.8)   
FUT2 rs601338 AA, AG (133) 4.8 (0.1–17.0) 0.04 NS 
  GG (69) 3.1 (0.02–12.3)   
LOC646538 rs630115 GG (108) 4.6 (0.1–15.1) 0.01 NS 
  AA, AG (118) 3.4 (0.02–17.0)   
IGF2BP2 rs4402960 GT, GG (219) 4.3 (0.02–17.0) 0.04 NS 
  TT (18) 2.8 (0.2–7.6)   
High-risk HLA genotype     
SH2B3 rs3184504 TT (12) 2.4 (0.1–11.0) 0.04 NS 
  CT, CC (75) 4.1 (0.1–12.0)   
CTSH rs3825932 TT (16) 2.3 (0.2–8.0) 0.01 NS 
  CT, CC (81) 4.1 (0.1–12.0)   
SLC30A8 rs13266634 TT (8) 7.5 (0.3–10.6) 0.04 NS 
  CT, CC (91) 3.5 (0.1–12.0)   
FUT2 rs601338 AA, AG (56) 4.7 (0.3–12.0) 0.02 NS 
  GG (31) 2.7 (0.1–11.4)   
Moderate-risk HLA genotype     
ERBB3 rs2292239 AA (15) 2.4 (0.1–15.4) 0.007 NS 
  AC, CC (120) 4.7 (0.02–17.0)   
IL2RA rs11594656 TT, AT (112) 4.4 (0.1–17.0) 0.04 NS 
  AA (3) 1.2 (0.2–3.4)   
GIMAP5 rs6965571 GG (100) 5.1 (0.1–15.4) 0.03 NS 
  AG, AA (36) 2.6 (0.02–17.0)   
SLC30A8 rs13266634 CC, TT (76) 3.9 (0.1–15.4) 0.03 NS 
  CT (63) 5.7 (0.02–17.0)   
Boys      
LOC646538 rs630115 GG (61) 5.6 (0.3–15.1) 0.004 NS 
  AG, AA (68) 3.3 (0.1–17.0)   
IGF2BP2 rs4402960 GT, GG (126) 4.5 (0.1–17.0) 0.02 NS 
  TT (8) 2.7 (0.2–4.1)   
NRP1 rs2666236 AA, AG (76) 5.3 (0.1–17.0) 0.04 NS 
  GG (40) 3.1 (0.1–12.3)   
Girls      
KIAA0350-CLEC16A rs2903692 GG (35) 3.0 (0.1–10.6) 0.045 NS 
  AG, AA (49) 5.3 (0.02–11.4)   
AFF3 rs9653442 CC (16) 2.3 (0.1–8.0) 0.02 NS 
  CT, TT (71) 4.4 (0.02–11.8)   
INS rs689 TT (2) 9.3 9.3 (8.0–10.7) 0.04 NS 
  AA, AT (101) 3.6 (0.02–11.8)   
 
Table 23. Comparison of the distributions of the predisposing SNPs in the groups of slow progressors, other progressors, and multipositive non-
progressors. Pc=corrected P-value by using the Benjamini-Hochberg procedure to control the false discovery rate. Reproduced with permission from 
J Clin Endocrinol Metab. 
Pa = Slow progressors vs. other progressors 
Pb = Slow progressors vs. multipositive non-progressors 
Pc = Other progressors vs. multipositive non-progressors 
 
Gene SNP Genotype Slow progressors Other 
progressors 
Multipositive  
non-progressors 
Pa Pca Pb Pcb Pc Pcc 
   N (%) N (%) N (%)       
DQX1 rs6546909 AA 29 (57) 108 (71) 94 (76) 0.06 0.84 0.01 0.81 0.38 0.88 
AFF3-
LOC150577 
rs9653442 CC 4 (8) 35 (23) 24 (19) 0.02 0.84 0.07 0.81 0.46 0.89 
GPR183/EBI2 rs9585056 CC, CT 28 (55) 75 (49) 46 (37) 0.49 0.98 0.03 0.81 0.04 0.58 
PHTF1 rs6679677 AA, AC 18 (35) 60 (40) 33 (27) 0.53 0.98 0.25 0.81 0.02 0.48 
IL2RA rs11594656 TT 35 (69) 110 (74) 77 (62) 0.47 0.98 0.41 0.81 0.04 0.58 
PTPN22 rs2476601 AA, AG 20 (33) 74 (41) 48 (27) 0.30 0.98 0.37 0.81 0.007 0.27 
CD226 rs763361 TT, CT 43 (74) 141 (79) 104 (65) 0.46 0.98 0.18 0.81 0.004 0.27 
 
Table 24. Predisposing SNPs associated with overall progression to type 1 diabetes (T1D). Pc=corrected P-value by using the Benjamini-Hochberg 
step-up procedure to control the false discovery rate. Reproduced with permission from J Clin Endocrinol Metab. 
 
 
Gene SNP Predisposing genotype to T1D Progressors Non-progressors P-value Pc 
   N (%) N (%)   
PTPN22 rs2476601 AA, AG 97 (38.2) 483 (23.4) <0.001 <0.001 
INS rs689 AA 199 (78.7) 1268 (63.5) <0.001 <0.001 
NRP1 rs2666236 AA, AG 150 (70.8) 738 (62.3) 0.02 0.13  
CD226 rs763361 TT, CT 192 (76.8) 1232 (70.2) 0.03 0.16 
PHTF1 rs6679677 AA, AC 78 (38.0) 282 (23.9) <0.001 <0.001 
PRKCQ rs11258747 TT 20 (9.5) 65 (5.5) 0.03 0.16  
GPR183 / EBI2 rs9585056 CC, CT 107 (50.5) 481 (40.7) 0.008 0.06 
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Approaches to screening for risk of type 1 diabetes 
 
Role of islet cell antibodies in disease prediction 
 
In Study I, we explored the role of ICA in preclinical screening for risk of type 1 diabetes. Sensitivity, 
specificity, and PPV of individual autoantibody reactivities and multipositivity for predicting type 1 
diabetes are presented in Table 25. Most importantly, the disease specificity and PPV of positivity 
for multiple biochemical autoantibodies were significantly higher than for ICA, when the threshold 
for ICA positivity was set at 2.5 JDFU, but not when it was set at 10 JDFU. 
 Among multipositive children, there were no ICA-negative individuals and positivity for 
individual biochemical autoantibodies occurred considerably less often in multipositive children than 
positivity for ICA. Altogether 48 (68%) of the multipositive children tested positive for IAA, 52 
(73%) for GADA, 40 (56%) for IA-2A, and 43 (61%) for ZnT8A. All available samples from these 
children had been analyzed for ICA, IAA, GADA, IA-2A, and ZnT8A. When ICA was omitted from 
the screening, 21 multipositive children (29.6%) would have been missed (Figure 8). Among these 
children, there was one progressor with multiple biochemical autoantibodies at the time of diagnosis. 
 Removing ICA from the autoantibody analyses did not affect the association of the high-risk 
HLA genotype with multipositivity compared with the moderate-risk HLA genotypes. With ICA in 
the analysis, 32 (35%) of the seroconverted children in the high-risk HLA group and 39 (21%) of 
those in the moderate-risk HLA group developed multiple autoantibodies (P=0.01) by 15 years of 
age. The corresponding figures without ICA in the analysis were 26 (58%) and 24 (35%; P=0.02). 
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Table 25. Sensitivities, specificities, and positive predictive values (PPV) of individual 
autoantibodies and their combinations by the age of 15.5 years when at least two consecutive positive 
samples were required for autoantibody positivity (A) and when one positive sample was required 
for positivity (B). Confidence intervals (95%) are shown in parentheses. JDFU=Juvenile Diabetes 
Foundation units. Table A reproduced with permission from J Clin Endocrinol Metab. 
 
A 
Autoantibody type Sensitivity, % Specificity, % PPV, % 
ICA 91 (76–98) 78 (78–78) 13 (11–14) 
IAA 77 (61–89) 96 (95–96) 39 (31–45) 
GADA 71 (55–84) 96 (95–96) 36 (28–43) 
IA-2A 69 (53–81) 98 (98–99) 57 (44–68) 
ZnT8A 71 (56–84) 98 (97–98) 52 (41–61) 
Multiple (≥2) autoantibodies 91 (77–98) 96 (96–96) 45 (38–48) 
Multiple (≥2) biochemical autoantibodies 89 (74–96) 98 (98–98) 62 (52–67) 
ICA threshold for positivity ≥10 JDFU 89 (74–96) 96 (95–96) 43 (36–47) 
 
B 
Autoantibody type Sensitivity, % Specificity, % PPV, % 
ICA 91 (76–98) 77 (76–77) 13 (10–13) 
IAA 80 (63–91) 91 (90–91) 24 (19–27) 
GADA 74 (58–87) 93 (93–94) 29 (22–34) 
IA-2A 77 (62–88) 97 (97–98) 52 (41–60) 
ZnT8A 80 (64–91) 96 (95–96) 42 (33–47) 
Multiple (≥2) autoantibodies 91 (77–98) 95 (94–95) 38 (32–41) 
Multiple (≥2) biochemical autoantibodies 91 (78–98) 98 (97–98) 58 (49–62) 
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Definition of autoantibody positivity 
 
In Study I, we examined whether the definition of autoantibody positivity as positivity for at least 
one autoantibody in at least one vs. two consecutive samples affected the screening for islet 
autoimmunity. When two consecutive positive samples instead of only one positive sample were 
required for autoantibody positivity, the cumulative proportion of children with only one positive 
autoantibody was markedly lower, while the life-table curve for children with multiple autoantibodies 
remained similar (Figure 8). Sensitivies, specificities, and PPV for predicting type 1 diabetes by using 
both definitions are shown in Table 25. 
 
 
Figure 8A. Development of at least one (orange line) or at least two (red line) autoantibodies by the 
age of 15.5 years when autoantibody positivity was defined as positivity for ICA, IAA, GADA, IA-
2A, and/or ZnT8A in at least one sample; development of at least one (blue line) or at least two (green 
line) autoantibodies when at least two consecutive samples were required for autoantibody positivity 
in 1006 children with increased HLA predisposition for type 1 diabetes.   
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Figure 8B. Development of at least one (orange line) or at least two (red line) autoantibodies by 15.5 
years of age when autoantibody positivity was defined as positivity for the biochemical 
autoantibodies (IAA, GADA, IA-2A, and/or ZnT8A) in at least one sample; development of at least 
one (blue line) or at least two (green line) autoantibodies when positivity was defined as positivity 
for the biochemical autoantibodies in at least two consecutive samples in 1006 children with increased 
HLA predisposition for type 1 diabetes. 
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SUMMARY OF FINDINGS 
 
The main findings of this thesis are summarized below. 
 
1. Among HLA-predisposed children recruited from the general population, rapid progressors 
to type 1 diabetes can be characterized by factors present at seroconversion to autoantibody 
positivity, including young age, higher autoantibody titers of especially IAA, IA-2A, and ICA, 
positivity for multiple autoantibodies, and higher prevalence of the high-risk HLA-
DQB1*02/*03:02 genotype and the homozygous secretor GG genotype of the FUT2 SNP 
predisposing to type 1 diabetes. 
 
2. The double-peak profile of seroconversion age among the rapid progressors demonstrates for 
the first time that rapid progression to type 1 diabetes may occur not only in young children 
below the age of 5 years, but also in children closer to puberty. At seroconversion, young 
rapid progressors are characterized by IAA positivity and high IAA titers, while older rapid 
progressors are characterized by GADA positivity and high GADA titers. This indicates age-
dependent heterogeneity in the triggers of rapid progression. 
 
3. Slow progressors to type 1 diabetes demonstrate lower titers of IAA and ICA, lower frequency 
of positivity for IA-2A or multiple autoantibodies at seroconversion, and a longer delay from 
single to multiple autoantibody positivity than other progressors. 
 
4. Season of birth is associated with pace of disease progression from seroconversion to clinical 
diabetes. Disease progression is accelerated in children born in the spring and slower among 
children born in the fall. 
 
5. None of the investigated SNPs predisposing to type 1 diabetes are associated with slow 
disease progression after correction for multiple testing. The predisposing PTPN22, INS 
(rs689), and PHTF1 SNPs are associated with overall progression to clinical type 1 diabetes. 
The EBI2/GPR183 SNP might also be associated with overall progression to type 1 diabetes. 
 
6. Over the first 15 years of life, the seroconversion rate to positivity for biochemically defined 
autoantibodies decreases with advancing age, but the ICA seroconversion rate increases 
continuously towards puberty. 
 
7. Among children with a single biochemical autoantibody at seroconversion, IAA or GADA is 
most often the primary biochemical autoantibody, but in young children, ZnT8A is the second 
most common primary autoantibody after IAA. This is the first study to demonstrate that 
ZnT8A may appear early in the disease process. 
 
8. Inverse seroconversions and fluctuations of autoantibody positivity are observed most 
frequently for IAA, followed by ICA, especially among non-progressors. Among progressors, 
ICA is the most stable and persistent autoantibody. Reversion to complete autoantibody 
negativity occurs rarely among children with multiple biochemical autoantibodies. 
 
9. Among progressors to type 1 diabetes, the loss of IAA positivity is associated with delayed 
progression from seroconversion to diagnosis.  
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DISCUSSION 
 
Dynamics of islet autoantibodies in childhood 
 
In this thesis, we explored the dynamics of islet autoantibodies in HLA-predisposed children to type 
1 diabetes during prospective follow-up from birth up to 15 years of age. This extensive general 
population-based study was carried out in Finland, which has the highest incidence of type 1 diabetes 
globally. Follow-up data from the same cohort up to the age of 2 and 5 years have been previously 
published (7, 112). 
 During the first 15 years the overall seroconversion rate increased, which was mostly explained 
by a continuous increase in the ICA seroconversion rate with increasing age. However, the 
biochemical autoantibodies demonstrated decreasing seroconversion rates with advancing age. 
Among the islet autoantibodies, ICA became the dominating autoantibody after the age of 3 years, 
but IAA seroconversions prevailed in younger children. The cumulative proportion of multipositive 
individuals showed a steady increase up to the age of 15 years, but positivity for multiple biochemical 
autoantibodies developed rarely in children older than 10 years. Multipositivity within a year from 
seroconversion indicated progression to clinical diabetes, but this observation no longer reached 
statistical significance when ICA was omitted from the autoantibody analysis. 
 By 15 years of age, there were no differences in the overall seroconversion rate between boys 
and girls. This was somewhat surprising considering that type 1 diabetes is more common among 
males than females after puberty (298). However, the cumulative frequency of seroconversion to 
biochemical autoantibody positivity was slightly higher among boys than girls. Also, the majority of 
children diagnosed with type 1 diabetes after the age of 10 years were boys, while in younger children 
there was no sex difference in the proportion of progressors. This might indicate that boys are more 
susceptible to progression to clinical diabetes when approaching puberty. 
 We described for the first time systematically the role of ZnT8A in the prediction of type 1 
diabetes as a part of the autoantibody repertoire used for screening purposes. During the first 15 years 
ZnT8A emerged commonly in young children and often as the primary autoantibody preceding even 
IAA. Together with IA-2A, ZnT8A demonstrated the highest specificity for type 1 diabetes, and, as 
the primary autoantibody at seroconversion, was strongly predictive of clinical disease. This probably 
reflects the strong beta-cell specificity of ZnT8. 
 Generally speaking, ZnT8A has been considered to appear relatively late in the disease process, 
but according to the current observations, this might not be entirely true. More likely, ZnT8A might 
reflect an aggressive disease process. Clinically, positivity for ZnT8A at diagnosis has been linked to 
a high risk of diabetic ketoacidosis and predicts increased need for exogenous insulin after diagnosis 
(163). Accordingly, our observations suggest that ZnT8A emerging early during the preclinical 
process indicates a high risk of type 1 diabetes. However, this conclusion should be interpreted 
cautiously due to the limited size of the study population. 
 The dynamics of islet autoantibodies might be utilized in preclinical screening when estimating 
the risk of type 1 diabetes in multipositive individuals. We observed that the titers of ZnT8A together 
with ICA and IA-2A increased in progressors months before diagnosis compared with matched 
multipositive controls. This is consistent with earlier studies reporting that ZnT8A is often seen 
together with ICA and/or IA-2A at diagnosis, but rarely with simultaneous IAA or GADA positivity 
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(154, 159, 163). The prevalence of ZnT8A at diagnosis in the current study (66%) was in accordance 
with earlier observations (159, 164). 
 As might be expected considering the heterogeneous nature of type 1 diabetes, we demonstrate 
that the primary autoantibody is characteristic of age. In young children, islet autoimmunity often 
begins with IAA or ZnT8A positivity, while at preschool age GADA and IA-2A-driven autoimmunity 
increases. After the preschool years, ICA begins to dominate as the primary autoantibody, but if 
remaining as a single autoantibody it does not mediate any risk for clinical diabetes. This indicates 
the existence of multiple paths of islet autoimmunity and highlights the concept of disease endotypes. 
Moreover, there are apparent differences in the primary autoantibody signatures between progressors 
and non-progressors at seroconversion, with IAA and ZnT8A associating most often with progression 
to clinical disease. The primary autoantibody might reflect the driving events of islet autoimmunity. 
However, assessing these mechanisms was beyond the scope of this thesis. 
 Notably, GADA as the first single autoantibody at seroconversion was rarely seen in 
progressors. Instead, GADA was the predominant primary autoantibody among multipositive non-
progressors. This might be explained by the typically older age at primary GADA positivity relative 
to primary IAA or ZnT8A positivity (52, 151, 320). In the DIPP study, no difference in disease 
progression was previously observed between individuals with IAA or GADA as the first 
autoantibody who had also developed secondary autoantibodies (117). The substantially longer 
follow-up in the current study has added to the number of older children with GADA as the first 
autoantibody in whom the disease process has not yet advanced further. 
 Considering the different genetic backgrounds (117, 128, 129, 320, 340) and etiological 
associations of the two major endotypes of islet autoimmunity (266), the current observations support 
the idea of heterogeneity in the disease process and suggest that age and the stage of immunological 
maturation contribute substantially to the features of islet autoimmunity. Environmental exposures in 
children of various ages might differ considerably. As an example, the frequency of infections often 
increases at preschool age, as children start daycare. Early childhood infections have, in fact, been 
temporally associated with the onset of islet autoimmunity in several prospective studies (249–251). 
These findings constitute a framework for understanding the disease heterogeneity and for 
individualizing the approach of predicting and preventing type 1 diabetes. The increase in ICA 
reactivity towards puberty might reflect the fact that ICA positivity is commonly seen in adults (395). 
 The labile state of autoantibodies might be of value when evaluating the risk of type 1 diabetes. 
Among the islet autoantibodies, inverse seroconversions and fluctuations of IAA were most common, 
followed by ICA in children who did not develop clinical type 1 diabetes. Inverse seroconversions of 
IAA and ICA were inversely associated with peak IAA and ICA titers, respectively. Our findings 
support previous observations stating that IAA appear at a young age, but are relatively unstable in 
character (7, 52, 112, 115, 117, 151, 191, 320). 
 Since IAA appear early in the disease process, it has been considered whether insulin is the 
primary autoantigen in type 1 diabetes (113, 114). In this respect, it was noteworthy that the loss of 
IAA positivity was associated with delayed progression from seroconversion to clinical diabetes 
compared with persistent IAA positivity. A similar finding has been previously described in 
multipositive children (194). This phenomenon evokes questions about why the insulin-specific 
autoantibody response might be suppressed during disease progression. First, the humoral immune 
response might be attenuated, but the cell-mediated immune response towards insulin might persist. 
Second, considering the heterogeneity in the residual beta-cell function in long-term type 1 diabetes, 
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it is possible that the beta cells in some individuals possess the ability to escape the immune attack 
rather than being entirely destroyed (58, 59). In non-obese diabetic (NOD) mice, a subset of beta cells 
has been observed to survive immune attack supposedly due to mechanisms capable of hiding the 
beta cells from the immune system (99). Third, some evidence exists that B cells might be actively 
involved in the pathogenesis, and when the support provided by humoral immunity is removed, 
disease progression might be decelerated (56). 
 At the beginning of the DIPP study, it was predicted that approximately 7% of children carrying 
the high-risk HLA-DQB1*02/*03:02 genotype and 2–3% of children with moderate-risk genotypes 
in the Finnish population might progress to clinical type 1 diabetes by 15 years of age (385). In this 
thesis, we observed this prediction to hold true. This emphasizes the role of HLA-mediated antigen 
presentation in the disease pathogenesis. However, the children in the current study cohort were born 
in 1994–1997, and due to the evolving disease process behind type 1 diabetes, the HLA associations 
are changing and might be different among more recently born individuals (204). 
 
Characteristics of rapid disease progression 
This is the first prospective study to demonstrate that children with rapid progression to type 1 
diabetes can be characterized by demographic, genetic, and immunological factors present at 
seroconversion to autoantibody positivity. These include young age, high autoantibody titers of 
especially IAA, IA-2A, and ICA, positivity for multiple autoantibodies, and higher prevalence of the 
high-risk HLA-DQB1*02/*03:02 genotype and the homozygous secretor genotype of the FUT2 SNP 
predisposing to type 1 diabetes. Sex does not affect the pace of disease progression. In the multivariate 
models, independent predictors of rapid progression were identified as the high-risk HLA genotype, 
young age at seroconversion, multipositivity, IAA positivity, and high ICA titer at seroconversion. 
Characteristics associated with the progression rate in this thesis are summarized in Table 26. 
 Our findings are consistent with previous observations that multipositivity at a young age, the 
emergence of IA-2A as the primary biochemical autoantibody, and high initial titers of IAA strongly 
indicate rapid progression to clinical diabetes in childhood (117, 149). Several of the characteristics 
associated with overall progression to clinical diabetes were found also to be factors related to the 
progression rate. These include high titers of IAA and ICA at seroconversion, multipositivity at a 
young age, and persistent IAA positivity compared with unstable IAA (51, 107, 108, 130, 149, 175, 
193). 
 As a novel discovery, we observed a double-peak profile of the seroconversion age among rapid 
progressors. The first peak occurred in young children and the second closer to puberty. Young rapid 
progressors were characterized by high frequency of IAA positivity and high titers of IAA at 
seroconversion, while the older subgroup demonstrated high frequency of GADA positivity and high 
titers of GADA at seroconversion. The differences in the autoantibody profiles between the subgroups 
were not explained by distributions of the HLA genotype or the analyzed non-HLA SNPs. The duality 
of seroconversion age among rapid progressors raises questions about whether the disease process is 
similar in all forms of rapid progression (117). The environmental triggers of islet autoimmunity 
might differ between young and prepubertal rapid progressors, both of whom are undergoing sensitive 
stages of development. The idea of multiple triggers behind rapid progression is supported by the fact 
that the majority of the older rapid progressors had tested autoantibody-negative within a year before 
seroconversion. This might suggest that the mechanisms mediating rapid progression are independent 
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of the triggers of islet autoimmunity. Considering the screening for risk of type 1 diabetes, the current 
observations indicate that in the future the assessment of islet autoantibodies might be targeted to 
selected age groups. 
 This is the first study to report an association between the FUT2 SNP predisposing to type 1 
diabetes and the pace of disease progression. Rapid progressors with the high-risk HLA genotype 
demonstrated an increased prevalence of the homozygous FUT2 secretor genotype. This is, however, 
not the FUT2 genotype predisposing to type 1 diabetes (220). The FUT2 gene encodes 1,2-α-
fucosyltransferase (FUT2), the enzyme responsible for synthesis of soluble ABO histo-blood group 
antigens found in bodily fluids and on intestinal mucosa, thereby defining the human secretor status 
(396). Non-secretor individuals homozygous for the non-functional FUT2 allele A do not express the 
functional enzyme, and, as a result, lack the soluble ABO antigens from secretions (397). The FUT2 
secretor genotype has been reported to predispose to several intestinal pathogens, including rotavirus 
and norovirus, whereas the non-secretor genotype provides protection against symptomatic norovirus 
infection (398–401). This effect is probably mediated through the function of ABO histo-blood group 
antigens as intestinal receptors for many pathogens, including rotavirus and norovirus (402, 403). 
Notably, it has been reported that the incidence of type 1 diabetes in Australia and the United States 
has decreased among children under the age of 5 years after the introduction of the rotavirus vaccine 
into the national vaccination program, although it is controversial whether rotaviruses induce islet 
autoimmunity (254, 255, 404). Recent studies have also suggested an association between ABO blood 
type and susceptibility to COVID-19 disease (405). Intriguingly, high concentrations of α-1,2-linked 
fucosylated glycans in human milk mediate protection against infectious diarrhea in breastfed infants 
(406). The impact of the FUT2 secretor status on the infant gut microbiota remains incompletely 
understood. According to the literature, the maternal FUT2 genotype modifies the composition of the 
gut microbiota in cesarean-born infants, but not in vaginally born infants (407). The association of 
the homozygous FUT2 secretor genotype with rapid disease progression suggests that high levels of 
soluble ABO antigens in bodily secretions might contribute to rapid progression to type 1 diabetes. 
Characteristics of slow disease progression 
 
Similarly, we set out to identify the demographic, genetic, and immunological characteristics of slow 
progressors to type 1 diabetes. The slow progressors tested less frequently positive for IA-2A and 
multiple autoantibodies and demonstrated lower titers of ICA and IAA at seroconversion than the 
other progressors. The delay from single to multiple autoantibody positivity was longer among slow 
progressors than other progressors. There was an interesting trend in the season of birth between 
progressors. The slow progressors were frequently born in the fall, while other progressors were born 
more often in the spring. However, no specific characteristics at seroconversion were explicitly 
predictive of slow progression. The main challenge was to distinguish characteristics predictive of 
slow progression from the ones associated with overall progression to type 1 diabetes. 
 The characteristics of slow progressors to type 1 diabetes have been explored in several studies. 
In the BABYDIAB study, slow progression from multipositivity to diagnosis was associated with 
delayed appearance of IA-2A (150). Certain differences were also found in the distributions of non-
HLA SNPs between progressors (150). In the TEDDY study, a genetic risk score based on multiple 
HLA and non-HLA SNPs predicted the pace of disease progression (334). In the DAISY study, slow 
 
Table 26. Summary of characteristics associated with the progression rate to clinical type 1 diabetes based on observations in this thesis.  
 
Clinical characteristic Progression to type 1 
diabetes 
Rapid progression Slow progression Possible ultraslow 
progression (multiple 
autoantibodies) 
Non-progressive 
autoimmunity 
Season of birth Any Spring Not spring / Fall Any Any 
Age at 
seroconversion 
Young Young or early 
puberty 
Young Preschool and later After preschool 
HLA risk genotype High risk High risk High risk High or moderate Moderate risk 
Autoantibody 
positivity at 
seroconversion 
Multipositive 
IAA 
ZnT8A 
Multipositive 
IA-2A 
Multipositive 
IAA without GADA 
GADA without IAA One autoantibody 
Mostly ICA 
Progression to 
multipositivity 
Within a year from 
seroconversion 
Fast Slower than rapid 
progressors 
Slower than 
progressors 
Not multipositive 
Autoantibody titers at 
seroconversion 
High ICA 
High IAA 
High ICA 
High IAA 
High IA-2A 
Moderate ICA 
Moderate IAA 
Moderate ICA 
Moderate IAA 
Low ICA 
Associated SNPs INS 
PTPN22 
PHTF1 
EBI2 
FUT2 supersecretor 
genotype (+ high risk 
HLA genotype and 
age ≤5 years at 
seroconversion) 
None found NA NA 
Primary autoantibody IAA 
ZnT8A 
IA-2A* ZnT8A?* GADA ICA 
Autoantibody stability Persistent ICA 
Relatively persistent 
IAA 
Persistent IAA Transient IAA Fluctuating IAA 
Transient ICA 
Fluctuating GADA 
Fluctuating ICA 
Transient ICA 
Transient IAA 
Transient IA-2A 
 
*As previously observed by Ilonen et al. in (151).
D
iscussion
94
Discussion 
 95 
progressors were characterized by later onset of islet autoimmunity, lower frequency of IAA 
positivity, and lower autoantibody titers, especially IAA, and demonstrated delayed progression to 
multipositivity compared with other progressors (337). Our observations are in accordance with 
earlier studies, implying that delayed development of multipositivity, lower frequency of IA-2A 
positivity at seroconversion, and lower initial autoantibody titers of especially IAA are characteristic 
of slow progressors. However, we found no associations between the investigated non-HLA SNPs 
and slow disease progression after correction for multiple testing. 
 Since most multipositive children progress to clinical diabetes within 15 years, a proportion of 
the current multipositive non-progressors may still progress to clinical diabetes, but extremely slowly 
(149). Comparisons of multipositive individuals with phenotypically distinguished slow progressors 
might promote the discovery of mechanisms capable of slowing down disease progression. In this 
thesis, we demonstrated a GADA-positive signature among multipositive non-progressors that was 
distinct at seroconversion from both progressors and single autoantibody-positive non-progressors. 
Apart from seroconverting to autoantibody positivity at an older age than progressors, the 
multipositive non-progressors tested more frequently GADA-positive at seroconversion without 
simultaneous positivity for IAA. In contrast, the progressors tested more often IAA-positive in the 
absence of GADA positivity. 
 Accordingly, the primary autoantibody seems to some extent predict the pace of progression to 
clinical diabetes. In a multicohort analysis comprising data from five prospective studies, GADA was 
the most frequent autoantibody in the first multipositive sample among individuals who remained 
disease-free for more than 10 years after seroconversion, suggesting that initial GADA positivity 
might indicate slower pace of the disease process (338). However, this might not hold entirely true 
since in this thesis high initial titers of GADA were commonly seen in prepubertal rapid progressors. 
This raises questions of whether e.g. GAD epitope-specific responses affect the pace of disease 
progression in GADA-positive individuals (135, 178). 
 It is also enticing to consider whether GADA might reflect the action of mechanisms opposing 
disease progression. The autoantigen of GADA, glutamic acid decarboxylase, is essential in the 
synthesis of the neurotransmitter GABA, which has been reported to exhibit anti-inflammatory 
properties, enhance beta-cell survival, and promote the maintenance of the human beta-cell mass 
(408). Intriguingly, high levels of GABA after birth indicate future seroconversion to primary IAA 
positivity, but do not contribute to future risk of primary GADA positivity (359). This might reflect 
the fact that the function of GAD in beta cells may not be affected until an older age in GADA-driven 
autoimmunity. However, increased levels of glutamic acid and decreased levels of metabolites 
derived from it precede seroconversion to GADA-first in young children (359). This might suggest 
that an abnormal glutamic acid metabolism is causally related to the underlying autoimmune response 
against GAD and/or to its altered function. Whereas the IAA-first endotype has been linked to the 
type 1 diabetes-associated coxsackievirus B1 infections, initial GADA positivity is likely to originate 
from a different etiological background (266). 
 None of the investigated non-HLA SNPs were associated with slow progression after 
corrections for multiple comparisons. This was not surprising since the HLA region contributes to 
approximately 50% of the genetic heritability of type 1 diabetes, whereas the non-HLA loci together 
account for an estimated 30% of the heritability (209). However, assessing this possibility was 
mechanistically important to rule out significant associations. As expected, the predisposing SNPs in 
the PTPN22, INS (rs689), and PHTF1 genes were associated with overall progression to clinical 
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diabetes. The PTPN22 and PHTF1 SNPs are in almost perfect LD, meaning that individuals who 
carry one particular SNP allele at one site in the genome also often carry specific alleles at another 
nearby site. Both the PTPN22 and PHTF1 SNPs are located within a massive LD block containing 
in addition several other genes (210, 409). Therefore, the association of the PHTF1 SNP with overall 
progression might be explained by LD with the PTPN22 SNP, which strongly predisposes to type 1 
diabetes. 
 Considering the development of immunological tolerance and the maturation of the immune 
system, it is noteworthy that the predisposing EBI2/GPR183 SNP tended to be associated with overall 
progression to clinical diabetes. The gene product of EBI2 is a chemokine receptor, the Ebstein-Barr 
virus-induced G protein-coupled receptor (EBI2), which guides the localization of immune cells in 
lymphoid tissues (410). In mice, EBI2 deficiency alters the migration rate of thymocytes into thymic 
medulla during negative selection and might affect the development of central tolerance (411). 
Deficiencies in EBI2 or its ligand 7α,25-dihydroxycholesterol result in impaired humoral immune 
responses in mice (410). Furthermore, efficient induction of adaptive immune responses in mice 
requires EBI2-mediated sensing of oxysterol gradients (412). Considering the essential role of EBI2 
for the localization of B cells in lymphoid tissues, EBI2-orchestrated humoral immune responses 
might be involved in the pathogenesis of type 1 diabetes, which is highly characterized by 
autoantibody production against islet antigens. In newly diagnosed patients with type 1 diabetes, two 
different phenotypes of insulitis have been described in which the number of CD20-positive B cells 
in the insulitic lesion is either high or low, reflecting a considerably different age at diagnosis (64). 
Also, since the migration of immune cells is controlled by a variety of chemokine receptors, EBI2 
might play a role in the localization of immune cells into tissues outside the lymphoid organs such as 
the pancreatic islets. In multiple sclerosis, EBI2 might mediate the migration of autoreactive T cells 
into inflamed tissues (413). The potential role of EBI2 in the pathogenesis of type 1 diabetes requires 
clarification in future studies. 
 
Season of birth and environmental etiologies of beta-cell autoimmunity 
 
This is the first study to report variation in the seasonality of birth between progressors to type 1 
diabetes with variable pace of disease progression. The current findings indicate that seasonal 
environmental factors, such as infections or dietary factors, may affect the progression rate to clinical 
diabetes. The contribution of seasonal factors to the disease process is not, however, a novel idea. 
Exposure to infectious pathogens, such as viruses, has been proposed to trigger islet autoimmunity as 
early as during the fetal or neonatal period (414). 
 The strongest evidence for an association between type 1 diabetes and seasonal pathogens exists 
for enteroviruses, especially group B coxsackieviruses (258). Taking into account that enteroviral 
infections peak in Finland in the late summer or early fall, the observed seasonality of birth among 
the progressors implies that enteroviral antigen presentation during the late prenatal or early neonatal 
period might slow down the disease process (National Infectious Diseases Register, National Institute 
for Health and Welfare, Finland). This effect might be mediated through stronger protection by 
maternal antibodies in infants born in the fall, while infants born in the spring might encounter the 
corresponding antigens at an older age when they are no longer protected by maternal antibodies. In 
the DIPP study, the presence of maternal antiviral antibodies in cord blood attenuated the risk of 
coxsackievirus B1 infection-associated islet autoimmunity in offspring (264). The seasonality of birth 
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among patients with type 1 diabetes has been observed in numerous populations, but the findings are 
inconsistent, most likely due to genetic, epidemiological, and lifestyle-related differences between 
the various populations (415). 
 In this thesis, positivity for multiple biochemical autoantibodies appeared at a younger age 
among children born in the winter than among those born in other seasons. This raises suspicions 
about whether children born in the winter are exposed to environmental factors that promote 
progressive islet autoimmunity at a younger age than children born in other seasons. One candidate 
for such environmental promoters might be infections that peak during the winter such as rotavirus 
or norovirus infections (416). Decreased levels of vitamin D have been associated with the 
development of multiple autoantibodies (303). In Finland, vitamin D levels can easily diminish during 
the winter when the amount of sunlight is limited. Therefore, a daily vitamin D supplement is 
recommended for all Finnish children up to the age of 18 years starting from the age of two weeks 
(National Institute for Health and Welfare, Finland). However, being born in the winter did not 
increase the risk of type 1 diabetes relative to being born in other seasons. The association between 
season of birth and the development of multipositivity requires confirmation in a larger study 
population. 
 
Islet cell antibodies in disease prediction 
 
Persistent positivity for multiple biochemical autoantibodies indicates high risk for clinical diabetes 
and has been used as an inclusion criterion in intervention studies (149). However, the assay used for 
the analysis of ICA is laborious and challenging to standardize. The idea of replacing ICA with 
biochemical autoantibodies is therefore alluring. 
 We explored the dynamics of ICA in detail and examined whether removing ICA from the 
autoantibody screening repertoire would affect the preclinical prediction of type 1 diabetes. In 
contrast to previously published 5-year follow-up data of the same cohort, ICA demonstrated rather 
poor specificity compared with biochemical autoantibodies (7). The significantly higher specificity 
and PPV of multipositivity for biochemical autoantibodies relative to ICA indicate that low-titer ICA 
can be replaced by testing for multiple biochemical autoantibodies when screening for risk of type 1 
diabetes (318, 417). However, when the threshold for ICA positivity is set at 10 JDF units, ICA 
predict type 1 diabetes with a high specificity (96%) and PPV (43%). The rather poor specificity of 
low-titer ICA indicates that most children identified only by ICA reactivity are not at any increased 
risk for type 1 diabetes, although the sensitivity for type 1 diabetes is relatively high (91%). 
 The ICA method is biological, using pancreatic tissue. Accordingly, the method detects a wide 
range of islet-specific antibodies and occasionally other cross-reactive antibodies (105). Because of 
this, the ICA method can never reach the specificity of biochemical methods, but it is more sensitive. 
By determining the optimal JDF level of ICA that provides the best combination of sensitivity and 
specificity, the ICA method can provide something more than is attainable in the four biochemical 
autoantibody method set and might improve the preclinical screening of type 1 diabetes. 
 The increasing ICA seroconversion rate towards adolescence is seen only in the case of low 
ICA titers, while seroconversions to high ICA titers decrease with advancing age in parallel with 
biochemical autoantibodies. Removing low-titer ICA from the preclinical screening plan in the 
general population would considerably decrease the age at seroconversion. This should be taken into 
account when explaining the risk of type 1 diabetes to physicians and families undergoing screening. 
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 Among progressors to type 1 diabetes, ICA was the most stable autoantibody. Interestingly, 
there were no inverse seroconversions or fluctuations of ICA in progressors, while over a third of 
ICA-positive non-progressors reverted back to ICA negativity. Moreover, no ICA-negative children 
were found among multipositive individuals. This might reflect the fact that in addition to reactivity 
against known islet autoantigens some undiscovered autoantigens probably mediate disease-
associated ICA reactivity (105). 
 
Strengths and limitations of the study 
 
The strength of the DIPP study is the long, regular, prospective follow-up starting from birth, allowing 
close collaboration between the study personnel and the participating families. The proportion of 
children completing the 15-year follow-up (55.8%) was acceptable considering the long duration of 
the follow-up. The DIPP study is carried out in Finland, which has the highest incidence of type 1 
diabetes in the world, thus providing the most extensive general population-based cohort on 
childhood type 1 diabetes. As a downside, the high incidence of type 1 diabetes in Finland might limit 
the generalizability of the results. In the Finnish population, the attitude towards screening of newborn 
infants for the genetic risk of type 1 diabetes is generally positive. The Finnish Pediatric Diabetes 
Register is a national cross-sectional project that comprises information on more than 90% of 
pediatric diabetes cases in Finland from 2002 onwards. This database enables detection of progression 
to type 1 diabetes also among children who have dropped out from the preclinical DIPP study and 
analysis of autoantibody data obtained at the diagnosis of type 1 diabetes from all preclinically 
followed individuals. 
 Compared with other longitudinal follow-up studies on type 1 diabetes, such as Type 1 Diabetes 
TrialNet or TEDDY, an advantage of the DIPP study is the inclusion of both ICA and ZnT8A in the 
screening protocol in addition to the three other biochemical autoantibodies. Another benefit of the 
DIPP study is the birth cohort-based ability to define age at seroconversion in all children. In the 
TrialNet protocol, for instance, this is not possible in study participants recruited to the follow-up 
based on positivity for islet autoantibodies. 
 The main limitation of the DIPP study is the inclusion of only children carrying HLA risk 
genotypes for type 1 diabetes, which limits the generalization of the study results. However, most 
children (62%) diagnosed with type 1 diabetes are positive for the selected risk genotypes used in the 
DIPP study screening (385). It is possible that children with a positive family history for type 1 
diabetes who are more genetically and environmentally prone to the disease might be more motivated 
to participate in the DIPP study and to complete the study follow-up than those who do not have a 
relative affected by type 1 diabetes. This together with the relatively high dropout rate (55.8%) might 
cause some selection bias in the study population. 
 Another limitation of the DIPP study is the ICA-based primary screening that was applied until 
the end of 2002, except for the selected group of the first 1006 children who were also analyzed for 
all four biochemical autoantibodies. Children testing positive for only biochemical autoantibodies 
and born before the beginning of 2003 might have been missed as autoantibody-positive since before 
2003 the biochemical autoantibodies were analyzed only if the child became ICA-positive or 
progressed to clinical type 1 diabetes. Among the 1006 children analyzed for ICA and all four 
biochemical autoantibodies, 30 (3.0%) tested positive for one or more biochemical autoantibodies 
without ICA and would have been missed in the ICA-based screening. Moreover, the relatively low 
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sensitivities of the autoantibody assays imply that a proportion of autoantibody-positive children have 
been missed as false negatives in the screening, especially as two consecutive positive samples were 
required for autoantibody positivity. This may have affected the study outcomes. 
 Although Studies II and III are based on the whole, initially large DIPP study cohort, the number 
of progressors and especially rapid progressors to type 1 diabetes is modest, limiting the power of 
statistical analyses. The definitions of rapid and slow progression are primarily based on practical 
considerations, but are also partly data-driven. This might limit the generalizability of the results. 
However, the findings of Study II indicate that 1.5 years from seroconversion to diagnosis is a 
justified cut-off to distinguish rapid progressors from slower progressors. The cut-off for slow 
progression at 7.26 years from seroconversion provides a setting that allows evaluation of the 
characteristics associated with a considerably longer delay from seroconversion to diagnosis than 
observed for most progressors in the DIPP study. 
 In Study I, the number of children in the study cohort is relatively modest, which limits the 
power of statistical analyses, but allows testing for statistical differences. By 15.5 years, only 35 
children (3.5%) had been diagnosed with type 1 diabetes. The dropout rate was relatively high, but 
acceptable taking into account the long duration of the follow-up. Due to the limited size of the study 
population, the results should be interpreted with caution. Corrections for multiple testing were not 
applied in the data analysis, which might limit the interpretation of the results, as positive associations 
may have been falsely detected by chance due to the multiple testing. Accordingly, the results should 
be replicated in another population. No data were available on metabolic risk factors for the study 
participants that might affect the risk for type 1 diabetes, which is another limitation in this thesis. 
 It should also be noted that although ZnT8A had been analyzed from all available samples in 
Study I, the information on ZnT8A was missing for some participants for the specific sample obtained 
at initial seroconversion. Therefore, some multipositive children at seroconversion and children with 
ZnT8A as the single first autoantibody at seroconversion might have been missed. This may, to some 
extent, have affected the observed primary autoantibody signatures among the groups of progressors, 
multipositive non-progressors, and single autoantibody-positive non-progressors. The associations 
observed between the primary autoantibodies and disease progression need to be replicated in a larger 
study population. However, it seems unlikely that positivity for ZnT8A during the follow-up would 
have remained completely undetected since ZnT8A had been analyzed from multiple samples from 
each individual during the long follow-up. 
 Considering the comparison of autoantibody titers between progressors to type 1 diabetes and 
their multipositive controls in Study I, the number of available matched controls was limited due to 
the relatively modest number of participants in the study cohort. Because of the limited selection of 
controls, the differences in the autoantibody titers between the two groups might have been observed 
by chance. Negative autoantibody titers were also included in that analysis. 
 In the non-HLA SNP analyses, the non-optimal data coverage and small sample size were the 
major limitations. SNP markers were originally analyzed for other purposes (128). As a consequence, 
many participants lacked data on the non-HLA SNP genotypes. The results achieved in this work 
require confirmation in larger study populations with more optimal data coverage. Also the 
association of the FUT2 SNP with rapid disease progression must be confirmed in future studies. 
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Future perspectives on prediction and prevention of type 1 diabetes 
 
As soon as a safe and effective preventive measure is available, screening for the risk of type 1 
diabetes in the general population becomes justified in high-incidence countries such as Finland. 
Cost-effective screening at selected time points would save resources and might decrease the burden 
experienced by children and their families. The discoveries made in this thesis improve the preclinical 
estimation of type 1 diabetes risk and the timing of disease onset and can be utilized to target 
screening and preventive measures to optimal populations. Rapid progressors to type 1 diabetes 
comprise the primary target group for clinical trials and might benefit from careful clinical monitoring 
and early preventive measures. Targeting this group may reduce the costs of clinical trials, but as a 
disadvantage the generalizability of any outcomes might be limited. 
 As autoantibody seroconversions peak at a young age, screening in the public health context 
might be most effective in preschool years. Most children who progress to clinical type 1 diabetes 
before puberty test positive for autoantibodies before the age of 5 years (51). However, beta-cell 
autoimmunity may begin at an older age, and, as demonstrated in this thesis, rapid progression to type 
1 diabetes occurs not exclusively in young children but also in older children approaching puberty, 
suggesting that additional screening points might be needed closer to puberty. 
 The recent staging of type 1 diabetes introduces the idea that type 1 diabetes begins as positivity 
for multiple biochemical autoantibodies (53). Accordingly, advanced islet autoimmunity might be 
seen as a disease, not only a risk for disease, and clinical interventions carried out at stage 1 or stage 
2 type 1 diabetes might be considered as treatment of early disease to preserve beta-cell function 
rather than actual prevention. 
 Therefore, cost-effective screening for type 1 diabetes risk in the general population may be 
best achieved by screening for multiple biochemical autoantibodies. Additional monitoring might be 
carried out to stratify the disease risk and the pace of disease progression by using e.g. metabolic 
assessments. Children with only one autoantibody might be invited to follow-up visits for a few years 
since progression to multipositivity usually occurs within the next couple of years after initial 
seroconversion, but rarely thereafter (146, 175). The use of modified islet autoantigens, such as N-
terminally truncated GAD, might improve our understanding of the disease pathomechanisms in the 
future and facilitate the identification of study subjects suitable for intervention trials (135). 
 To date, the treatment of type 1 diabetes is largely missing immunomodulatory therapies 
targeted to biological pathomechanisms. Evidence from clinical trials suggests that beta cells can be 
preserved to some extent at stage 2 and stage 3 (56, 71, 366, 372). However, efficacy of primary 
prevention, or immunotherapy at stage 1 preclinical diabetes, remains to be demonstrated. 
Randomized trials are challenging to carry out because any intervention administered to human 
populations needs to be safe, tolerable, and easily administered, with costs carefully considered in 
relation to benefits. In this respect, the heterogeneity in type 1 diabetes sets a challenge for conducting 
successful trials. For any given treatment, a therapeutic effect is seen only in a subset of treated 
individuals, whereas a proportion of individuals will demonstrate no effect. This implies that there 
are multiple pathways leading to the same phenotype and that therapeutic agents affecting one 
biological pathway do not reach their full potential when administered to a population comprising 
many individuals in whom this pathway is not active (5). 
 In trial design, the selection of the target population therefore plays a key role and raises the 
question of how to identify populations that benefit from a given treatment. Age, genetic 
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susceptibility, and disease severity are likely to affect outcome. The stage of disease progression sets 
the frame for the intensity of the applied treatment (374). As therapies targeting a single biological 
pathway have failed in most cases to preserve beta-cell function, the use of multifaceted therapies 
combining multiple mechanisms of action might improve the probability of detecting a therapeutic 
effect in a diverse population (371). 
 Disease endotypes are likely driven by distinct physiological mechanisms, but currently there 
is no understanding of any exact mechanisms. Factors associated with type 1 diabetes are often linked 
together in a way that suggests they might form pathobiological entities such as the triad of age, HLA 
genotype, and development of IAA vs. GADA as the first autoantibody (117, 129, 320). One 
important question is whether disease endotypes are driven by distinct etiological events or whether 
they arise in the background of shared causal mechanisms similar to all cases of type 1 diabetes such 
as beta-cell damage resulting from persistent viral infection (5). Age has a great impact on disease 
heterogeneity, but this might reflect changes in immunological maturation, metabolic function, and 
gene-environment interactions (diet, infections, physical and social activity) with advancing age 
rather than heterogeneity in causal mechanisms (325). In older children, beta-cell dysfunction rather 
than direct beta-cell damage might be a central mechanism in type 1 diabetes (64). 
 Responses to preventive therapies in clinical trials may provide important clues to disease 
endotypes. In the anti-CD3 teplizumab trial, for instance, persons most likely to demonstrate a 
therapeutic effect were characterized by the HLA-DR4 genotype and the absence of ZnT8A (71). 
Disease endotypes might be identified based on the primary autoantibody, but in the public health 
context this would require autoantibody testing close to the time of initial seroconversion. If 
autoantibody screening in the general population was targeted to a few selected time points, additional 
biomarkers for endotyping would be required. These might include e.g. heterogeneous metabolic and 
cellular responses and proteomic, metabolomic, or transcriptomic patterns in prediabetic individuals. 
Given the multifactorial nature of type 1 diabetes, mathematical modeling of longitudinal 
autoantibody profiles and clusters of immune and metabolic phenotypes might facilitate the 
identification of complex disease endotypes and underlying biological pathways (5). 
 The endeavor to identify the mechanisms behind the heterogeneity in type 1 diabetes continues. 
A personalized approach to disease prediction and prevention would enhance the beneficial effects 
of a preventive treatment and decrease the potential risks and costs.
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CONCLUSIONS 
 
1. Among HLA-predisposed children recruited from the general population in Finland, 
conspicuous differences are present in the dynamics of islet autoantibodies during the first 15 
years of life. The ICA seroconversion rate increases continuously towards puberty, but 
biochemical autoantibodies peak already at a young age. The primary autoantibody is 
characteristic of age and might reflect the etiological background driving the disease process 
towards clinical type 1 diabetes. In children under the age of 2 years, IAA or ZnT8A emerge 
commonly as the primary autoantibody, but in preschool years IA-2A and especially GADA-
initiated islet autoimmunity increases. ICA becomes the prevailing autoantibody after 3 years 
of age, but if remaining as the only autoantibody does not confer any risk for type 1 diabetes. 
In young children, ZnT8A especially as the primary autoantibody might be a strong indicator 
of risk for type 1 diabetes. 
 
2. The increasing ICA seroconversion rate towards adolescence is restricted to low ICA titers. 
High-titer ICA seroconversions decrease with advancing age in parallel with biochemical 
autoantibodies. The significantly higher specificity and PPV of positivity for multiple 
biochemical autoantibodies than for ICA indicate that low-titer ICA (<10 JDF units) can be 
replaced by positivity for multiple biochemical autoantibodies when screening for risk of type 
1 diabetes in children. However, high ICA titers predict type 1 diabetes and in preclinical 
screening might provide information beyond that available in the four biochemical 
autoantibody method set. Excluding low-titer ICA from the screening plan in the general 
population would significantly affect the age at seroconversion. 
  
3. The labile patterns of autoantibodies, especially IAA, might affect the risk for type 1 diabetes. 
Reversions and fluctuations of IAA are common in HLA-predisposed children, with nearly 
half of IAA-positive individuals returning to persistent IAA-negativity by 15 years of age. 
Reversions and fluctuations of ICA are also common among non-progressors, but among 
progressors to type 1 diabetes, ICA is the most persistent autoantibody. Children with multiple 
biochemical autoantibodies seem to have proceeded to a stage in the disease process at which 
they rarely revert to complete autoantibody negativity. Among progressors to type 1 diabetes, 
transient IAA positivity is associated with delayed progression from seroconversion to 
diagnosis, suggesting a role for the humoral immune response against insulin in the 
determination of the progression rate to clinical disease. 
 
4. Rapid progressors to type 1 diabetes can be characterized among HLA-susceptible children 
by demographic, genetic, and immunological factors present at the initial seroconversion to 
autoantibody positivity. These include young age, high autoantibody titers of especially IAA, 
IA-2A, and ICA, multipositivity, and higher prevalence of the HLA-DQB1*02/*03:02 
genotype and the homozygous secretor genotype of the FUT2 SNP. Rapid progression occurs 
not exclusively in young children under the age of 5 years, but also in children approaching 
puberty. Young rapid progressors are characterized by IAA positivity and high IAA titers at 
seroconversion, and older rapid progressors by GADA positivity and high GADA titers. These 
 Conclusions  
 103 
differences might reflect the IAA vs. GADA-driven endotypes of type 1 diabetes and suggest 
that mechanisms behind rapid progression might be independent of the etiological triggers of 
the disease process. The association of the homozygous FUT2 secretor genotype with rapid 
progression suggests that a higher amount of soluble ABO histo-blood group antigens in 
bodily secretions and on the intestinal mucosa might promote events that contribute to rapid 
progression to type 1 diabetes. Rapid progressors to type 1 diabetes comprise the primary 
target group for clinical prevention trials. To cover both young and prepubertal populations 
of rapid progressors, future screening for risk of type 1 diabetes in the public health context 
might be targeted to a few selected age points, e.g. one at preschool age and another closer to 
puberty. 
  
5. Slow progressors to type 1 diabetes may be distinguished from other progressors by 
immunological characteristics present at seroconversion, including lower titers of IAA and 
ICA and lower frequency of positivity for IA-2A and multiple biochemical autoantibodies. 
Progression from single to multiple autoantibody positivity is delayed among slow 
progressors. Season of birth contributes to the progression rate from seroconversion to clinical 
diabetes. Disease progression is accelerated among children born in the spring and is slower 
among children born in the fall. The impact of season of birth on the rate of functional beta-
cell loss indicates that seasonal environmental factors contribute substantially to the 
pathogenesis of type 1 diabetes. The timing of exposure to certain environmental factors in 
relation to a child’s immunological development might be a major determinant in setting the 
pace of disease progression. 
 
6. No associations were found between the non-HLA SNPs analyzed and slow disease 
progression after corrections for multiple testing. As expected, the predisposing SNPs in the 
PTPN22, INS (rs689), and PHTF1 genes showed associations with overall progression to type 
1 diabetes. Also the predisposing EBI2/GPR183 SNP tended to associate with progression to 
type 1 diabetes. EBI2 might be of relevance in future pathomechanistic studies of type 1 
diabetes considering its pivotal role in humoral immune responses and its potential 
contribution to the development of central tolerance. However, this finding must be confirmed 
in a larger study population with improved data coverage. 
 
In summary, several demographic, genetic, and autoantibody characteristics were found to be 
associated with progression rate to type 1 diabetes in this work, but we observed no unambiguous 
characteristics specifically predictive for slow disease progression. The unique variations in the 
dynamics of islet autoantibodies support the idea of heterogeneity in the disease process. Apart from 
genetic and etiological elements, age and the stage of immunological maturation contribute 
substantially to the characteristics of islet autoimmunity. These findings provide an important 
framework for understanding the heterogeneous nature of type 1 diabetes and might be utilized in 
future trial design to personalize the efforts to delay or prevent the onset of type 1 diabetes. Further 
investigation of the age-specific features of beta-cell autoimmunity might provide mechanistic clues 
to the driving events of the disease process. The observed associations between the season of birth 
and positivity for multiple autoantibodies, the primary autoantibodies and disease progression, and 
the FUT2 SNP and rapid progression require confirmation in future studies.  
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